nach oben

Erschienen in:

Open Access 01.12.2017 | Review

Looking back to move forward: a twenty-year audit of herpes zoster in Asia-Pacific

verfasst von: Liang-Kung Chen, Hidenori Arai, Liang-Yu Chen, Ming-Yueh Chou, Samsuridjal Djauzi, Birong Dong, Taro Kojima, Ki Tae Kwon, Hoe Nam Leong, Edward M. F. Leung, Chih-Kuang Liang, Xiaohong Liu, Dilip Mathai, Jiun Yit Pan, Li-Ning Peng, Eduardo Rommel S. Poblete, Philip J. H. Poi, Stewart Reid, Terapong Tantawichien, Chang Won Won

Erschienen in: BMC Infectious Diseases | Ausgabe 1/2017

Abstract

Background

Herpes zoster (HZ) is a prevalent viral disease that inflicts substantial morbidity and associated healthcare and socioeconomic burdens. Current treatments are not fully effective, especially among the most vulnerable patients. Although widely recommended, vaccination against HZ is not routine; barriers in Asia-Pacific include long-standing neglect of adult immunisation and sparse local data. To address knowledge gaps, raise awareness, and disseminate best practice, we reviewed recent data and guidelines on HZ from the Asia-Pacific region.

Methods

We searched PubMed, Scopus, and World Health Organization databases for articles about HZ published from 1994 to 2014 by authors from Australia, China, Hong Kong, India, Indonesia, Japan, Korea, Malaysia, New Zealand, the Philippines, Singapore, Taiwan, Thailand, and Vietnam. We selected articles about epidemiology, burden, complications, comorbidities, management, prevention, and recommendations/guidelines. Internet searches retrieved additional HZ immunisation guidelines.

Results

From 4007 retrieved articles, we screened-out 1501 duplicates and excluded 1264 extraneous articles, leaving 1242 unique articles. We found guidelines on adult immunisation from Australia, India, Indonesia, Malaysia, New Zealand, the Philippines, South Korea, and Thailand.

HZ epidemiology in Asia-Pacific is similar to elsewhere; incidence rises with age and peaks at around 70 years – lifetime risk is approximately one-third. Average incidence of 3–10/1000 person-years is rising at around 5% per year. The principal risk factors are immunosenescence and immunosuppression. HZ almost always causes pain, and post-herpetic neuralgia is its most common complication. Half or more of hospitalised HZ patients have post-herpetic neuralgia, secondary infections, or inflammatory sequelae that are occasionally fatal. These disease burdens severely diminish patients’ quality of life and incur heavy healthcare utilisation.

Conclusions

Several countries have abundant data on HZ, but others, especially in South-East Asia, very few. However, Asia-Pacific countries generally lack data on HZ vaccine safety, efficacy and cost-effectiveness. Physicians treating HZ and its complications in Asia-Pacific face familiar challenges but, with a vast aged population, Asia bears a unique and growing burden of disease. Given the strong rationale for prevention, most adult immunisation guidelines include HZ vaccine, yet it remains underused. We urge all stakeholders to give higher priority to adult immunisation in general and HZ in particular.

Additional file 1: Appendix 1. Alternative approaches to treating herpes zoster and herpetic neuralgia. (PDF 340 kb)

Electronic supplementary material

The online version of this article (doi:10.1186/s12879-017-2198-y) contains supplementary material, which is available to authorized users.

ACIP

Advisory Committee on Immunization Practices

AIDS

Acquired immunodeficiency syndrome

CLIPPERS

Chronic lymphocytic inflammation with pontine perivascular enhancement responsive to steroids

CMI

Cell-mediated immunity

HAART

Highly-active antiretroviral therapy

HIV

Human immunodeficiency virus

HSCT

Haematopoietic stem cell transplant

Herpes zoster

HZO

Herpes zoster ophthalmicus

PHN

Post-herpetic neuralgia

Person-years

QoL

Quality of life

SLE

Systemic lupus erythematosus

SPS

Shingles Prevention Study

United States

VZV

Varicella zoster virus

WHO

World Health Organization

Background

Herpes zoster (HZ) is a prevalent and debilitating viral disease that often causes serious complications and proves challenging to treat. Consequently, HZ results in substantial morbidity, healthcare expenditure, loss of productivity, and diminished quality of life (QoL). Older people bear the greatest burden of disease, which is increasing as populations age. Despite a strong rationale for prevention, availability of an effective vaccine, and guidelines recommending HZ immunisation, vaccination has not become routine practice. One reason was limited availability of HZ vaccine after its launch in 2006 [1, 2]. Although an ample supply was restored, a fundamental barrier in Asia is long-standing neglect of preventive adult healthcare. Since Ilina Isahak highlighted this issue in 2000 [3], progress been limited and adult immunisation is still not given the priority that it merits [4, 5, 6]. Moreover, existing HZ immunisation guidelines are based on evidence from Western populations, which creates a perceptual barrier to changing management practices in Asia. Conversely, more locally-relevant data may promote guideline implementation; however, many Asian countries lack such data [7]. To address these concerns, we systematically reviewed literature on HZ from the Asia-Pacific region. Our objectives were: 1) To provide a comprehensive overview of the epidemiology, burden, and current management of HZ; 2) To disseminate best practice in HZ immunisation; and 3) To provide an up-to-date source of reference and information for stakeholders concerned with reducing the burden of HZ in Asia-Pacific. This review summarises our key findings and recommendations.

Methodology

Literature search strategy

We reviewed literature on HZ published over 21 years by authors from 14 Asia-Pacific countries. We searched three databases: PubMed (United States [US] National Library of Medicine National Institutes of Health), Scopus (Elsevier), and the World Health Organization (WHO) Global Health Library Regional Indexes. PubMed and Scopus searches used the search term ‘zoster’ in title, abstract, and author keywords fields, AND the term ‘country name’ in the affiliation field. The countries/regions were: Australia, China, Hong Kong, India, Indonesia, Japan, Korea, Malaysia, New Zealand, the Philippines, Singapore, Taiwan, Thailand, and Vietnam OR Viet Nam. WHO searches used the terms ‘country name’ AND ‘zoster’. Searches were limited to articles with abstracts in English published electronically since 1 January 1994 and before 31 December 2014; alerts were set to capture eligible articles added to PubMed and Scopus after the initial search dates.

We performed separate internet searches for guidelines on HZ immunisation. These used the country names and also vernacular terms for their inhabitants, eg, Thai, Filipino, Malay, combined with the terms herpes zoster, guidelines, recommendations, adult immunisation, vaccine, vaccination.

Data management

PubMed and Scopus results were downloaded in Comma Separated Value format then saved to Microsoft Excel files. WHO Global Health Library searches were exported as text files then imported into Microsoft Excel. Results from each database were screened to remove duplicates before entering the results for each country into a Microsoft Excel workbook. Duplicates between databases were identified by using conditional formatting to highlight entries with the same title. Duplicates between countries were identified similarly, by highlighting entries with the same database identity codes.

Inclusion and inclusion criteria

We included articles about four topics: epidemiology and burden; complications and comorbidities; management and prevention; and recommendations/guidelines. We excluded articles about: subjects only younger than 18, or from another country; primary varicella zoster virus (VZV) infection or not specifying that VZV infection was reactivated; negative disease associations, cases of coincidental HZ, or diseases other than HZ; extraneous research topics, eg, basic/molecular/experimental, diagnosis, technology; or reviews without country-specific information. Miscellaneous exclusions were editorials, correspondence or errata concerning included articles; study protocols, and articles on terminology, hypotheses, non-human subjects, or knowledge, attitudes and behaviour relating to HZ and its treatment.

Literature search results

The database searches returned 4007 articles (Fig. 1a). Having excluded 1493 duplicates and 1264 non-relevant articles, 1250 were assigned to four categories: epidemiology and burden (421); complications and comorbidities (538); management and prevention (287); and guidelines (4) (Fig. 1b). The separate search for guidelines found recommendations on adult immunisation from Australia, India, Indonesia, Malaysia, New Zealand, the Philippines, South Korea, Taiwan, and Thailand.

‘Grey literature’ included other key studies/data cited in retrieved articles or not stored in the searched databases, eg, national statistics or reports published locally; 16 such sources were added.

Clinicopathology

Herpes zoster is caused by reactivation of VZV dormant in nerve root ganglia since a primary varicella infection (Chickenpox). The cardinal symptom is neuropathic pain, often accompanied by a self-limiting vesicular rash and/or inflammation disclosing the source nerve [8‐10]. In Asia, as elsewhere, the classic presentation is unilateral HZ affecting a single thoracic dermatome, although HZ frequently involves the trigeminal, cranial, or cervical nerves; lumbosacral HZ is less common (Fig. 2) [11‐31]. The presentations and course of HZ also vary depending on patients’ age, health, and immune status. Older people are more likely to have trigeminal VZV reactivation and worse and longer-lasting rash and pain [20, 32], whereas immunocompromised patients tend to have relatively more thoracic HZ [14, 33]. All physicians should therefore beware that HZ assumes an array of guises.

Atypical HZ

Reactivated VZV can affect any part of the body. Ocular symptoms due to involvement of the ophthalmic division of the trigeminal nerve are common [34]; however, the maxillary and mandibular branches may occasionally be affected, resulting in oro-cutaneous manifestations [35, 36]. Atypical presentations usually reflect underlying immunocompromise, and other unusual locations have included the eardrum [37], genitalia [38, 39], papilla [40], and finger [41].

Zoster sine herpete

VZV reactivation does not always manifest cutaneously. Zoster “sine herpete” causes unexplained pathologies, including neuralgia [42], ocular [43], facial [44], or neuromotor palsy or paralysis [45, 46], and cerebral or ocular inflammations [47, 48].

Multidermatomal, disseminated and visceral HZ

Rarely, especially in patients who are elderly or otherwise immunocompromised, HZ involves two or more distinct dermatomes [49, 50], spreads across multiple sites [51, 52], appears as a generalised rash [53, 54], or worse, affects internal organs [9, 10]. Although occasionally seen in immunocompetent individuals [55‐64], such unusual presentations constitute fewer than 1% of total cases, being particularly characteristic of iatrogenic immunosuppression in transplant recipients [65, 66] or cancer patients [67‐71], or human immunodeficiency virus (HIV) infection, in which bilateral [72, 73], multidermatomal [74], disseminated [75], or recurrent [73, 76, 77] HZ are often the presenting symptom [72, 78‐80].

Disseminated HZ predicts higher risk of complications [81] and may portend abdominal HZ, which has high mortality despite antiviral therapy, especially in profoundly immunocompromised patients [9, 10, 82]. For example, haematopoietic stem cell transplant (HSCT) recipients have died of fulminant VZV hepatitis [83, 84]. Such patients may present with severe abdominal pain [82, 85‐87] either sine herpete or before lesions appear [9, 10]. Besides hepatitis, viscerally disseminated HZ may also cause pancreatitis [88, 89], colitis [90], pneumonitis [91, 92], or pneumonia [69, 93], which causes most fatalities [10].

Pain

Irrespective of its outward appearance, pain is the hallmark of HZ in adulthood. Acute pain and post-herpetic neuralgia (PHN) are its most unbearable and debilitating symptoms and severely impair QoL and everyday activities [15, 18, 20, 30]. Pain is notoriously challenging to manage, especially once established, making this the most compelling reason for early intervention [9, 25, 94, 95].

Almost all adult HZ patients suffer pain, which can be excruciating and is often described as the worst ever experienced [10, 96]. Many cases are presaged by prodromal neuralgia or malaise, with abnormal sensations such as itching, paraesthesia and hyperaesthesia [10, 18]. In India, Korea, Singapore and Taiwan, around two-thirds of patients reported prodromal pain, which more than 90% rated moderate-to-severe [18, 20, 25, 31]. Among 150 Taiwanese patients, 98% had acute pain at enrolment (87% moderate-to-severe) [20]; similarly, 95% of Indian and Singaporean patients experienced pain during the course of disease [12, 18]. Pain is more frequent and severe in older patients and can have devastating impacts; patients feel anxious and miserable, have disturbed sleep and cannot work normally or enjoy life [10, 12, 15, 18, 20, 25, 30]. Besides age, the severity and duration of acute herpetic pain correlates with the degree of prodromal pain, the severity of skin lesions, trigeminal/ophthalmic involvement, anxiety or depression, and comorbid disease [23, 32, 33, 97‐100].

Epidemiology and risk factors

Seroepidemiology

The aetiologic prerequisite of HZ is prior VZV infection, which most people contract in childhood, unless vaccinated preemptively [2, 7, 101, 102]. Although acquisition may be delayed in tropical climes, around 90% of adults age 30–39 in Asia-Pacific countries/regions have seroconverted, with almost all aged ≥40 years VZV seropositive and therefore at risk of HZ (Fig. 3) [7, 103‐135].

Incidence

HZ is very common in the Asia-Pacific region. Alike Western populations, estimated lifetime risk is approximately one-third [10, 136], and incidence of 3–10/1000 person-years (PY) rises steeply above age 40 and peaks between 70–80 years (Table 1, Fig. 4); there is female predominance in diverse Asia-Pacific populations, especially between ages 50–70 [11, 17, 26, 104, 126, 132, 133, 136‐144]. Authors ascribe higher age-specific incidence rates in Korea than other countries, to heavy use of state-insured healthcare by patients with mild HZ symptoms, besides being based on data from recent years during which HZ incidence has risen steeply [138, 140]; on the other hand, much lower incidence in Thailand [30, 144] probably reflects under-reporting.

Table 1

Herpes zoster incidence rates in Asia-Pacific

Country (source)	Study year(s)	HZ cases	Age range (years)	Incidence (cases/1000 person years)
				Overall	By sex		Age-range (years)
					Male	Female	<10	10–19	20–29	30–39	40–49	50–59	60–69	70–79	>80
Australia (MacIntyre 2003) [102]	1999	59200	All ages	8.3^a
Australia (Stein 2009) [104](MacIntyre 2015) [807]	1998–2005	379	≥50	9.7^a			1.4 (<25)			3.4 (25–49)		6.5	8.6	14.5	15.6
Japan (Toyama 2009) [139]	1997–2006	48388	0– ≥ 90	4.2	3.7	4.6*	2.5	2.9	2.3	2.0	2.5	5.2	7.0	7.8	6.9^b
New Zealand (Reid 2014) [17]	2009–2013	339	All ages	3.0	5.8^c	6.4^c	1.3 (≤50)								13.9
Korea (Kim YJ 2014) [138]	2011	529690	0– ≥ 80	10.4	8.3	12.6	2.0	3.3	6.3	7.8	10.2	17.4	22.4	21.8	16.5
Korea (Kang 2008) [129]	2004–2005	705	19–24	1.4				1.4 (19–24)
Korea (Choi 2010) [130]	2003–2007	2431744	All ages	10.0^d
Korea (Park SY 2004) [26]	1994–2003	1089	All ages	3.0
Thailand (Aunhachoke 2011) [30]	2008	180	≥50	0.3^e
Taiwan (Wu PY 2013) [141]	2000–2009		All ages	6.2
Taiwan (Wu CY 2010) [142]	2000–2005	24527	20– ≥ 60	7.0
Taiwan (Chao DY 2012) [143]	2004–2008	7574	All ages	5.7
Taiwan (Jih 2009) [137]	2000–2006	34280	1– > 80	4.9	4.7	5.1	2.1								13.7
Taiwan (Lin 2010) [136]	2000–2005	672782	≤1– ≥ 80	5.0	4.7	5.2*	1.6			3.5	5.2	8.4	11.1	12.3	10.2
Median (range)				5.0^f (0.3–10.4)	4.7 (3.7–8.3)	5.2 (4.6–12.6)	2.0 (1.6–2.5)	3.1 (2.9–3.3)	4.3 (2.3–6.3)	3.5 (2.0–7.8)	5.2 (2.5–10.2)	7.4 (5.2–17.4)	9.8 (7.0–22.4)	13.4 (7.8–21.8)	13.8 (6.9–16.5)
Quartile range (IQR)				3.6–7.3 (3.7)	4.7–5.8 (1.0)	5.1–6.4 (1.3)	1.9–2.2 (0.3)	3.0–3.2 (0.2)	3.3–5.3 (2.0)	2.7–5.7 (2.9)	3.9–7.7 (3.8)	6.8–12.9 (6.1)	9.0–16.8 (7.7)	10.1–17.1 (7.0)	10.2–13.9 (3.7)

HZ Herpes zoster, IQR Interquartile range

^aNational estimate extrapolated from sample

^b80–89

^cAge >50 years

^dClinic visits for herpes zoster

^e Based on reported cases per 100000 population

^fSubjects of all ages

*P < 0.001

Bold data values signify significant difference between incidence rate in females vs. males

As in other populations, HZ incidence rates are increasing in countries across Asia-Pacific (Table 2, Fig. 5) [2, 102, 139‐150]; the principal cause is most likely rising incidence in ageing populations, especially among women, together with growing prevalence of chronic diseases and use of immunosuppressive medications [2, 102, 139‐141, 143, 147]. HZ incidence in Taiwan rose by 20% from 2004–05 to 2006–08 despite remaining stable in 10–49 year-olds, with a significant increase in older people [143]. Hypothetically, mass varicella immunisation might also contribute to this trend; if natural exposure to VZV strengthens immunity to HZ – exogenous boosting – HZ incidence in countries that institute routine childhood varicella immunisation (Table 3) would be expected to rise subsequently among the unvaccinated population, due to declining prevalence of varicella [2, 141, 146, 151, 152]. Although there is some evidence that exogenous boosting does occur [151], there is very little for a substantive contribution to HZ, and its role, if any, in HZ epidemiology remains obscure [2, 141, 143, 146, 147, 151, 152]. Rising HZ rates predating mass varicella immunization (Fig. 5) suggest that other factors are more important; besides those already mentioned, these may also include changes in health-seeking behaviour and more comprehensive and accurate disease surveillance [151, 152].

Table 2

Trends in herpes zoster incidence, hospitalisation and healthcare costs in Asia-Pacific countries

Country (source)	Metric	Years compared	Herpes zoster rate	Annual increase (%)
Australia (Kelly 2014) [146]	Cases/1000 consultations	1998 2006–12	1.03 1.81	6.3
Australia (Nelson 2010) [145]	Management/1000 GP consultations	1998 2008	1.71 2.35	3.4
Australia (MacIntyre 2003) [102]	Hospitalisations/100000 population	1993 1998	20 25	4.2
Australia (Carville 2010) [147]	Hospitalisations/100000 population^a	1995–99 2006–07	6.3 9.1	3.1
Australia (Heywood 2014) [2]	Hospitalisations/100000 population	1998 2004 2006–10	9.2 10.6 10.4	2.2 −0.4
Korea (Choi 2010) [130]	Hospitalisations/1000 population	2003 2007	0.22 0.32	9.1
	Consultations/1000 population	2003 2007	7.93 12.54	11.6
	Total socioeconomic cost (US$)	2003 2007	75,921,348 143,774,888	17.9
Japan (Toyama 2009) [139]	Incidence/1000 person-years	1997 2006	3.61 4.55	2.6
Taiwan (Lin 2010) [136]	Healthcare cost (NT$)	2000 2004	250,000,000 319,000,000	5.5
Taiwan (Wu CY 2010) [142]	Incidence/1000 population	2000 2005	4.94 7.00	7.0
Taiwan (Chao DY 2012) [143]	Incidence/1000 population	2000 2008	4.45 6.89	6.1
Taiwan (Wu PY 2013) [141]	Incidence/1000 person-years	2000 2009	4.40 6.24	5.5
Thailand (Bureau of Epidemiology)	Reported cases/100000 population	2001 2010 2014	6.44 40.49 7.65	52.9 −8.1
Median (range)				5.5 (−8.1–17.9)
Quartile range (IQR)				3.0–7.5 (4.6)

GP General practitioner, IQR Interquartile range

^aPrincipal diagnosis of herpes zoster

Table 3

Asia-Pacific countries with national varicella immunisation programmes

Country	Varicella vaccine schedule		Planned extent of coverage	Programme commenced (month, year)
Country	Dose(s)	Age	Planned extent of coverage	Programme commenced (month, year)
Australia	1	18 months, with catch-up at 10–13 years^a	Entire population	November 2005
Hong Kong	2	12 months & 6 years^b	Entire population	November 2005
Japan	2	12–36 months	Entire population (voluntary category)^c	October 2014
New Zealand	1	15 months, with catch-up at 11 years^d	Entire population	July 2017
South Korea	1	12–15 months	Entire population	January 2005
Taiwan	1	12–18 months	Entire population	January 2004

^aSchools programme

^bPrimary 1 school age

^cNot covered under the Preventive Vaccinations Act for Routine Vaccination against Category A Diseases

^dFor non-vaccinated children who have not already had a varicella infection

Recurrence

Reported HZ recurrence rates range from 2.3% to 8.0% overall [13, 153, 154] and are higher in women, immunocompromised patients, and individuals aged 50–70 or with PHN [153].

Risk factors and comorbidities

The constitutional cause of HZ is failing cell-mediated immunity (CMI) that becomes too weakened to suppress latent VZV [155]. CMI wanes naturally with age [156], explaining why advanced age is the preeminent risk factor for HZ and PHN among all populations [10, 95]. Besides immune senescence, other conditions that diminish CMI likewise increase the risk of HZ. The principal predisposing factors are iatrogenic or pathologic immunosuppression (Fig. 6) [137, 157‐167]. Inpatients with severe illnesses or recovering from surgery develop HZ more frequently than others [168].

Immunosuppressant therapies

Transplantation

Organ, tissue or cell transplant recipients require immunosuppressive therapy with cyclosporine and/or other drugs that prevent transplant rejection. Consequently, they often develop HZ or other opportunistic infections, especially within the first year following transplantation [16, 66, 169‐180]. HZ rates of up to >80% have been reported [170, 181], and transplant recipients are especially prone to disseminated and visceral HZ with potentially fatal inflammatory complications [70, 82, 181‐186].

Anti-inflammatory and cytotoxic agents

Corticosteroids

Systemic glucocorticosteroids are immunosuppressant and have been associated with HZ rates above 30% in long-term use [187‐189].

Cyclophosphamide and others

Cyclophosphamide-based and other chemotherapeutic regimens substantially increase the risk of HZ in patients with lymphoma [190‐192]. High rates have also been reported in leukaemia patients treated with arsenic trioxide [193‐196]. Systemic lupus erythematosus (SLE) and lupus nephritis are also treated with cyclophosphamide, often combined sequentially with azathioprine and prednisolone or mycophenolate mofetil. HZ is the most common drug-related infection, with rates of up to 40% [166, 197‐201].

HZ is also an adverse effect of azathioprine and mycophenolate mofetil in SLE and other therapeutic settings [202‐214]. Cases of disseminated HZ have occurred in rheumatoid arthritis patients treated with leflunomide, with increased risk in those taking concomitant methotrexate and corticosteroids [215, 216]. HZ was the most common infection in leflunomide-treated lupus nephritis [217]. The multiple sclerosis drug cladribine is associated with an increased rate of HZ versus placebo [218].

Biologic agents

Antibody therapies for cancer, transplant rejection and other conditions are associated with elevated rates of VZV reactivation, both alone and combined with other biologics or chemotherapies. These include alemtuzumab [219], rituximab [220‐224], and abatacept [225]. Tofacitinib is associated with significantly higher rates HZ in Asians than other races [226, 227]. Increased relative risk of HZ has also been reported with ustekinumab, adalimumab and infliximab [165, 228‐230].

Bortezomib Bortezomib directly impairs CMI and is an independent risk factor for HZ [166], with incidence of up to 40% in some Asia-Pacific studies [231‐250]. HZ prophylaxis is advisable before commencing such therapy [251].

Other iatrogenic risk factors

Trauma

Accidental or iatrogenic trauma can trigger HZ [252‐258]. This is particularly associated with ocular, facial or dental surgeries [259‐268], and heightened vigilance is warranted following such procedures, particularly in elderly or immunocompromised patients. Ironically, neurosurgical treatment of PHN occasionally causes HZ [269‐271].

Anaesthesia

General anaesthesia may compromise immune function, and mothers anaesthetised for caesarean delivery have a small increased risk of HZ during the following year [272].

Statin therapy

Statin users have slightly increased risk of HZ, likely due to statin-mediated immunosuppression [273, 274].

Drug-induced hypersensitivity syndrome

Drug-induced hypersensitivity is a severe reaction to certain drugs that involves the reactivation of herpes viruses, including VZV. Systemic corticosteroids may contribute to this risk, and like immune restoration syndrome, withdrawal of corticosteroid may trigger HZ [275].

Infections

HIV/AIDS

HIV/Acquired Immunodeficiency Syndrome (AIDS) is a major healthcare problem in Asia. With prevalence of up to 30% and incidence as high as 40–50/1000 PY [276‐303], HZ is so common in HIV-infected individuals that it may be a pragmatic prognostic marker [14, 27, 28, 76], especially among younger individuals [304‐309]. AIDS patients may have recurrent [73, 76, 77, 80], disseminated [27, 78], or cerebral HZ infections [310, 311]. HZ incidence correlates with low CD4+ cell count [310, 312‐314] and may be significantly reduced by highly-active antiretroviral therapy (HAART); however rates in the post-HAART era remain double-digit [281, 303].

Immune reconstitution syndrome Paradoxically, patients regaining immunocompetence following HAART are at higher risk of HZ than when immunodeficient, probably due to increasing CD8 cell count, a phenomenon termed immune reconstitution inflammatory syndrome [315‐318].

Varicella zoster virus

Counterintuitively, Taiwanese healthcare workers frequently exposed to VZV did not gain enhanced immunological protection, and had higher incidence of HZ than the general population; however, this may be because their very stressful working environment dampened CMI, overriding any protective effect [142]. Epidemiology data from Japan [319] and elsewhere suggests that varicella exposure boosts immunity to HZ [102, 151]. Nevertheless, rare localised HZ clusters suggest that VZV re-exposure might occasionally provoke recrudescent HZ; the mechanism is unknown, but may involve disruption of CMI by the humoral response to VZV reinfection [320]. Although VZV transmission from patients with HZ is rare, due to less and more localised viremia, exudate from open HZ lesions may potentially infect close contacts who have not had varicella or been immunised [10, 320‐324].

Other pathogens

Rare cases of HZ associated with tuberculosis or malaria have been reported in China and India [325‐328].

Intrinsic risk factors

Pregnancy

Pregnancy is another immunosuppressed state that may potentiate HZ [120]. Although this seldom occurs, HZ is the most common skin infection that dermatologists encounter in pregnant women, accounting for up to 30% of cases [329]. While challenging to treat, unlike congenital varicella, HZ poses minimal risk to the foetus [330, 331].

Good’s syndrome

Good’s syndrome is a very rare immunodeficiency disease predisposing to HZ [332].

Nutritional deficiency

Micronutrient deficiencies that diminish CMI may increase susceptibility to HZ and PHN; supplements, particularly vitamin D, can boost VZV immunity [333‐335].

Genetic predisposition

Asians have genetic predispositions to HZ; specifically, human leukocyte antigen gene polymorphisms have been linked to VZV reactivation in East Asian populations [336‐338].

Associated diseases

Unsurprisingly, many HZ patients have common diseases of older age (Table 4), most frequently hyper-tension, diabetes, malignancies, and pulmonary disorders [11, 12, 15, 23, 26, 28, 137, 154, 166, 339]; however, since comorbidities and/or complications account for high proportion of hospitalised HZ cases [11, 12, 15, 23, 26, 28, 102, 104, 136, 137, 154, 166, 340], these may be more prevalent among such patients than in the general population.

Table 4

Common comorbidities of herpes zoster in Asia-Pacific patient populations

Country (source)	Setting (patient number)	Age profile (years)	Proportions with comorbidities (%)
Country (source)	Setting (patient number)	Age profile (years)	Any	Hypertension	Diabetes	Malignancy	Pulmonary	Cardiovascular
Korea (Park SY 2004) [26]	Dermatology (1089)	NA	36.5	12.6	7.9	0.6	1.7^a	1.6^c
Korea (Kim YM 2008) [11]	Dermatology (297)	NA	56.2	32.1	17.5	10.4	7.5^a	NA
China (Yuan LL 2014) [339]	Hospitals (2960)	Median 60		22.2	11.7		6.2^b	10.7
Philippines (Jara 2010) [15]	Hospital (221)	Mean 43	28.0	13.6		1.8	8.1	2.7
Japan (Kurokawa 2002) [23]	Hospitals (263)	Mean 59	41.1		9.6	13.7
Thailand (Tunsuriyawong 2005) [154]	Hospital (339)	Mean 59	26.8	4.0	2.5	1.0
India (Abdul Latheef 2011) [12]	Hospital (205)	47% >40	14.6		5.3	9.2
Taiwan (Jih 2009) [137]	National (34380)	33% >60			20.6	2.7
Taiwan (Hu 2013) [166]	Hospital (2306)		24.3			14.8
Taiwan (Wu CY 2010) [142]	National (702932)					1.0
Japan (Kurokawa 2007) [28]	Dermatology (316)		42.1	4.1	6.6	15.2
		Median (range)	32.3 (14.6–56.2	13.1 (4.0–32.1	8.8 (2.5–20.6)	6.0 (0.6–14.8)	6.9 (1.7–8.1)	2.7 (1.6–10.7)
		Quartile range (IQR)	26.2–41.4 (15.2)	6.2–20.1 (13.8)	6.3–13.2 (6.9)	1.2–12.9 (11.7)	5.1–7.7 (2.6)	2.2–6.7 (4.6)

NA Data not available, IQR Interquartile range

^aAsthma

^bRespiratory infections

^cAngina pectoris

Patients with certain underlying diseases have apparently increased risk of HZ; however, it may be difficult to ascertain whether such relationships are causal, reflect underlying pathology, or are coincidental. In cancer, SLE, and other diseases treated with immunosuppressants, HZ may be largely treatment-related, although the disease too may make an indeterminate contribution to increasing the risk [10]. In others, for example, diabetes and renal disease, impaired CMI may be a common factor. Adjusted for age and other confounding variables, several comorbidities have been identified as independent risk factors for HZ, most notably renal disease, malignancies, and SLE (Fig. 6) [137, 157‐167].

Renal disease

The incidence of HZ increases across the spectrum of renal disease, with transplant patients at highest risk followed by peritoneal dialysis and haemodialysis [157, 159, 160, 341‐343]. The risk of HZ in haemodialysis is heightened by corticosteroid use, but may be mitigated by iron and vitamin D supplementation [334, 335].

Inflammatory autoimmune diseases

HZ frequently afflicts patients with connective tissue disorders [344], with double the risk in rheumatoid arthritis [158]. Patients with SLE have impaired CMI and are treated with immunosuppressant anti-inflammatory drugs, which significantly increases their risk of HZ [137, 161, 345, 346], particularly if they have neuropsychiatric manifestations, renal involvement, or receive cyclophosphamide [166]. Likewise, increased risk of HZ associated with inflammatory bowel disease probably reflects iatrogenic immunosuppression in many patients [162, 347].

Cancer

Cancer patients may be immunosuppressed due to malignancy, its treatment, or both [12, 39, 348]. Risk of HZ is increased in both solid and haematologic cancers [158, 349, 350], especially leukaemia and lymphoma [137, 158].

Pulmonary disease

Both immune dysregulation and corticosteroid therapy may account for increased risk of HZ in chronic obstructive pulmonary disease. Patients taking oral corticosteroids are at the greatest risk [164].

Diabetes

Patients with diabetes have impaired VZV-specific CMI [351]; however, evidence that diabetes is a risk factor for HZ [137, 158, 352] is inconclusive.

Peptic ulcer disease

Peptic ulcer disease independently predicts HZ, having excluded confounding effects of anti-inflammatory drugs and Helicobacter pylori infection [163].

Psychiatric disorders

CMI is also diminished in psychiatric disorders. The risk of HZ is increased in patients with affective psychoses, neurotic illness, personality disorders and other mental disorders, especially among those younger than 60 [353].

Complicating presentations and disease associations

Post-herpetic neuralgia

The most common complication of HZ in adults everywhere is pain outlasting the eruptive phase [94]. Definitions of PHN are inconsistent, ranging from ≥1 to ≥6 months since rash onset; however, PHN may persist for years [10]. Reported rates vary widely, depending on patients’ age profiles and the definitions used [20]; nonetheless, the incidence generally ranges between ≤10 to ≥25%, with up to 20% still enduring pain after 6 months (Table 5) [11, 12, 15, 18, 20, 21, 23, 25, 26, 28, 30, 96, 104, 130, 137, 154, 340, 354‐359]. PHN correlates strongly with advancing age [15, 18, 21, 96, 102, 137, 340, 356, 357], the other major prognostic factors being the severity of HZ and intensity of acute pain [23, 99, 137, 356, 357, 360‐362]. Comorbid risk factors include diabetes, lymphoma/leukaemia, SLE [137, 363], peptic ulcer disease [364], and micro-nutrient deficiencies [333]. There is also evidence of specific phenotypic [358] and genotypic predispositions [365‐368]. Bortezomib may aggravate PHN independently of VZV reactivation [369].

Table 5

Herpes zoster complication rates in Asia-Pacific patients

Country (source)	Setting (number of patients)	Age profile (years)	Proportions with complications (%)
			Post-herpetic neuralgia (months)				Ocular	Otic	Motor	Infections		≥1 overall
			NS	≥1	≥3	≥6				Skin	LRT
Taiwan (Lin 2010) [136]	Hospitals (2.93% of 672783)	63% >40	52.5 (neurologic including PHN)				24.1	52.4		19.0	10.1	47.0
Australia (MacIntyre 2003) [102]	Hospitals (4718)	Mean 69	33.1 neurologic				16.0					58.5
Korea (Kim YM 2008) [11]	Dermatology (297)	NA	30.0				7.7	NA	1.4^a	9.8		40.7
Korea (Lee 2006) [354]	Hospital (333)	NA	15.6				6.9	0.6	0.3^a	1.5		NA
Korea (Park 2004) [26]	Dermatology (1089)	NA	7.4				3.2	0.2	0.4^a	1.8		NA
Philippines (Jara 2010) [15]	Hospital (221)	Mean 43			2.3		5.0			6.3		12.2
Thailand (Aunhachoke 2011) [30]	Hospitals/tertiary centres (180)	Mean 59			19.4		7.2
Singapore (Oh 1997) [340]	Hospital (67)	Mean 50	13.4				5.0			61.0		85.0
India (Abdul Latheef 2011) [12]	Hospital (205)	47% >40	10.2					1.0	0.5	13.6		34.6
Australia (Stein 2009) [104]	General Practice (379)^b	100% >50	15.0				16.2^c					61.3^c
Japan (Akiyama 2000) [454]	Hospital (1432)	Mean 54							0.8
India (Gopal 2010) [449]	Dermatology (100)								3.0
Korea (Son 2011) [448]	Hospital (711)								2.1
Korea (Min 2007) [418]	Dermatology (1787)	Mean 62						4.7
Korea (Kim SH 2008) [372]	Dermatology (1496)						8.7
New Zealand (Wallis 2014) [22]	General Practice (278)	55% >50					11.2
New Zealand (Reid 2014) [17]	General Practice (339)	71% ≥51					6.3
Thailand (Tunsuriyawong 2005) [154]	Hospital (399)	Mean 59	16.8				6.3
Singapore (Goh 1997) [18]	Dermatology outpatients (164)	Mean 49		50.0	28.0	17.0
Japan (Imafuku 2014) [359]	Dermatology (764)	Median 61		31.6	12.4	7.1
Taiwan (Tsai TF 2014) [20]	General Practice & Hospitals (150)	Mean 65				20.7
Korea (Song 2014) [25]	Specialist centres (151)	Mean 64			38.4	24.1
Japan (Kurokawa 2002) [23]	Hospitals (263)	Mean 59				26.2
Japan (Kurokawa 2007) [28]	Hospitals (316)				24.7	12.4
Korea (Cho 2014) [357]	Dermatology (305)	Mean 53			6.2
Taiwan (Jih 2009) [137]	National (34280)	33% >60		13.3	8.6
Korea (Choi 2010) [130]	Cancer screening (282)			17.7
China (Yang 2005) [355]	Dermatology (178)	NA		21.9
Korea (Herr 2002) [356]	Dermatology (188)	NA		17.0
China (Zhu 2009) [358]	Anaesthesiology (49)	Mean 65		20.4
Korea (Cheong 2014) [96]	National (11502)	100% >50	20.6
China (Song 2002) [21]	Dermatology (522)	Mean 47	6.9
		Median (range)	17.0 (2.3–50.0)				7.2 (3.2–24.1)	1.0 (0.2–52.4)	0.8 (0.8–3.0)	10.0 (1.5–61.0)		47.0 (12.2–85.0)
		Quartile range (IQR)	11.3–23.0 (11.7)				6.3–11.2 (4.9)	0.6–4.7 (4.1)	0.5–1.8 (1.3)	5.6–15.0 (9.4)		37.7–59.9 (22.3)

NS Not specified, LRT Lower respiratory tract, PHN Post-herpetic neuralgia, NA Data not available, IQR Interquartile range

^aNeurogenic bladder

^bIncident cases

^cHospitalised patients

Neuropathy, inflammation and secondary complications

HZ causes multifarious complications, especially inflammatory sequelae, which affect up to half or more of hospitalised HZ patients. The most common besides PHN involve the skin, eyes or, less often, ear, nose and throat (Table 5) [11, 12, 15, 26, 30, 102, 104, 136, 340, 354]. Uncommon complications include muscular weakness or paralysis and serious – sometimes life-threatening – cerebral or visceral inflammation. Elderly or immunocompromised individuals are more frequently and often worse affected [30, 96, 340, 370].

Eye

The most common and severe complications stem from VZV reactivation in trigeminal ganglion, which is the most frequently affected non-spinal location [11, 12, 23, 26, 29, 34, 371]. In particular, HZ ophthalmicus (HZO) arising from the ophthalmic division accounts for 5% to 25% of HZ cases in Asia-Pacific countries [11, 15, 17, 22, 30, 102, 104, 136, 154, 340, 354] (Table 5). The majority of cases, especially those accompanied by nose eruptions (Hutchinson's sign) [372‐375], are complicated by secondary inflammation such as conjunctivitis, keratitis [376‐378], scleritis, and uveitis/iridocyclitis [372‐374, 379‐381]. Such complications can cause glaucoma and are potentially blinding, especially if not treated promptly [379, 382]. However, inflammatory sequelae may not manifest until some time after an HZ episode [383]. Early and intensive antiviral therapy is particularly important for patients with HIV/AIDS, who tend to have worse and treatment-refractory inflammation, with resultant vision loss [384‐386].

Molecular diagnostic techniques have revealed VZV reactivation to be a predominant cause of anterior uveitis in South and East Asian countries [387‐389], with significantly increased risk within 1 year following HZ, especially HZO [390]. VZV is also a major cause of acute retinal necrosis [391‐397] in the region, and of progressive outer retinal necrosis, which is usually seen in severely immunocompromised patients [398‐402]. Both conditions have particularly poor visual outcomes, even when treated appropriately [375, 391, 392, 397, 399, 403‐407].

Less common ocular complications include, corneal endotheliitis [408], retinochoroiditis [381], optic neuritis [409‐411], oculomotor palsy [371], dacryoadenitis [412, 413], superior orbital fissure syndrome [414], orbital apex syndrome [415, 416], and central retinal vein occlusion [417].

Ear, nose and throat

Occasionally, VZV reactivation in the facial nerve genicular ganglion causes HZ oticus (Ramsay Hunt syndrome) [418, 419]. Patients often have multiple neuropathies and diverse symptoms, depending on the cranial and facial nerve branches involved. As elsewhere, the characteristic triad is facial palsy, auricular rash and ear pain [418, 420‐422]; however, some cases affect the tongue, soft palate, or throat [423, 424], and the rash may precede facial paralysis, not appear until afterwards [420], or be absent [424]. Many patients experience hearing loss and vestibulo-cochlear symptoms such as tinnitus and vertigo [418, 420, 425, 426]. The seventh and eighth cranial nerves are most commonly affected [420, 427], but many atypical cranial neuropathies have also been identified [428‐431]; Ramsay Hunt syndrome has been associated with dysphonia [46, 424, 429, 432, 433], laryngitis [434, 435], loss of taste [436], chronic cough [437], hiccups [435, 438], dysphagia [46, 424, 429, 439], and persistent vomiting [438]. Other rare complications include jugular foramen syndrome [440] and non-facial neuromotor deficits [441]. In addition to Ramsay Hunt syndrome, zoster sine herpete is increasingly recognised as a major aetiologic factor in idiopathic Bell’s palsy [442‐444] and Ménière's disease [445, 446].

HZ oticus generally responds to prompt antiviral therapy, with good outcomes [421, 430]; however, half of patients may not recover fully from facial palsy [420, 421], with even lower rates among those who are older [427], have multiple cranial neuropathies [420], or are not treated [419]. The diversity of manifestations, often occurring sine herpete, creates potential for misdiagnosis [419]. It is vital for clinicians to remain alert to the possibility of HZ, so that treatment can begin early enough to avoid potentially life-threatening sequelae of VZV reactivation in the head and/or neck [438, 447].

Neuromuscular

Fewer than 5% of HZ cases in Asian patients cause motor neuropathy [448‐450]. Though more common in the elderly or immunocompromised [450, 451], such complications also affect immunocompetent individuals [452, 453]. Among 711 Korean HZ patients, 2.1% had neuromotor weakness, predominantly affecting cranial rather than spinal nerves [448]. The incidence was 0.8% among 1432 Japanese patients [454] and 3% in an Indian cohort [449]. Such complications may arise before skin lesions appear and are likely underdiagnosed because they are masked by overriding pain [455, 456]; they may also occur some time after HZ onset [452, 457, 458]. Other presentations include gastrointestinal or bladder dysfunction [10], myelitis [450, 459‐461], and myositis [462]. VZV infection is implicated in the aetiology of Guillain-Barré syndrome [463‐465].

Face and eye

VZV reactivation is a common cause of Bell's palsy [466]. HZO may present as orbital myositis preceding skin eruptions [462], and sometimes causes complete ophthalmoplegia [467‐472].

Limbs

Paresis of the ipsilateral shoulder or arm [473‐477], occurs in 3–5% of HZ cases, but is underdiagnosed [478, 479]. Some cases are due to brachial plexopathy [480, 481], and others to Brown-Séquard hemiplegia [460, 482]. Lower limb neuropathy may manifest as foot drop [449, 483], and HZ paresis-induced femoral fracture has been reported [484].

Trunk and abdomen

Cervical myelitis can cause diaphragmatic paralysis with resultant dyspnoea [457, 485‐487]. Segmental paresis may cause abdominal protrusion or pseudohernia [488‐492], which are associated with gastrointestinal complications, notably constipation due to intestinal pseudo-obstruction or colonic ileus [488, 493‐496].

Lumbosacral

Voiding dysfunction associated with sacral HZ is uncommon but not rare, especially among immunocompromised patients [497]. The incidence among 423 Taiwanese HZ patients was 4% overall, and 29% among those with lumbosacral HZ [498]. Urinary problems include neuropathic bladder [499], loss of voiding sensation [500] and occasional acute urinary retention [461, 501‐503]. Other complications include faecal incontinence [504] rectal ulcer [505] and sciatica [506].

Vasculopathy

Though rare, vasculitic cerebral inflammation is the most serious neurologic complication of HZ; VZV from intracranial branches of the trigeminal nerve that invades and inflames the carotid artery or its branches, may cause fatal strokes [9, 10].

Cerebrovascular

Cerebral arteritis arising from HZ, especially HZO, significantly increases the risk of thromboembolic or haemorrhagic strokes [507, 508]. Those affected may have no visible lesions [509, 510] and strokes may be delayed [511‐516] or occur without characteristic risk factors or symptoms [512, 513, 517, 518], leading HZ-associated stroke to be underdiagnosed [514, 519]. HIV/AIDS might be suspected in otherwise healthy younger individuals [518, 520].

Cerebral inflammation

Rare but severe and sometimes fatal neurologic complications include meningitis or meningo-encephalitis [521‐526], cerebellitis [527], and encephalitis [528, 529]. Other reports include posterior reversible encephalopathy syndrome [530], CLIPPERS syndrome [531], and fatal meningo-encephalomyelitis [532]. Again, those affected are generally immunocompromised [9, 10], although accruing evidence suggests that such complications affect young and/or immunocompetent individuals more often than was supposed [521, 533‐538].

Ocular

Cases of Horner’s syndrome and related cranial nerve palsies [539‐542] have been attributed to HZO-induced arteritis and VZV meningitis [543]. Reported HZ retinopathies include visual loss due to central retinal artery occlusion and vasculitic chorioretinopathy [404, 544, 545].

Cardiovascular

Intriguing evidence hints at a link between HZ and cardiovascular disease in Asia. There are modestly elevated risks of acute coronary syndrome, arrhythmia and coronary artery disease following HZ [546, 547]. Herpetic infections may also be associated with atherosclerosis and thrombosis [546], with reports of HZ-associated deep vein thrombosis [548] and peripheral vascular disease [525]. Myocarditis [549] and unexplained recurrent asystole [550] following HZ have also been reported. Interestingly, however, Japanese patients with prior HZ had lower blood pressure than those with no history [551].

Skin

The most common dermatologic complications are secondary infections but numerous others have been described [9]. Rare complications include folliculitis, syringitis, and vasculitis [552‐554]. HZ can also cause hair loss [555, 556].

Infections

Secondary infections complicate up to 30% of HZ cases [136], rising to 60% in vulnerable hospitalised patients [340]. The most common are staphylococcus or streptococcus superinfections [9, 10]. Other opportunistic organisms include moraxella [557], and aspergillus [558]. Bacterial infections are more likely in patients with diabetes [559, 560] and potentially serious, with necrotising fasciitis reported in one immunocompromised patient [561]. Immunocompromised patients, particularly those with HIV/AIDS, may rarely become reinfected by varicella despite a history of HZ [562].

Isotopic responses

HZ may render affected skin susceptible to other infections or dermatoses, for example, moloscum contagiosum, mycosis fungoides [154], erythema multiforme [563], and psoriasis [564, 565]. Diverse ‘isotopic’ responses at healed HZ sites include: vitiligo [566], fungal granuloma [567], furuncles [568], granulomatous reactions [569‐574], erythemas [575‐578], lichen planus [579, 580], morphea and bullae [581‐583], perforating collagenosis [584, 585], keratolysis [586] and sarcoidosis [587, 588], reticulohystiocytosis [589], nodular degeneration [590, 591], verrucous hyperplasia [592], mucinosis [593], urticaria [594], prurigo nodularis [595], graft-versus-host reaction [596], drug-induced eruption [597], adenocarcinoma [598], leukaemia cutis [599], Kaposi’s sarcoma [600], and tufted angioma [601].

Dental

Jaw osteonecrosis and tooth loss are rare complications of trigeminal HZ. Cases have been reported in both immunocompetent and immunocompromised Asians; the mechanism remains unknown [602‐610].

Disease associations

Emerging evidence from Taiwan and Japan suggests that patients with HZ are at increased subsequent risk of cardiovascular disease [546, 547], lymphoma [611] and other cancers [466, 612, 613], renal failure [614], SLE [615], multiple sclerosis [616], chronic fatigue syndrome [617], depression [618, 619] and erectile dysfunction [620]; however, the causality and significance of these associations remains unclear. Prevalent comorbidities such as metabolic syndrome disorders probably contribute to cardiovascular risk [547], while immunosuppression may underlie other conditions. Like HZ, kidney disease [160, 335], cancer [466, 612, 621, 622], and depression [158] are also associated with immunosuppression, and HZ may occur coincidentally either before or after these conditions manifest.

Anecdotal reports implicate VZV reactivation in rare conditions such as inappropriate secretion of antidiuretic hormone [85, 87, 623‐626], drug-induced hypersensitivity syndrome [627], mononucleosis syndrome [628], thrombocytopenia [629], and graft-versus-host disease [630].

Healthcare utilisation

As in the West, HZ-associated pain, morbidity and debility, result in heavy healthcare utilisation, especially among elderly patients, which imposes major burdens on healthcare systems and incurs substantial socio-economic costs in Asia-Pacific countries [20, 25, 30, 96, 102, 104, 136, 137, 140]. Although uncomplicated cases can usually be treated in community or outpatient settings, this usually entails several visits [20, 30, 96, 102]; Korean HZ patients averaged seven visits to a primary physician [96], and among 150 elderly Taiwanese patients, more than 80% consulted a doctor, with 20% hospitalised [20].

Hospitalisation

Throughout Asia-Pacific, HZ is consistently among the disorders that dermatologists or pain specialists treat most often, and is the most common dermatosis in patients aged 60–70 years [149, 631‐641]. Hospitalisation rates for HZ range from ~9–51/100000 PY (Table 6) [2, 7, 102, 104, 136‐138, 140, 147]; complications account for around half of admissions (Table 5) [102, 104, 136] and, therefore, hospitalisation rates likewise increase with age and are highest among elderly or immunocompromised patients [96, 102, 104, 136, 138, 140, 147, 642]. Older patients and those with complications stay longer in hospital [136, 137].

Table 6

Herpes zoster hospitalisation rates, durations and associated healthcare costs in Asia-Pacific countries

Country (source)	Study period	Age profile (years)	Hospitalisations (100000 person years)	Hospitalisation duration (days)			Healthcare costs (US$ equivalent)^c
				Overall average	Complications		Per patient		Annual total (millions)
					None	With	Outpatient	Inpatient
Taiwan (Lin 2010) [136]	2000–2005	All ages	14.6	8.3	8.0	8.6			7.7 in 2000 → 9.8 in 2004 (NT$ 319,000,000)
Taiwan (Lin 2010) [136]	2000–2005	≥80	105.1					204.0	7.7 in 2000 → 9.8 in 2004 (NT$ 319,000,000)
Taiwan (Jih 2009) [137]	2000–2006	All ages	16.1	8.3			78.4	1800.3	0.669773 (NT$ 14,147,543)
		0–20		6.06					0.669773 (NT$ 14,147,543)
		≥60	59.5% of total	9.19					59.5% of total
Korea (Cheong 2014) [96]	2009	≥50 years	88.8^d	10.93		14.75^e	176.0 (161.0–240.0^f)		63.2
Australia (Stein 2009) [104]	1998–2005	≥50 years	28.0^a	6.8^a	6.0	8.6 (5.2–14.6^b)		3922.2^a	27.5
Australia (Stein 2009) [104]	1998–2005	≥80	95.8
Thailand (Aunhachoke 2011) [30]	2007–2008	Mean 59					90.4 (by 180 days follow-up)		~1.1% per capita income
Korea (Choi WS) [140]	2003–2007	All ages	22.0–32.0						75.9 increasing by 14–20% per year to 143.8
Australia (MacIntyre 2003) [102]	1998–1999	Mean 69	25.0	12.7
		>50	53.0% of total
		≥80	>150.0
Korea (Song 2014) [25]	2009–2010	Mean 64		8.9
Korea (Kim YJ) [138]	2011	All ages	51.2
Korea (Kim YJ) [138]	2011	≥80	266.3
Australia (Carville 2010) [147]	2006–2007	All ages	9.1^a
Australia (Carville 2010) [147]	2006–2007	≥80	89.4^a
Australia (Araújo 2007) [7]	2000–2002	All ages	10.0^a
Australia (Heywood 2014) [2]	2006–2010	All ages	10.4

^aPrincipal diagnosis of herpes zoster

^bHerpes zoster encephalitis

^cValues not already stated in US$ equivalent, converted at average annual exchange rate in year prior to publication

^dBased on prevalence rate of 18.54/1000 persons

^ePost-herpetic neuralgia

^fSeverely immunocompromised

Healthcare expenditure

Accordingly, HZ-related healthcare costs also increase proportionally with patients’ age and parallel rising incidence [136, 137]. Total expenditure in Taiwan rose by 1.22-fold from US$7.7 million in 2000 to $US 9.8 million in 2004 [136], and in Korea by 20% between 2003 and 2007 (Table 6) [140]. Direct healthcare costs in Thailand are equivalent to 1.1% of annual per capita income, a similar ratio to that in developed nations [30].

HZ in the Asia-Pacific region evidently imposes very substantial burdens on both patients and the wider community, strongly supporting the case for early intervention and prevention to reduce both HZ-related morbidity and associated healthcare expenditure [20, 25, 30, 96, 102, 104, 140].

Management and prevention

Routine HZ management in Asia-Pacific is the same as elsewhere, mainly relying on antiviral and analgesic drugs to reduce the severity and duration of acute herpetic rash and pain, which may in turn decrease the risk and intensity of PHN [643, 644].

Antiviral therapies

Standard care entails aciclovir, valaciclovir, or famciclovir for 7 days [643]. These are most effective if commenced within 3 days of onset [645] but as starting later may still be beneficial, patients with HZO, who are immunocompromised, have disseminated HZ, or are at high risk for PHN, should start antiviral therapy even beyond 72 hours [643‐646]. Topical or oral aciclovir are effective in most mild-moderate HZ, including HZO [647‐651]; nevertheless aciclovir is least favoured nowadays because its lower bioavailability necessitates more frequent dosing [9, 644, 652]. Though comparative data are sparse [643, 652], Asian studies support the use of other antivirals.

A meta-analysis including data from Taiwan [653, 654] and China, found valaciclovir and famciclovir superior to aciclovir in reducing HZ-associated pain, with comparable safety [652]. Valaciclovir resolves pain significantly faster than aciclovir [31, 653‐655], while famciclovir has comparable efficacy but fewer adverse effects, and may also be more cost-effective [656, 657]. Penciclovir is also effective at lower doses than aciclovir, with better safety [658]. Specifically, aciclovir or its prodrug valaciclovir have been associated with neurotoxicity, and nephrotoxicity in East Asian patients with renal impairment [659‐669], whereas famciclovir was safe and effective in patients with renal dysfunction [670, 671]. Treating HZ keratopathy with aciclovir ointment has been reported to cause superficial punctate keratopathy [672]. Ganciclovir may be a more effective alternative [673, 674], especially in aciclovir-resistant acute retinal necrosis [675]; success with intravitreal foscarnet following acyclovir failure has also been reported [676]. Valaciclovir and famciclovir are thought to have similar efficacy [643, 677], but Japanese researchers reported significantly faster pain relief with famciclovir [678]. In Caucasians, sirovudine treated acute HZ as safely and effectively as aciclovir but with fewer recurrences [679]; however, sirovudine has potentially fatal interactions with 5-fluorouracil prodrugs, which killed 18 Japanese cancer patients [680].

Pain relief

Pain control is crucial to HZ management, not only for acute analgesia, but also because pain severity predicts PHN [9, 643, 644]. Although prompt antiviral therapy reduces acute HZ-associated pain, an updated meta-analysis concluded that aciclovir does not reduce the incidence of PHN and found insufficient evidence to evaluate the effect of other antiviral agents [681]. In practice, antiviral therapy is usually given concomitantly with corticosteroids or analgesics, according to the degree of pain.

Corticosteroids

Oral corticosteroids relieve pain, accelerate lesion healing and hasten functional recovery; however, being immunosuppressive they cannot be given without concomitant antiviral therapy. Moreover, corticosteroids should be used with caution in patients with common comorbidities such as diabetes and hypertension and do not prevent or relieve PHN [643, 645, 646]. Nevertheless, corticosteroid injections have successfully treated cases of Ramsay Hunt syndrome and refractory PHN in Chinese patients [682, 683].

Analgesia

Pain relief should start early and be intensified as necessary during acute HZ to control pain and reduce the likelihood of developing PHN, which is much harder to treat [656, 684, 685]. Pain management steps-up from first-line acetaminophen or non-steroidal anti-inflammatory drugs to opioid narcotics for moderate-to-severe pain, to which anticonvulsants, tricyclic antidepressants or corticosteroids are added if pain remains uncontrolled [646]. The same second- and third-line analgesics are used to treat PHN if topical agents prove ineffective [643, 646].

Indian physicians have reported rapid and effective pain relief with topical acetylsalicylic acid dissolved in chloroform [686]. Others confirmed the efficacy of the anticonvulsants pregabalin and gabapentin for relieving acute herpetic pain [687, 688], and found pregabalin superior to amitriptyline for PHN [684]. Compared with placebo, pregabalin relieved PHN and was also associated with decreased sleep interference and significant improvements in health-related QoL [689]. Gabapentin is another effective and well-tolerated treatment for PHN [690] and combined with morphine in another trial, reduced pain more than either agent alone [691]. Chinese investigators found oxycodone-acetaminophen effective, safe and superior to other analgesics in HZ and PHN [692‐696]. Reports from Australia, Japan, New Zealand and Taiwan have affirmed the efficacy of topical [697‐699] or injected lidocaine [700, 701]. Transdermal fentanyl was found to be more effective than tramadol, providing excellent pain relief in HZ and PHN and improving QoL, both alone [702, 703] and combined with clodine [704]. Other experimental therapies with good reported outcomes in patients from Asia-Pacific countries include: topical interferon alpha [705, 706], adenine arabinoside (vidarabine) [707, 708], povidone-iodine [709], transdermal ribavirin [710], bromovinyl deoxyuridine (brivudin) [711], intravenous prostaglandin E1 [355, 712‐715], the anticoagulant argatroban [716]; the tricyclic antidepressant milnacipran [717], human immunoglobulin [718], injected methylcobalamin [719], and botulinum toxin [720].

Nerve blockade is increasingly popular for treating intractable PHN or preventing PHN by reducing severe pain, particularly in East Asia [363, 721‐742]; ambulatory patient-controlled systems have been successful in Taiwan [743, 744]. However, the true efficacy of nerve blocks is difficult to quantify because many trials were uncontrolled [9]. Furthermore, epidural injections require utmost caution due to the potential for infection and/or life-threatening complications [745‐755]. An implanted injection port may lessen the risk of infection [756].

Neurosurgery may trigger HZ [269‐271] and though neuroablation has also been used, its efficacy is unproven and it may exacerbate PHN [757]; neuromodulation may provide an alternative but needs further investigation [758, 759].

Alternative treatment modalities

Asia-Pacific authors have contributed substantial literature on alternative HZ therapies (Additional file 1). Success has been reported with herbal decoctions, acupuncture and other traditional Chinese medicine techniques, energy-based modalities, and combination therapies. Treatments evaluated in intractable HZ and PHN, include Ganoderma lucidum [760, 761], Keishikajutsubuto and Bushi-matsu [762], bee venom [763], intravenous vitamin C [764], computed tomography-guided radiofrequency thermo-coagulation [765], spinal cord stimulation [758], ultrasound-guided pulsed radiofrequency [766], and scrambler therapy [767]. Although many studies found these alternatives superior to conventional medicine, the strength of this evidence is dubious – due to conceptual differences between traditional Asian and Western medicine, many such studies do not conform to conventional evidence-based precepts [768‐770].

Unmet treatment needs

Despite an armamentarium of potentially effective medications, current therapies have limitations and are not used to best advantage in older patients, who bear the brunt of HZ [646]. In particular, many patients start therapy too late, the optimal combination of therapies remains uncertain, antiviral agents are underprescribed [22, 645, 771], and even with prompt intervention a substantial proportion remain refractory to treatment; up to 20% of patients with PHN still have persistent neuralgia after 6 months (Table 5) [18‐20, 23, 28, 359, 771]. Aciclovir-resistant ocular VZV infections have been encountered [675, 676, 772, 773].

Given the substantial and rising burden of HZ and formidable treatment challenges facing physicians in the Asia-Pacific region, especially among elderly, immunocompromised or other high risk adults, such as those with renal disease, prevention is both rational and appealing [20, 25, 94‐96, 104, 136, 140, 144‐147, 160, 644]. Accordingly, investigators have evaluated HZ prophylaxis with antiviral drugs or vaccines.

Prevention approaches

Antiviral prophylaxis in high-risk patients

HZ is a very common complication following HSCT [170, 774]. Long-term prophylaxis with low-dose aciclovir [775‐778] or valaciclovir [779] significantly reduces the incidence of VZV reactivation and serious complications, and is recommended for the duration of immunotherapy and continuing through 1 year after HSCT [776, 778]. Such prophylaxis also prevents HZ in patients receiving bortezomib [780, 781]. Similarly, no bone marrow transplant recipients developed HZ during 3–6 months of low-dose aciclovir and ganciclovir therapy; however, rapid onset of HZ after antiviral therapy was discontinued highlighted the need for ongoing prophylaxis [782]. Immunisation against VZV may be necessary to preclude HZ in high-risk patients [776]; therefore, Asian researchers have evaluated the potential of HZ prophylaxis with varicella vaccines.

VZV immunisation

A survey of Japanese paediatricians, who might have enhanced immunity through VZV re-exposures, confirmed lower incidence of HZ than the general population, suggesting that varicella vaccine may likewise protect against HZ [319]. Also in Japan, immunisation with live varicella vaccine (Oka/BIKEN) enhanced CMI to VZV in adults age ≥50 years [783, 784], and in subjects aged 60–70 with or without diabetes [785]. A case of recurrent HZO cured by varicella vaccination was also reported [786]. In studies that evaluated live-attenuated VZV vaccine in HSCT [774, 787], Oka/RIT (Varilrix™ Glaxo-SmithKline Biologicals, Rixensart, Belgium) was safe but poorly immunogenic. A systematic review concluded that although inactivated VZV vaccine may reduce HZ severity in stem cell transplant recipients, more research was required [788]. Thus, alternative approaches to preventing HZ in such patients are probably needed [787].

During a 20-year endeavour to develop the first specific HZ vaccine, researchers reformulated Oka/Merck varicella vaccine (Varivax® Merck & Co. Inc., Whitehouse Station, NJ, USA.) to produce a higher-titre live-attenuated VZV vaccine – Zostavax® (Merck & Co. Inc.) [10, 789]. In the culminating Shingles Prevention Study (SPS), Zostavax® immunisation reduced the incidence of HZ among adults ≥60 years old by 51%, PHN by 67% and the HZ-related burden of illness by 61%, as well as improving QoL and performance of daily activities in subjects who developed HZ [95]. The US Food and Drug Administration licenced Zostavax® in 2006 [644]; it was also approved by the European Medicines Agency [96] and subsequently by authorities in Australia [644] New Zealand [652], Korea [790, 791], Malaysia [792], and other Asian countries [793‐796]. The US Centers for Disease Control and Prevention Advisory Committee on Immunization Practices (ACIP), recommends routine vaccination for all non-contraindicated persons age ≥60 years; importantly though, Zostavax® is not indicated to treat extant HZ or PHN [10]. An independent review of SPS concluded that there is insufficient proof that Zostavax® prevents PHN beyond reducing the incidence of HZ. Further, since SPS patients were predominantly Caucasian, its findings might not apply to other races [797].

Zostavax® in Asia-Pacific

Production shortfalls of Zostavax® after initial licensure restricted its supply [1, 2]. Though since resolved, this issue affected vaccine availability and uptake in Asia-Pacific countries [2]. For example, 2011 vaccination rates among Australian inpatients in 2011 were 34% for HZ, compared with 52% for pneumococcal vaccine and 64% for influenza [798]. This explains the scarcity of Asian data on Zostavax®. One pilot study of 21 healthy adults ≥30 years old, including eight Filipinos, found Zostavax® to be immunogenic and generally well-tolerated [799].

Cost-effectiveness

The substantial economic burden of HZ includes direct healthcare costs as well as indirect costs of disability and lost productivity [10, 30, 140]. US and European researchers have modelled the pharmaco-economics of HZ vaccination. US estimates of cost per quality-adjusted life-years gained (QALY), varied widely depending on the assumptions used. Routine immunisation at age 70 or 60 cost US$ 37000 and US$ 86000 respectively, within the range of standard thresholds, whereas the estimated cost of US$ 287000 at age 50 was deemed too high [800]. Analyses in European countries predicted that vaccinating adults above the ages of 50, 60, 65 or aged 70–79 would be cost-effective, with high likelihood of not exceeding accepted thresholds of £ 30000 in the United Kingdom or € 30000 in Belgium [801]. A systematic review of 11 US and European studies concluded that vaccination at age 65–70 would probably be cost-effective in terms of QALYs gained, assuming it confers more than 10–15 years’ protection against PHN [802]; however, cost-effectiveness data from high-income countries may not apply worldwide, because healthcare provision and costs differ considerably between nations [801, 802]. Although high and rising healthcare costs of treating HZ documented in several Asia-Pacific countries [30, 104, 136, 137, 140] suggest that it would probably be no less cost-effective to immunise elders from this region than others, specific pharmacoeconomic data are lacking [790, 802]; such analyses are needed urgently to resolve current uncertainties and inform evidence-based decision-making by healthcare funders and providers.

HZ immunisation guidelines and recommendations

Given the potential for HZ immunisation to efficaciously and safely reduce the associated burden of illness [10], as well as cost-effectiveness considerations, organisations in several Asia-Pacific countries have incorporated HZ vaccination into adult immunisation schedules (Table 7) [2, 5, 8, 642, 791‐796]. Neither Japan nor Singapore has such guidelines and The Association of Physicians of India does not recommend HZ immunisation, due to lack of national epidemiology data [803].

Table 7

Asia-Pacific guidelines for immunisation against herpes zoster

Country	Title	Issuing organisation		Year (last update)	Age thresholds
Country	Title	Name	Status	Year (last update)	Routine	Optional
Australia [8]	The Australian Immunisation Handbook	Technical Advisory Group on Immunisation	Government	2015	60–79
Australia & New Zealand [5]	Immunisation of Older People	Australia & New Zealand Society for Geriatric Medicine	Society	2011	≥60
India [803]	Medicine Update. Adult Immunization	Association of Physicians of India	Society	2013	No recommendation^a
Indonesia [793]	Adult Immunization Schedule	Specialist Doctors Association of Indonesia	Society	2014	≥50
Malaysia [792]	Position Statement on Vaccination Against the Herpes Zoster Virus in Older Adults	Malaysian Society of Geriatric Medicine	Society	2014	60–79	50–59
New Zealand [642]	Immunisation Handbook	New Zealand Ministry of Health	Government	2016	>50
Philippines [794]	Handbook on Adult Immunization for Filipinos	Philippine Society for Microbiology and Infectious Diseases	Society	2012	≥60
South Korea [791]	Recommended Immunization Schedule for Adults in Korea	Korean Society of Infectious Diseases	Society	2012	>65	50–59
Taiwan [796]	Clinical Handbook for Adult Immunization	Taiwan Association of Family Medicine	Society	2010	≥60
Thailand [795]	Recommended Adult and Elderly Immunization Schedule	Thailand Royal College of Physicians	Society	2014	≥60

^aThe Association of Physicians of India does not recommend herpes zoster vaccine for adults, due to lack of reliable data on the epidemiology and burden of herpes zoster in India

Most HZ immunisation guidelines are published by professional societies, with only Australia and New Zealand having government-issued guidelines [8, 642]. Since Asian epidemiological and clinical data are sparse, local guidelines generally follow the ACIP [10], with very similar recommendations for indicated and non-licenced uses, administration, and precautions or contraindications (Table 8). Like ACIP, most Asia-Pacific guidelines recommend routine immunisation from age 60; however, some age thresholds vary. The New Zealand Ministry of Health and Indonesia Specialist Doctors Association both recommend immunisation from age 50 [642, 793], though this is not state funded. The Korean Society of Infectious Diseases recommends routine vaccination above age 65 [791], with vaccination from age 50 at patients’ own discretion. Similarly, The Australian Department of Health [8] and the Malaysian Society of Geriatric Medicine [792] do not recommend routine vaccination for persons aged 50–59, but sanction this as a personal option, with the caveats that the duration of protection remains undetermined. However, the Malaysian Society of Geriatric Medicine does not recommend vaccinating patients older than 80, due to lack of efficacy, and the Australian guidelines likewise note that vaccination may confer less clinical benefit in this age group [8]. The New Zealand guidelines [642] uniquely specify active untreated tuberculosis as a contraindication and the Australian guidelines are alone in indicating vaccination of persons from age 50 who are household contacts of immunocompromised individuals [8]. Based on evidence that co-administering Zostavax® with pneumococcal polysaccharide vaccine may reduce its immunogenicity compared with administration 4 weeks apart [804], the Australian and New Zealand Society for Geriatric Medicine recommended against giving these vaccines concomitantly [5]; however, a later study suggested that this may not compromise Zostavax® effectiveness [8, 805], and the Australian 2015 guidelines recommend that Zostavax® can be given at the same time as pneumococcal polysaccharide vaccine, using separate syringes and injection sites [8].

Table 8

Concordance between herpes zoster immunisation recommendations from US ACIP and Asia-Pacific countries

Indications and administration	• Routine immunisation with one dose of HZ vaccine for all persons age ≥60: – With or without prior HZ – With chronic medical conditions (eg, chronic kidney disease, diabetes, rheumatoid arthritis, lung disease), except those listed as contraindications or precautions • HZ vaccine can be co-administered with other indicated adult vaccines, eg, influenza
Unlicensed categories/ purposes	• Persons immunised with varicella zoster vaccine • Persons younger than the minimum recommended or optional age threshold • HZ vaccine is not to be used to treat existing HZ or its complications
Precautions	• Moderate/severe acute illness • Anticipated immunosuppression • Anti-herpetic pharmacotherapy
Contraindications	• Hypersensitivity to vaccine components • Morbid or medical immunosuppression or immunodeficiency: – HIV/AIDS – Transplant recipients – Systemic immunosuppressive therapy (including high-dose steroids and recombinant immune modulators • Pregnancy

HZ Herpes zoster, US ACIP United States Centers for Disease Control and Prevention Advisory Committee on Immunization Practices, HIV/AIDS human immunodeficiency virus/acquired immunodeficiency syndrome

Discussion

Ours is the most comprehensive audit yet of HZ in the Asia-Pacific region. We have reviewed almost every available paper published on the subject over 21 years since 1994 in 14 countries whose populations constitute the majority of not only Asians, but indeed the global population. The information collated provides a valuable resource and reference by which to gauge future progress.

Knowledge and data gaps

Contrary to a preconception that there may be a dearth of Asian data, we discovered a wealth of evidence on all aspects of HZ. However, our review does affirm that Asian data are patchy; in particular, there is very little information from South-East Asian populations numbering hundreds of millions, which probably reflects pragmatic healthcare imperatives in resource-limited settings [3]. Limiting the scope of the survey to 21 years may have missed epidemiology data published prior to 1994. The review may have excluded some relevant articles which did not specify that VZV infection was reactivated. It is also possible that some articles with no country affiliation field in the databases searched may have been overlooked; however, searching several databases reduced this possibility. Epidemiology data from Indonesia, Malaysia, the Philippines, and Vietnam are needed to provide a more balanced picture. There are also limited Asian data on the safety and efficacy of the HZ vaccine and, in particular, its cost-effectiveness [137, 140, 790, 802].

Conclusions

Data gaps notwithstanding, there is compelling evidence to conclude that the epidemiology and risk factors for HZ in the Asia-Pacific region are not remarkably different from those in Western populations [7]. However, with a vastly larger absolute aged population, Asia bears a unique burden of HZ. The estimated number of Asians¹ age >60 in 2015 is 489,397,421, which by 2035 will nearly double to 924,520,454 [806]. Assuming an annual incidence of HZ in unvaccinated individuals of approximately 12/1000 person-years [136, 137], this equates to approximately 16089 new HZ cases daily in 2015 and 30395 in 2035, more than half of which might be prevented by HZ immunisation. Data affirming rising incidence of HZ in countries across Asia-Pacific bear out these projections. Consequently, HZ in the Asia-Pacific region exacts huge and increasing tolls of morbidity, debility and diminished life quality that incur significant healthcare expenditure and indirect socioeconomic costs [20, 25, 30, 96, 104, 136, 137, 140].

This review also highlights that HZ is uniquely complex among infectious diseases, often complicated and defies disciplinary boundaries. Despite a plethora of conventional and alternative treatments, none is singularly effective [25]; current approaches can go only so far to alleviating the disease burden, especially among the elderly who constitute most patients, and then at considerable expense [95]. Thus, the rationale for prevention is very strong [20, 102, 145]. Yet although a specific HZ vaccine is available and recommended by immunisation guidelines in many countries, it remains underused. This typifies how preventive healthcare for the elderly continues to be neglected in Asia, despite repeated calls to make this a higher public health priority [3, 4, 6]. It is more urgent now than ever to address this situation.

Call to action

We look forward to being able to report in future that advances in preventive healthcare have alleviated the growing burden of HZ in the Asia-Pacific region. This audit is just a beginning – realising this ambition will be impossible without redoubled efforts by the medical fraternity, healthcare authorities and all other stakeholders to change prevailing mindsets and afford higher priority to adult immunisation in general and HZ in particular. We urge all concerned to heed this call to action.

Acknowledgements

MSD funded preparation of the manuscript, but had no role in designing the study, data collection or analysis, drafting or approving the manuscript, or the decision to submit for publication. The authors thank Dr. David Neil (PhD), of Content Ed Net (Taiwan) for providing professional medical writing services, which were remunerated by Merck Sharp & Dohme (I.A.) Corp, Taiwan.

Funding

The authors received no specific research funding for the work described in this manuscript.

Availability of data and materials

All supporting data are either contained within the manuscript or were excerpted from the sources cited, and can be shared upon request.

Authors’ contributions

LKC conceived and coordinated the study, acquired and interpreted data, and revised manuscript drafts for important intellectual content. HA, LYC, SD, BD, TK, XL, DM, JYP, PJHP, SR, TT, and CWW, refined the review protocol, provided and/or reviewed or interpreted data, and revised manuscript drafts for important intellectual content. MYC, KTK, HNL, EMFL, CKL, LNP, and ERSP, contributed to refining the review protocol, and reviewed data and manuscript drafts. All authors read and approved the final manuscript.

Competing interests

The authors are members of The Asia-Pacific Working Group for Herpes Zoster, which is supported financially by Merck Sharp & Dohme (I.A.) Corp. (MSD), Taiwan, and received honoraria for consultancy services in this capacity. The authors declare no other competing interests besides membership of this MSD Advisory Board.

Not applicable.

Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.

Additional file

Additional file 1: Appendix 1. Alternative approaches to treating herpes zoster and herpetic neuralgia. (PDF 340 kb)

Afghanistan, Bangladesh, Bhutan, Brunei, Burma, Cambodia, China, Hong Kong, India, Indonesia, Iran, Japan, Laos, Macau, Malaysia, Maldives, Mongolia, Nepal, North Korea, Pakistan, Philippines, Singapore, South Korea, Sri Lanka, Taiwan, Thailand, Timor-Leste, Vietnam.

Harpaz R, Hales CM, Bialek S. Update on herpes zoster vaccine: licensure for persons aged 50 through 59 years. MMWR Morb Mortal Wkly Rep. 2011;60:1528.

Heywood AE, Wang H, Macartney KK, McIntyre P. Varicella and herpes zoster hospitalizations before and after implementation of one-dose varicella vaccination in Australia: an ecological study. Bull World Health Organ. 2014;92:593–604.

Isahak I. Steering Committee for Prevention and Control of Infectious Diseases in Asia. Adult immunization—a neglected issue in Southeast Asia. Southeast Asian J Trop Med Public Health. 2000;31:173–84.

Verma R, Khanna P, Chawla S. Vaccines for the elderly need to be introduced into the immunization program in India. Hum Vaccin Immunother. 2014;10:2468–70.

Woodward M. Immunisation of older people. J Pharm Pract Res. 2012;42:316–22.

Wong SY. Adult vaccination update 2014. The Singapore Fam Physician. 2014;40:27–32.

Araújo LQ, MacIntyre CR, Vujacich C. Epidemiology and burden of herpes zoster and post-herpetic neuralgia in Australia, Asia and South America. Herpes. 2007;14(Suppl 2):40–4.

Australian Technical Advisory Group on Immunisation. The Australian Immunisation Handbook. 10th ed (updated June 2015). Canberra: Australian Government Department of Health. 2015. http://www.health.gov.au/internet/immunise/publishing.nsf/content/7B28E87511E08905CA257D4D001DB1F8/$File/Aus-Imm-Handbook.pdf. Accessed 17 Jan 2017.

Thomas J. Herpes zoster: Complications and management. J Pak Assoc Dermatol. 2004;14:237–43.

10.

Harpaz R, Ortega-Saznchez IR, Seward JF. Centers for Disease Control and Prevention (CDC). Prevention of herpes zoster: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep. 2008;57(RR-5):1–30.PubMed

11.

Kim YM, Lee SY, Lee JS, Park YL, Whang KU, Cho MK, et al. Epidemiological and clinical study on herpes zoster in the Province of Chungcheongnam-do (2004–2006). Korean J Dermatol. 2008;46:1488–94.

12.

Abdul Latheef EN, Pavithran K. Herpes zoster: a clinical study in 205 patients. Indian J Dermatol. 2011;56:529–32.PubMedPubMedCentralCrossRef

13.

Shukuwa T, Chen WY, Kobayashi A. Statistical analysis of herpes zoster observed at Sasebo City General Hospital. Nishinihon J Dermatol. 2002;64:477–82.CrossRef

14.

Naveen KN, Tophakane RS, Hanumanthayya K, Pv B, Pai VV. A study of HIV seropositivity with various clinical manifestation of herpes zoster among patients from Karnataka, India. Dermatol Online J. 2011;17:3.PubMed

15.

Jara MFA, Roa FC. The clinical presentation of herpes zoster patients and predictors of postherpetic neuralgia: A 5-year retrospective study at the section of dermatology, University of the Philippines - Philippine General Hospital. J Phil Dermatol Soc. 2010;19:8–12.

16.

Leung AYH, Yuen KY, Cheng VCC, Lie AKW, Liang R, Kwong YL. Clinical characteristics of and risk factors for herpes zoster after hematopoietic stem cell transplantation. Haematologica. 2002;87:444–6.PubMed

17.

Reid JS, Ah WB. Herpes zoster (shingles) at a large New Zealand general practice: incidence over 5 years. N Z Med J. 2014;127:56–60.PubMed

18.

Goh CL, Khoo L. A retrospective study of the clinical presentation and outcome of herpes zoster in a tertiary dermatology outpatient referral clinic. Int J Dermatol. 1997;36:667–72.PubMedCrossRef

19.

Song JY, Chung BS, Choi KC, Shin BS. A 5-year period clinical observation on herpes zoster and the incidence of postherpetic neuralgia (2002–2006); a comparative analysis with the historical control group of a previous study (1995–1999). Korean J Dermatol. 2008;46:431–6.

20.

Tsai TF, Yao CA, Yu HS, Lan CC, Chao SC, Yang JH, et al. Herpes zoster-associated severity and duration of pain, health-related quality of life, and healthcare utilization in Taiwan: a prospective observational study. Int J Dermatol. 2015;54:529–36.PubMedCrossRef

21.

Song T. Statistical analysis of 522 cases of patient with herpes-zoster. Med J Wuhan Univ. 2002;23:379–82.

22.

Wallis KA, Hood LJ, Rao K. Herpes zoster: when do patients present and who gets antiviral treatment? J Prim Health Care. 2014;6:108–13.PubMed

23.

Kurokawa I, Kumano K, Murakawa K. Clinical correlates of prolonged pain in Japanese patients with acute herpes zoster. J Int Med Res. 2002;30:56–65.PubMedCrossRef

24.

Kang CI, Choi CM, Hong SS, Kim HB, Kim NJ, Oh MD, et al. The incidence of herpes zoster in otherwise healthy young soldiers of Korean army. Infect Chemother. 2006;38:45–6.

25.

Song H, Lee J, Lee M, Choi WS, Choi JH, Lee MS, et al. Burden of illness, quality of life, and healthcare utilization among patients with herpes zoster in South Korea: a prospective clinical-epidemiological study. Int J Infect Dis. 2014;20:23–30.PubMedCrossRef

26.

Park SY, Kim JY, Kim CD, Kim CW, Lee KS. A clinical study on herpes zoster during the last 10-year-period (1994–2003). Korean J Dermatol. 2004;42:1531–5.

27.

Das AL, Sayal SK, Gupta CM, Chatterjee M. Herpes zoster in patients with HIV infection. Indian J Dermatol Venereol Leprol. 1997;63:101–4.PubMed

28.

Kurokawa I, Murakawa K, Kumano K. The change in zoster-associated pain treated with oral valaciclovir in immunocompetent patients with acute herpes zoster. Int J Clin Pract. 2007;61:1223–9.PubMedCrossRef

29.

Sawhney MPS, Sharma YK, Sayal SK. Mode of detection of HIV infection - A retrospective study of 612 cases. Med J Armed Forces India. 2005;61:220–3.PubMedPubMedCentralCrossRef

30.

Aunhachoke K, Bussaratid V, Chirachanakul P, Chua-Intra B, Dhitavat J, Jaisathaporn K, et al. Measuring herpes zoster, zoster-associated pain, post-herpetic neuralgia-associated loss of quality of life, and healthcare utilization and costs in Thailand. Int J Dermatol. 2011;50:428–35.PubMedCrossRef

31.

Achar A, Chakraborty PP, Ghosh T, Naskar B, Guharay T, Bisai S. Clinical efficacy and tolerability of valacyclovir versus acyclovir in treatment of herpes zoster. Iran J Dermatol. 2011;14:52–7.

32.

Kim CG, Na CH, Choi KC, Shin BS. A comparative study of the clinical findings associated with herpes zoster and according to age. Korean J Dermatol. 2009;47:1338–44.

33.

Kim HJ, Sung HC, Kim DW, Lee WJ, Lee SJ, Na GY. Clinical features of herpes zoster according to immune state. Korean J Dermatol. 2006;44:149–56.

34.

Cockburn DM, Douglas IS. Herpes zoster opthalmicus. Clin Exp Optom. 2000;83:59–64.PubMedCrossRef

35.

Naveen KN, Pradeep AV, Kumar JS, Hegde SP, Pai VV, Athanikar SB. Herpes zoster affecting all three divisions of trigeminal nerve in an immunocompetent male: a rare presentation. Indian J Dermatol. 2014;59:423.

36.

Sangeeta N, Robindro Singh W, Brajach SO. Herpes zoster in a healthy adult: Report of a case with oro-cutaneous presentations. JMS J Med Soc. 2011;25:99–101.

37.

Watanabe K, Funaki M. Images in clinical medicine: Zoster of the tympanic membrane. N Engl J Med. 2011;365:e40.PubMedCrossRef

38.

Hong SB, Lee JW, Chang SG, Lee MH, Haw CR. Herpes zoster of the penis. Korean J Urol. 2005;46:1001–3.

39.

Gopalan V, Nair RG, Pillai S, Oberholzer T. Genital herpes zoster as a consequence of cancer chemotherapy-induced immunosuppression: report of a case. J Infect Chemother. 2012;18:955–7.PubMedCrossRef

40.

Watanabe D, Kuhara T, Ishida N, Takama H, Tamada Y, Matsumoto Y. Herpes zoster of the nipple: rapid DNA-based diagnosis by the loop-mediated isothermal amplification method. Int J STD AIDS. 2010;21:66–7.PubMedCrossRef

41.

Izu K, Yamamoto O, Yasumoto S, Hashimoto T, Sata T, Tokura Y. Herpes zoster occurring as a solitary nodule on the index finger. Br J Dermatol. 2004;150:365–6.PubMedCrossRef

42.

Chen WH, Li TH, Lee LH, Huang CC. Varicella-zoster virus infection and nummular headache: a possible association with epicranial neuralgia. Intern Med. 2012;51:2439–41.PubMedCrossRef

43.

Hon C, Au WY, Cheng VC. Ophthalmic zoster sine herpete presenting as oculomotor palsy after marrow transplantation for acute myeloid leukemia. Haematologica. 2005;90 Suppl 12:EIM04.PubMed

44.

Kim YH, Choi IJ, Kim HM, Ban JH, Cho CH, Ahn JH. Bilateral simultaneous facial nerve palsy: clinical analysis in seven cases. Otol Neurotol. 2008;29:397–400.PubMedCrossRef

45.

Furuta Y, Fukuda S, Suzuki S, Takasu T, Inuyama Y, Nagashima K. Detection of varicella-zoster virus DNA in patients with acute peripheral facial palsy by the polymerase chain reaction, and its use for early diagnosis of zoster sine herpete. J Med Virol. 1997;52:316–9.PubMedCrossRef

46.

Fujiwara K, Furuta Y, Fukuda S. A case of associated laryngeal paralysis caused by varicella zoster virus without eruption. Case Rep Med. 2014;2014:916265.PubMedPubMedCentral

47.

Powell KF, Wilson HG, Croxson MC, Marshall MR, Wong EH, Anderson NE, et al. Herpes zoster meningoencephalitis without rash: Varicella zoster virus DNA in CSF. J Neurol Neurosurg Psychiatry. 1995;59:198–9.PubMedPubMedCentralCrossRef

48.

Chen MJ, Chen KH, Chung YM, Li AF, Chou CK, Hsu WM. Detection of varicella-zoster virus DNA in the iris of a zoster sine herpete patient. Int J Biomed Sci. 2006;2:302–4.PubMedPubMedCentral

49.

Lo CH, Chiang CP. Herpes zoster duplex bilateralis. Intern Med. 2013;52:2841.PubMedCrossRef

50.

Shin JW, Kim DH, Whang KU, Lee J, Park Y, Cho MK, et al. A case of zoster duplex bilateralis. Ann Dermatol. 2009;21:423–5.PubMedPubMedCentralCrossRef

51.

Mabuchi T, Yamaoka H, Kato M, Ikoma N, Tamiya S, Song HJ, et al. Case of disseminated vesicles of herpes zoster developing one day before the onset of local eruption in a hospitalized immunocompromised patient. Tokai J Exp Clin Med. 2013;38:52–4.PubMed

52.

Kim H, Kang JN, Seol JE, Seo JK, Sung HS. Epidemiology and clinical features of disseminated herpes zoster. Korean J Dermatol. 2013;51:507–12.

53.

Qi X-L, Li C-X, Gao T-W. Herpes zoster generalisatus caused by long-term treatment of cyclosporin: A case report. J Clin Dermatol. 2006;35:313–14.

54.

Park S-H, Lee SY, Yi JH, Choi HS, Yun SK, Kim HU, Ihm CW. A case of herpes zoster duplex unilateralis with herpes zoster generalisatus. Korean J Dermatol. 2005;43:1579–81.

55.

Takaoka Y, Miyachi Y, Yoshikawa Y, Tanioka M, Fujisawa A, Endo Y. Bilateral disseminated herpes zoster in an immunocompetent host. Dermatol Online J. 2013;19:13.PubMed

56.

Gupta LK, Kuldeep CM, Mittal A, Singhal H. Multidermatomal herpes zoster in an immunocompetent female. Indian J Dermatol Venereol Leprol. 2005;71:210–11.PubMedCrossRef

57.

Sun ZH, Guo YY, Li M, Yao ZR. Disseminated herpes zoster in immunocompetent patients not due to varicella-zoster virus gene mutation. Chin Med J. 2013;126:3193.PubMed

58.

Mittal RR. Disseminated herpes zoster. Indian J Dermatol Venereol Leprol. 1995;61:148–9.PubMed

59.

Gahalaut P, Chauhan S. Herpes zoster duplex bilateralis in an immunocompetent host. Indian Dermatol Online J. 2012;3:31–3.PubMedPubMedCentralCrossRef

60.

Lee H, Jung HJ, Park MY, Ann JY. Herpes zoster duplex symmetricus in a healthy patient. Korean J Dermatol. 2011;49:1098–101.

61.

Tsai YC, Tsai TF. Herpes zoster duplex bilateralis symmetricus. Dermatol Sin. 2015;33:37–8.CrossRef

62.

Yoon KJ, Kim SH, Lee EH, Choi JH. Disseminated herpes zoster in an immunocompetent elderly patient. Korean J Pain. 2013;26:195–8.PubMedPubMedCentralCrossRef

63.

Brar BK, Gupta RR, Saghni SS. Bilateral herpes - zoster of widely separated dermatomes in a non-immunocompromised female. Indian J Dermatol Venereol Leprol. 2002;68:48–9.PubMed

64.

Agrawal S, Aara N, Bumb R. Herpes zoster duplex bilateralis symmetricus in an immunocompetent subject. Int J Dermatol. 2014;53:e281–2.PubMedCrossRef

65.

Oh KH, Ahn C, Kim YS, Han JS, Kim S, Lee JS, et al. Atypical generalized zoster with suspicious esophageal involvement and early relapse in an adult renal transplant recepient. Transplant Proc. 2002;34:1174–7.PubMedCrossRef

66.

Tan HH, Goh CL. Viral infections affecting the skin in organ transplant recipients: epidemiology and current management strategies. Am J Clin Dermatol. 2006;7:13–29.PubMedCrossRef

67.

Kui YP, Hye IL, Ji YK, Kap SL, Seong JS, Chang KH. A case of herpes zoster multiplex in five disparate dermatomes. Korean J Dermatol. 2008;46:973–6.

68.

Yoo KH, Park JH, Kim BJ, Kim MN, Song KY. Herpes zoster duplex bilateralis in a patient with breast cancer. Cancer Res Treat. 2009;41:50–2.PubMedPubMedCentralCrossRef

69.

Ko DH, Park SY, Yoon TJ. A case of bilateral recurrent herpes zoster in multiple myeloma. Korean J Dermatol. 2006;44:1460–3.

70.

Teranishi H, Sakiyama M, Nagatoshi Y, Nomura Y, Inagaki J, Yanai F, et al. Acute lymphoblastic leukemia complicated with varicella zoster virus meningoencephalitis and visceral dissemination after related bone marrow transplantation. Rinsho Ketsueki. 2011;52:287–92.PubMed

71.

Endoh K, Kawai N, Itoh K, Tominaga K, Kusumoto S, Fukuda M, et al. An autopsy case of non-Hodgkin's lymphoma complicated by fulminant infiltration by disseminated herpes zoster. Jpn J Chemother. 2000;48:75–8.

72.

Ryu DJ, Jung JY, Lee S, Lee JH. A case of herpes zoster duplex bilateralis, a diagnostic clue of human immunodeficiency virus infection. Korean J Dermatol. 2010;48:339–41.

73.

Rajashekar TS, Singh G, Shivakumar V, Okade R. Recurrent herpes zoster duplex symmetricus in HIV infection. Indian J Dermatol. 2008;53:33–4.PubMedPubMedCentralCrossRef

74.

Sundriyal D, Kapoor R, Kumar N, Walia M. Multidermatomal herpes zoster. BMJ Case Rep. 2014. doi:10.1136/bcr-2014-205024.

75.

Zhang B, Zhao HX, Lun WH, Sun N, Yang D, Liang HY, et al. Generalized varicella-zoster virus infection: A case report. J Clin Dermatol. 2013;42:595–7.

76.

Chacko S, John TJ, Babu PG, Jacob M, Kaur A, Mathai D. Clinical profile of AIDS in India: a review of 61 cases. J Assoc Physicians India. 1995;43:535–8.PubMed

77.

Higashitake I, Higaki T, Souda N, Yamada H. Recurrent herpes zoster seen in the patient of human immunodeficiency virus infection. Skin Res. 2004;3:216–9.

78.

Kar HK, Gautam RK, Jain RK, Puri P, Doda V. Disseminated cutaneous herpes zoster: A clinical predictor of human immunodeficiency virus infection. Indian J Dermatol Venereol Leprol. 1995;61:40–1.PubMed

79.

Shin BS, Na CH, Song IG, Choi KC. A case of human immunodeficiency virus infection initially presented with disseminated herpes zoster. Ann Dermatol. 2010;22:199–202.PubMedPubMedCentralCrossRef

80.

Kim WJ, Park JW, Shin DH, Choi JS, Kim KH. A case of human immunodeficiency virus infection in recurrent herpes zoster. Korean J Dermatol. 2005;43:271–3.

81.

Kim MS, Choi H, Na CH, Shin BS. A 5-year period clinical study of 16 cases with disseminated herpes zoster (2008–2012). Korean J Dermatol. 2013;51:322–8.

82.

Doki N, Miyawaki S, Tanaka M, Kudo D, Wake A, Oshima K, et al. Visceral varicella zoster virus infection after allogeneic stem cell transplantation. Transpl Infect Dis. 2013;15:314–8.PubMedCrossRef

83.

Saitoh H, Takahashi N, Nanjo H, Kawabata Y, Hirokawa M, Sawada K. Varicella-zoster virus-associated fulminant hepatitis following allogeneic hematopoietic stem cell transplantation for multiple myeloma. Intern Med. 2013;52:1727–30.PubMedCrossRef

84.

Ni XS, Ouyang J, Zhu WH, Wang C, Chen B. Autologous hematopoietic stem cell transplantation for progressive multiple sclerosis: report of efficacy and safety at three yr of follow up in 21 patients. Clin Transplant. 2006;20:485–9.PubMedCrossRef

85.

Ohara F, Kobayashi Y, Akabane D, Maruyama D, Tanimoto K, Kim SW, et al. Abdominal pain and syndrome of inappropriate antidiuretic hormone secretion as a manifestation of visceral varicella zoster virus infection in a patient with non-Hodgkin's lymphoma. Am J Hematol. 2007;82:416.PubMedCrossRef

86.

Yakushijin Y, Minamoto Y, Takada K, Otsuka M, Yasukawa M, Fujita S. A case of fatal varicella zoster infection with refractory abdominal pain as an early symptom. Kansenshogaku Zasshi. 2004;78:64–9.PubMedCrossRef

87.

Au WY, Ma SY, Cheng VC, Ooi CG, Lie AK. Disseminated zoster, hyponatraemia, severe abdominal pain and leukaemia relapse: recognition of a new clinical quartet after bone marrow transplantation. Br J Dermatol. 2003;149:862–5.PubMedCrossRef

88.

Kurtovic J, Webster GJM, Singh-Grewal I, Bullpitt P, Haindl W, Wakefield D, et al. Acalculous cholecystitis, multifocal gastrointestinal infarction and pancreatitis resulting from Varicella-zoster virus. Intern Med J. 2005;35:69–70.PubMedCrossRef

89.

Wang Z, Ye J, Han YH. Acute pancreatitis associated with herpes zoster: Case report and literature review. World J Gastroenterol. 2014;20:18053–6.PubMedPubMedCentral

90.

Okimura H, Muto M, Ichimiya M, Mogami S, Takahata H, Asagami C. A case of herpes zoster associated with colitis. J Dermatol. 1996;23:631–4.PubMedCrossRef

91.

Ching DW. Severe, disseminated, life threatening herpes zoster infection in a patient with rheumatoid arthritis treated with methotrexate. Ann Rheum Dis. 1995;54:155.PubMedPubMedCentralCrossRef

92.

Hashizume H, Umayahara T. Acute respiratory distress syndrome due to varicella zoster virus pneumonitis in an immunocompromised patient with herpes zoster. J Dermatol. 2013;40:1064–5.PubMedCrossRef

93.

Nakamura M, Kanazawa M, Yamaguchi K, Akizuki M, Satoh S, Inada S. Pneumonia caused by varicella-zoster virus in a patient with rheumatoid arthritis. Nihon Kyobu Shikkan Gakkai Zasshi. 1996;34:610–5.PubMed

94.

Miyazaki T, Tanabe Y, Iseki M. Treatment and recent topics of postherpetic neuralgia. Japan Med Assoc J. 2005;48:505–10.

95.

Sanford M, Keating GM. Zoster vaccine (Zostavax): a review of its use in preventing herpes zoster and postherpetic neuralgia in older adults. Drugs Aging. 2010;27:159–76.PubMedCrossRef

96.

Cheong C, Lee TJ. Prevalence and healthcare utilization of herpes zoster and postherpetic neuralgia in South Korea: disparity among patients with different immune statuses. Epidemiol Health. 2014;36:e2014012.PubMedPubMedCentralCrossRef

97.

Higa K, Mori M, Hirata K, Hori K, Manabe H, Dan K. Severity of skin lesions of herpes zoster at the worst phase rather than age and involved region most influences the duration of acute herpetic pain. Pain. 1997;69:245–53.PubMedCrossRef

98.

Sagong C, Yeo KY, Kim JS, Yu HJ, Kim DH. The relationship among pain, depression, and anxiety in patients with herpes zoster. Korean J Dermatol. 2009;47:403–10.

99.

Decroix J, Partsch H, Gonzalez R, Mobacken H, Goh CL, Walsh JB, et al. Factors influencing pain outcome in herpes zoster: An observational study with valaciclovir. J Eur Acad Dermatol Venereol. 2000;14:23–33.PubMedCrossRef

100.

Noh TW, Park HJ, Kim SH, Kang YS, Lee UH, Park HS. A clinical study of herpes zoster focused on the characteristics of pruritus in herpes zoster. Korean J Dermatol. 2012;50:591–8.

101.

Chant KG, Sullivan EA, Burgess MA, Ferson MJ, Forrest JM, Baird LM, et al. Varicella-zoster virus infection in Australia. Aust N Z J Public Health. 1998;22:413–8.PubMedCrossRef

102.

MacIntyre CR, Chu CP, Burgess MA. Use of hospitalization and pharmaceutical prescribing data to compare the prevaccination burden of varicella and herpes zoster in Australia. Epidemiol Infect. 2003;131:675–82.PubMedPubMedCentralCrossRef

103.

Lee BW. Review of varicella zoster seroepidemiology in India and Southeast Asia. Trop Med Int Health. 1998;3:886–90.PubMedCrossRef

104.

Stein AN, Britt H, Harrison C, Conway EL, Cunningham A, Macintyre CR. Herpes zoster burden of illness and health care resource utilisation in the Australian population aged 50 years and older. Vaccine. 2009;27:520–9.PubMedCrossRef

105.

Dashraath P, Ong ES, Lee VJ. Seroepidemiology of varicella and the reliability of a self-reported history of varicella infection in Singapore military recruits. Ann Acad Med Singapore. 2007;36:636–41.PubMed

106.

Chow VTK. Rapid detection of varicella-zoster viral antibodies by latex agglutination assay: A practical experience for medical and science undergraduates. Biochem Educ. 1998;26:248–51.CrossRef

107.

Fatha N, Ang LW, Goh KT. Changing seroprevalence of varicella zoster virus infection in a tropical city state, Singapore. Int J Infect Dis. 2014;22:73–7.PubMedCrossRef

108.

Juffrie M, Graham RR, Tan RI, Widjaja S, Mulyadi S, Weil J, et al. Seroprevalence of hepatitis A virus and varicella zoster antibodies in a Javanese community (Yogyakarta, Indonesia). Southeast Asian J Trop Med Public Health. 2000;31:21–4.PubMed

109.

Sam IC, Tariman H, Chan YF, Bador MK, Yusof MY, Hassan H. Varicella-zoster virus seroprevalence in healthcare workers in Kuala Lumpur, Malaysia. Med J Malaysia. 2008;63:429–30.PubMed

110.

Barzaga NG, Roxas JR, Florese RH. Varicella zoster virus prevalence in Metro Manila, Philippines. J Am Med Assoc (SE Asia). 1994;274(Suppl):S633–35.

111.

Lokeshwar MR, Agrawal A, Subbarao SD, Chakraborty MS, Ram Prasad AV, Weil J, et al. Age related seroprevalence of antibodies to varicella in India. Indian Pediatr. 2000;37:714–9.PubMed

112.

Migasena S, Simasathien S, Desakorn V, Phonrat B, Suntharasamai P, Pitisuttitham P, et al. Seroprevalence of varicella-zoster virus antibody in Thailand. Int J Infect Dis. 1997;2:26–30.CrossRef

113.

Bhattarakosol P, Chantarabul S, Pittayathikhun K, Mung-mee V, Punnarugsa V. Prevalence of anti-varicella zoster IgG antibody in undergraduate students. Asian Pac J Allergy Immunol. 1996;14:129–31.PubMed

114.

Lolekha S, Tanthiphabha W, Sornchai P, Kosuwan P, Sutra S, Warachit B, et al. Effect of climatic factors and population density on varicella zoster virus epidemiology within a tropical country. Am J Trop Med Hyg. 2001;64:131–6.PubMed

115.

Srichomkwun P, Apisarnthanarak A, Thongphubeth K, Yuekyen C, Mundy LM. Evidence of vaccine protection among Thai medical students and implications for occupational health. Infect Control Hosp Epidemiol. 2009;30:585–8.PubMedCrossRef

116.

Suwanpakdee D, Laohapand C, Moolasart V, Lomtong P, Krairojananan N, Srisawat P, et al. Serosurveillance of varicella and hepatitis B infection after reported cases in medical students and the relationship between past varicella disease history and immunity status. J Med Assoc Thai. 2012;95 Suppl 5:S80–5.PubMed

117.

Kowitdamrong E, Pancharoen C, Thammaborvorn R, Bhattarakosol P. The prevalence of varicella-zoster virus infection in normal healthy individuals aged above 6 months. J Med Assoc Thai. 2005;88 Suppl 4:S7–11.PubMed

118.

O'Grady KA, Merianos A, Patel M, Gilbert L. High seroprevalence of antibodies to varicella zoster virus in adult women in a tropical climate. Trop Med Int Health. 2000;5:732–6.PubMedCrossRef

119.

Gidding HF, MacIntyre CR, Burgess MA, Gilbert GL. The seroepidemiology and transmission dynamics of varicella in Australia. Epidemiol Infect. 2003;131:1085–9.PubMedPubMedCentralCrossRef

120.

Lin YJ, Huang LM, Lee CY, Chih TW, Lee PL, Chang LY, et al. A seroepidemiological study of Varicella-Zoster virus in Taipei City. Zhonghua Min Guo Xiao Er Ke Yi Xue Hui Za Zhi. 1996;37:11–5.PubMed

121.

Wu MF, Yang YW, Lin WY, Chang CY, Soon MS, Liu CE. Varicella zoster virus infection among healthcare workers in Taiwan: seroprevalence and predictive value of history of varicella infection. J Hosp Infect. 2012;80:162–7.PubMedCrossRef

122.

Kangro HO, Osman HK, Lau YL, Heath RB, Yeung CY, Ng MH. Seroprevalence of antibodies to human herpesviruses in England and Hong Kong. J Med Virol. 1994;43:91–6.PubMedCrossRef

123.

Fung LW, Lao TT, Suen SS, Chan OK, Lau TK, Ngai KL, et al. Seroprevalence of varicella zoster virus among pregnant women in Hong Kong: comparison with self-reported history. Vaccine. 2011;29:8186–8.PubMedCrossRef

124.

Liu JJ, Wang ML, Gan L, Liao WJ, Chen J. Seroepidemiology of varicella-zoster virus infection measured by the fluorescent antibody to membrane antigen test. Zhonghua Liu Xing Bing Xue Za Zhi. 2009;30:371–5.PubMed

125.

Zhou Z, Wang S, Chu Y, Xie G. Survey of seroprevalence of varicella zoster virus in healthy population in Shanghai. Chin J Vaccin Immun. 2006;2:137–9.

126.

Wang Y. Seroepidemiological survey of prevalence of varicella-zoster virus in healthy population in Shenzen City. Chin Trop Med. 2006;7:1166–7.

127.

Pan W, Zhang X, Cai Z, Zhang H. A sero-epidemiological investigation on varicella-zoster virus in healthy people in Fujian. Pract Prev Med. 2003;6:864–5.

128.

Han SB, Kang KR, Huh DH, Lee HC, Kim JH, Kang JH, et al. Seroepidemiology of varicella-zoster virus in Korean adolescents and adults using fluorescent antibody to membrane antigen test. Epidemiol Infect. 2015;143:1643–50.PubMedCrossRef

129.

Kang CI, Choi CM, Park TS, Lee DJ, Oh MD, Choe KW. Incidence of herpes zoster and seroprevalence of varicella-zoster virus in young adults of South Korea. Int J Infect Dis. 2008;12:245–7.PubMedCrossRef

130.

Choi YJ, Kim KH, Oh MD. Genotype of varicella zoster virus isolated from Korean elderly patients with herpes zoster. Infect Chemother. 2010;42:162–70.CrossRef

131.

Lee H, Cho HK, Kim KH. Seroepidemiology of varicella-zoster virus in Korea. J Korean Med Sci. 2013;28:195–9.PubMedPubMedCentralCrossRef

132.

Kang JH, Park YS, Park SY, Kim SB, Ko KP, Seo YH. Varicella seroprevalence among health care workers in Korea: validity of self-reported history and cost-effectiveness of prevaccination screening. Am J Infect Control. 2014;42:885–7.PubMedCrossRef

133.

Kim YH, Hwang JY, Lee KM, Choi JH, Lee TY, Choi JS, et al. Seroepidemiologic survey of varicella-zoster virus in Korean adults using glycoprotein enzyme immuno assay and fluorescent antibody to membrane antigen test. Ann Dermatol. 2011;23:39–43.PubMedPubMedCentralCrossRef

134.

Yoshida N, Tsumura N, Toyomasu K, Sagawa K. Antibody titers against measles, rubella, mumps and varicella-zoster viruses in medical students. Sangyo Eiseigaku Zasshi. 2007;49:21–6.PubMedCrossRef

135.

National Institute of Infectious Diseases, Japan. National Epidemiological Surveillance of Vaccine-Preventable Diseases, 2015. Age distribution of varicella EIA-IgG antibody positives in Japan, 2015. http://www.nih.go.jp/niid/ja/y-graphs/6358-varicella-yosoku-serum2015.html. Accessed 27 Sept 2016.

136.

Lin YH, Huang LM, Chang IS, Tsai FY, Lu CY, Shao PL, et al. Disease burden and epidemiology of herpes zoster in pre-vaccine Taiwan. Vaccine. 2010;28:1217–20.PubMedCrossRef

137.

Jih JS, Chen YJ, Lin MW, Chen YC, Chen TJ, Huang YL, et al. Epidemiological features and costs of herpes zoster in Taiwan: a national study 2000 to 2006. Acta Derm Venereol. 2009;89:612–6.PubMedCrossRef

138.

Kim YJ, Lee CN, Lim CY, Jeon WS, Park YM. Population-based study of the epidemiology of herpes zoster in Korea. J Korean Med Sci. 2014;29:1706–10.PubMedPubMedCentralCrossRef

139.

Toyama N, Shiraki K. Epidemiology of herpes zoster and its relationship to varicella in Japan: A 10-year survey of 48,388 herpes zoster cases in Miyazaki prefecture. J Med Virol. 2009;81:2053–8.PubMedCrossRef

140.

Choi WS, Noh JY, Huh JY, Jo YM, Lee J, Song JY, et al. Disease burden of herpes zoster in Korea. J Clin Virol. 2010;47:325–9.PubMedCrossRef

141.

Wu PY, Wu HD, Chou TC, Sung FC. Varicella vaccination alters the chronological trends of herpes zoster and varicella. PLoS One. 2013;8:e77709.PubMedPubMedCentralCrossRef

142.

Wu CY, Hu HY, Huang N, Pu CY, Shen HC, Chou YJ. Do the health-care workers gain protection against herpes zoster infection? A 6-year population-based study in Taiwan. J Dermatol. 2010;37:463–70.PubMedCrossRef

143.

Chao DY, Chien YZ, Yeh YP, Hsu PS, Lian IB. The incidence of varicella and herpes zoster in Taiwan during a period of increasing varicella vaccine coverage, 2000–2008. Epidemiol Infect. 2012;140:1131–40.PubMedCrossRef

144.

Pongsumpun P. Local stability analysis of age structural model for herpes zoster in Thailand. Int J Math Comput Stat Nat Phys Eng. 2013;7:1146–52.

145.

Nelson MR, Britt HC, Harrison CM. Evidence of increasing frequency of herpes zoster management in Australian general practice since the introduction of a varicella vaccine. Med J Aust. 2010;193:110–3.PubMed

146.

Kelly HA, Grant KA, Gidding H, Carville KS. Decreased varicella and increased herpes zoster incidence at a sentinel medical deputising service in a setting of increasing varicella vaccine coverage in Victoria, Australia, 1998 to 2012. Euro Surveill. 2014;19(41):pii=20926. http://www.eurosurveillance.org/ViewArticle.aspx?ArticleId=20926.

147.

Carville KS, Riddell MA, Kelly HA. A decline in varicella but an uncertain impact on zoster following varicella vaccination in Victoria, Australia. Vaccine. 2010;28:2532–8.PubMedCrossRef

148.

Bak H, Ahn SK. A statistical study of dermatoses (2000–2004). Korean J Dermatol. 2005;43:1192–9.

149.

Lee H-J, Choi SI, Ahn SK. A statistical study of dermatoses in Wonju (2005 ~ 2009). Korean J Dermatol. 2010;48:460–7.

150.

Bureau of Epidemiology, Department of Disease Control, Ministry of Public Health, Thailand. Annual Epidemiological Surveillance Reports. 1993–2014. http://www.boe.moph.go.th/boedb/surdata/disease.php?dcontent=old&ds=77. Accessed 03 Aug 2015.

151.

Ogunjimi B, Van Damme P, Beutels P. Herpes zoster risk reduction through exposure to chickenpox patients: A systematic multidisciplinary review. PLoS One. 2013;8:e66485.

152.

Jardine A, Conaty SJ, Vally H. Herpes zoster in Australia: Evidence of increase in incidence in adults attributable to varicella immunization? Epidemiol Infect. 2011;139:658–65.PubMedCrossRef

153.

Jeong SK, Kim IH. Recurrence rate of herpes zoster during the previous decade. Korean J Dermatol. 2012;50:287–9.

154.

Tunsuriyawong S, Puavilai S. Herpes zoster, clinical course and associated diseases: A 5-year retrospective study at Ramathibodi Hospital. J Med Assoc Thai. 2005;88:678–81.PubMed

155.

Ikeda M, Hiroshige K, Abiko Y, Onoda K. Impaired specific cellular immunity to the varicella-zoster virus in patients with herpes zoster oticus. J Laryngol Otol. 1996;110:918–21.PubMedCrossRef

156.

Tang H, Moriishi E, Okamoto S, Okuno Y, Iso H, Asada H, et al. A community-based survey of varicella-zoster virus-specific immune responses in the elderly. J Clin Virol. 2012;55:46–50.PubMedCrossRef

157.

Lin SY, Liu JH, Lin CL, Tsai IJ, Chen PC, Chung CJ, et al. A comparison of herpes zoster incidence across the spectrum of chronic kidney disease, dialysis and transplantation. Am J Nephrol. 2012;36:27–33.PubMedCrossRef

158.

Hata A, Kuniyoshi M, Ohkusa Y. Risk of Herpes zoster in patients with underlying diseases: a retrospective hospital-based cohort study. Infection. 2011;39:537–44.PubMedPubMedCentralCrossRef

159.

Kuo CC, Lee CT, Lee IM, Ho SC, Yang CY. Risk of herpes zoster in patients treated with long-term hemodialysis: a matched cohort study. Am J Kidney Dis. 2012;59:428–33.PubMedCrossRef

160.

Wu MY, Hsu YH, Su CL, Lin YF, Lin HW. Risk of herpes zoster in CKD: a matched-cohort study based on administrative data. Am J Kidney Dis. 2012;60:548–52.PubMedCrossRef

161.

Chen HH, Chen YM, Chen TJ, Lan JL, Lin CH, Chen DY. Risk of herpes zoster in patients with systemic lupus erythematosus: a three-year follow-up study using a nationwide population-based cohort. Clinics (Sao Paulo). 2011;66:1177–82.CrossRef

162.

Tsai SY, Yang TY, Lin CL, Tsai YH, Kuo CF, Kao CH. Increased risk of varicella zoster virus infection in inflammatory bowel disease in an Asian population: a nationwide population-based cohort study. Int J Clin Pract. 2015;69:228–34.PubMedCrossRef

163.

Chen JY, Cheng TJ, Chang CY, Lan KM, Weng SF, Sheu MJ, et al. Increased incidence of herpes zoster in adult patients with peptic ulcer disease: A population-based cohort study. Int J Epidemiol. 2013;42:1873–81.PubMedCrossRef

164.

Yang YW, Chen YH, Wang KH, Wang CY, Lin HW. Risk of herpes zoster among patients with chronic obstructive pulmonary disease: a population-based study. CMAJ. 2011;183:E275–80.PubMedPubMedCentralCrossRef

165.

Umezawa Y, Fukuchi O, Ito T, Saeki H, Nakagawa H. Risk of herpes zoster in psoriatic patients undergoing biologic treatment. J Dermatol. 2014;41:168–70.PubMedCrossRef

166.

Hu SC, Lin CL, Lu YW, Chen GS, Yu HS, Wu CS, et al. Lymphopaenia, anti-Ro/anti-RNP autoantibodies, renal involvement and cyclophosphamide use correlate with increased risk of herpes zoster in patients with systemic lupus erythematosus. Acta Derm Venereol. 2013;93:314–8.PubMedCrossRef

167.

Zou Y, Lin M, Sheng Z, Niu S. Bortezomib and lenalidomide as front-line therapy for multiple myeloma. Leuk Lymphoma. 2014;55:2024–31.PubMedCrossRef

168.

Lyu SM, Byun JY, Choi YW, Choi HY. Clinical features of dermatology-consulted inpatients - Focus on the differences between individual departments. Korean J Dermatol. 2014;52:215–21.

169.

Oh SI, Oh BH, Rho JR, Kim KB, Kim JJ, Song MG, et al. Results of heart transplantation in Korea. Korean J Med. 2001;60:228–33.

170.

Tzeng CH, Liu JH, Fan S, Wang SY, Wang SR, Chen KY, et al. Varicella zoster virus infection after allogeneic or autologous hemopoietic stem cell transplantation. J Formos Med Assoc. 1995;94:313–7.PubMed

171.

Nakasone H, Izutsu K, Wakita S, Yamaguchi H, Muramatsu-Kida M, Usuki K. Autologous stem cell transplantation with PCR-negative graft would be associated with a favorable outcome in core-binding factor acute myeloid leukemia. Biol Blood Marrow Transplant. 2008;14:1262–9.PubMedCrossRef

172.

Tsukamoto H, Nagafuji K, Horiuchi T, Miyamoto T, Aoki K, Takase K, et al. A phase I-II trial of autologous peripheral blood stem cell transplantation in the treatment of refractory autoimmune disease. Ann Rheum Dis. 2006;65:508–14.PubMedCrossRef

173.

Jiang Z, Xiao H, Pang Y, Xiao Y. The incidence of herpes zoster after hematopoietic stem cell transplantation. Chin J Infect Chemother. 2012;12:88–91.

174.

Chugh KS, Sharma SC, Singh V, Sakhuja V, Jha V, Gupta KL. Spectrum of dermatological lesions in renal allograft recipients in a tropical environment. Dermatology. 1994;188:108–12.PubMedCrossRef

175.

Prakash J, Singh S, Prashant GK, Kar B, Tripathi K, Singh PB. Mucocutaneous lesions in transplant recipient in a tropical country. Transplant Proc. 2004;36:2162–4.PubMedCrossRef

176.

Hwang EA, Kang MJ, Han SY, Park SB, Kim HC. Viral infection following kidney transplantation: long-term follow-up in a single center. Transplant Proc. 2004;36:2118–9.PubMedCrossRef

177.

Ko GB, Kim T, Kim SH, Choi SH, Kim YS, Woo JH, et al. Increased incidence of herpes zoster in the setting of cytomegalovirus preemptive therapy after kidney transplantation. Transpl Infect Dis. 2013;15:416–23.PubMedCrossRef

178.

Vinod PB, Sharma RK. Opportunistic infections (non-cytomegalovirus) in live related renal transplant recipients. Indian J Urol. 2009;25:161–8.PubMedPubMedCentralCrossRef

179.

Ng P, McCluskey P, McCaughan G, Glanville A, MacDonald P, Keogh A. Ocular complications of heart, lung, and liver transplantation. Br J Ophthalmol. 1998;82:423–8.PubMedPubMedCentralCrossRef

180.

Kreis H, Oberbauer R, Campistol JM, Mathew T, Daloze P, Schena FP, et al. Long-term benefits with sirolimus-based therapy after early cyclosporine withdrawal. J Am Soc Nephrol. 2004;15:809–17.PubMedCrossRef

181.

Tomonari A, Iseki T, Takahashi S, Ooi J, Takasugi K, Shimohakamada Y, et al. Varicella-zoster virus infection in adult patients after unrelated cord blood transplantation: a single institute experience in Japan. Br J Haematol. 2003;122:802–5.PubMedCrossRef

182.

Onozawa M, Hashino S, Haseyama Y, Hirayama Y, Iizuka S, Ishida T, et al. Incidence and risk of postherpetic neuralgia after varicella zoster virus infection in hematopoietic cell transplantation recipients: Hokkaido Hematology Study Group. Biol Blood Marrow Transplant. 2009;15:724–9.PubMedCrossRef

183.

Wu M, Huang F, Jiang X, Fan Z, Zhou H, Liu C, et al. Herpesvirus-associated central nervous system diseases after allogeneic hematopoietic stem cell transplantation. PLoS One. 2013;8:e77805.PubMedPubMedCentralCrossRef

184.

Suzuki J, Ashizawa M, Okuda S, Wada H, Sakamoto K, Terasako K, et al. Varicella zoster virus meningoencephalitis after allogeneic hematopoietic stem cell transplantation. Transpl Infect Dis. 2012;14:E7–12.PubMedCrossRef

185.

Au WY, Hon C, Cheng VCC, Ma ESK. Concomitant zoster myelitis and cerebral leukemia relapse after stem cell transplantation. Ann Hematol. 2005;84:59–60.PubMedCrossRef

186.

Fukuno K, Tomonari A, Takahashi S, Ooi J, Takasugi K, Tsukada N, et al. Varicella-zoster virus encephalitis in a patient undergoing unrelated cord blood transplantation for myelodysplastic syndrome-overt leukemia. Int J Hematol. 2006;84:79–82.PubMedCrossRef

187.

Kang EH, Chung MP, Kang SJ, An CH, Ahn JW, Han J, Lee. Clinical features and treatment response in 18 cases with idiopathic nonspecific interstitial pneumonia. Tuberc Respir Dis. 2000;48:530–41.CrossRef

188.

Ozono Y, Harada T, Yamaguchi K, Taura K, Hara K, Taguchi T. Nephrotic syndrome in the elderly–clinicopathological study. Nihon Jinzo Gakkai Shi. 1994;36:44–50.PubMed

189.

Satoh N, Abe T, Nakajima A, Sakuragi S. Recurrent varicella-zoster virus retinitis in a patient treated with systemic corticosteroids. Ocul Immunol Inflamm. 1998;6:185–8.PubMedCrossRef

190.

Xiao X, Lu Y, Su H, Zhong K, Chen X, Da Y, et al. Clinical features and treatment of angioimmunoblastic T-cell lymphoma. Chin J Clin Oncol. 2011;38:1103–6.

191.

Usami E, Kimura M, Matsuoka T, Okada K, Nakao T, Yoshimura T, et al. The frequency and risk factor of herpes zoster infection in non-Hodgkin's lymphoma patients. Jpn J Cancer Chemother. 2011;38:243–7.

192.

Mills AK, Taylor KM, Wright SJ, Bunce LH, Bashford J, White K, et al. Sustained responses following alternating chlorodeoxyadenosine (2CDA) and VAC regimen in poor-risk de-novo follicular non-hodgkin's lymphoma (NHL). In: Blood 2000;96(11) Part II: The 2nd Annual Scientific Meeting of the Haematology Society of Australia and New Zealand, Perth, WA, 25–28 July 2000. p. 243b.

193.

Au WY, Kwong YL. Frequent varicella zoster reactivation associated with therapeutic use of arsenic trioxide: portents of an old scourge. J Am Acad Dermatol. 2005;53:890–2.PubMedCrossRef

194.

Zhang Q, Mu LJ, Wang XB, Li L, Kang ZJ, Yan JS. Clinical analysis of hematologic disorders complicated with herpes zoster after treating with arsenic trioxide. J Leuk Lymphoma. 2011;20:412–4.

195.

Yamakura M, Tsuda K, Ugai T, Sugihara H, Nisihida Y, Takeuchi M, et al. High frequency of varicella zoster virus reactivation associated with the use of arsenic trioxide in patients with acute promyelocytic leukemia. Acta Haematol. 2014;131:76–7.PubMedCrossRef

196.

Au WY, Kumana CR, Lee HK, Lin SY, Liu H, Yeung DY, et al. Oral arsenic trioxide-based maintenance regimens for first complete remission of acute promyelocytic leukemia: a 10-year follow-up study. Blood. 2011;118:6535–43.PubMedCrossRef

197.

Chan AYK, Hooi LS. Outcome of 85 lupus nephritis patients treated with intravenous clophosphamide: A single centre 10 year experience. Med J Malays. 2000;55:14–20.

198.

Chan TM, Li FK, Wong RW, Wong KL, Chan KW, Cheng IK. Sequential therapy for diffuse proliferative and membranous lupus nephritis: cyclophosphamide and prednisolone followed by azathioprine and prednisolone. Nephron. 1995;71:321–7.PubMedCrossRef

199.

Chan TM, Li FK, Hao WK, Chan KW, Lui SL, Tang S, et al. Treatment of membranous lupus nephritis with nephrotic syndrome by sequential immunosuppression. Lupus. 1999;8:545–51.PubMedCrossRef

200.

Mok CC, Ho CT, Siu YP, Chan KW, Kwan TH, Lau CS, et al. Treatment of diffuse proliferative lupus glomerulonephritis: a comparison of two cyclophosphamide-containing regimens. Am J Kidney Dis. 2001;38:256–64.PubMedCrossRef

201.

Liu G, Chen Y, Zuo C, Xie Q, Wang Z, Wang L, et al. Study on bolus cyclosphamide treatment for 64 cases of lupus nephritis. J West China Univ Med Sci. 2001;32:129–130,139.

202.

Mok CC, Ying KY, Mak A, To CH, Szeto ML. Outcome of protein-losing gastroenteropathy in systemic lupus erythematosus treated with prednisolone and azathioprine. Rheumatology (Oxford). 2006;45:425–9.CrossRef

203.

Kim JH, Cheon JH, Kim WH. The frequency and the course of the adverse effects of azathioprine/6-mercaptopurine treatment in patients with inflammatory bowel disease. Korean J Gastroenterol. 2008;51:291–7.PubMed

204.

Eisen HJ, Kobashigawa J, Keogh A, Bourge R, Renlund D, Mentzer R, et al. Three-year results of a randomized, double-blind, controlled trial of mycophenolate mofetil versus azathioprine in cardiac transplant recipients. J Heart Lung Transplant. 2005;24:517–25.PubMedCrossRef

205.

Zeher M, Doria A, Lan J, Aroca G, Jayne D, Boletis I, et al. Efficacy and safety of enteric-coated mycophenolate sodium in combination with two glucocorticoid regimens for the treatment of active lupus nephritis. Lupus. 2011;20:1484–93.PubMedCrossRef

206.

Hu W, Liu C, Xie H, Chen H, Liu Z, Li L. Mycophenolate mofetil versus cyclophosphamide for inducing remission of ANCA vasculitis with moderate renal involvement. Nephrol Dial Transplant. 2008;23:1307–12.PubMedCrossRef

207.

Kim YS, Moon JI, Kim SI, Park K. Clear benefit of mycophenolate mofetil-based triple therapy in reducing the incidence of acute rejection after living donor renal transplantations. Transplantation. 1999;68:578–81.PubMedCrossRef

208.

Lu F, Tu Y, Peng X, Wang L, Wang H, Sun Z, et al. A prospective multicentre study of mycophenolate mofetil combined with prednisolone as induction therapy in 213 patients with active lupus nephritis. Lupus. 2008;17:622–9.CrossRef

209.

Hegde S, Annamalai R, Biswas J. Extensive herpes zoster involvement following mycophenolate mofetil therapy for sarcoidosis. J Ophthalmic Inflamm Infect. 2012;2:47–8.PubMedCrossRef

210.

Satoh S, Tada H, Murakami M, Tsuchiya N, Inoue T, Togashi H, et al. The influence of mycophenolate mofetil versus azathioprine and mycophenolic acid pharmacokinetics on the incidence of acute rejection and infectious complications after renal transplantation. Transplant Proc. 2005;37:1751–3.PubMedCrossRef

211.

Yap DY, Yu X, Chen XM, Lu F, Chen N, Li XW, et al. Pilot 24 month study to compare mycophenolate mofetil and tacrolimus in the treatment of membranous lupus nephritis with nephrotic syndrome. Nephrology (Carlton). 2012;17:352–7.CrossRef

212.

Mak SK, Lo KY, Lo MW, Chan SF, Tong GM, Wong PN, et al. Efficacy of enteric-coated mycophenolate sodium in patients with active lupus nephritis. Nephrology (Carlton). 2008;13:331–6.CrossRef

213.

Li L, Wang H, Lin S, et al. Mycophenolate mofetil treatment for diffuse proliferative lupus nephritis: a multicenter clinical trial in China. Zhonghua Nei Ke Za Zhi. 2002;41:476–9.PubMed

214.

Xie QX, Han CX, Li JY, Lin XC, Zhao L, Huang HW, et al. Application of low-dosage mycophenolate mofetil in living renal transplantation of lineal consanguinity. J Clin Rehab Tissue Eng Res. 2009;13:924–6.

215.

Jenks KA, Stamp LK, O'Donnell JL, Savage RL, Chapman PT. Leflunomide-associated infections in rheumatoid arthritis. J Rheumatol. 2007;34:2201–3.PubMed

216.

Yoo HG, Yu HM, Jun JB, Jeon HS, Yoo WH. Risk factors of severe infections in patients with rheumatoid arthritis treated with leflunomide. Mod Rheumatol. 2013;23:709–15.PubMedCrossRef

217.

Cui TG, Hou FF, Ni ZH, Chen XM, Zhang FS, Zhu TY, et al. Treatment of proliferative lupus nephritis with leflunomide and steroid: a prospective multi-center controlled clinical trial. Zhonghua Nei Ke Za Zhi. 2005;44:672–6.PubMed

218.

Muir VJ, Plosker GL. Cladribine tablets: in relapsing-remitting multiple sclerosis. CNS Drugs. 2011;25:239–49.PubMedCrossRef

219.

Kim SJ, Moon JH, Kim H, Kim JS, Hwang YY, Intragumtornchai T, et al. Non-bacterial infections in Asian patients treated with alemtuzumab: A retrospective study of the Asian Lymphoma Study Group. Leuk Lymphoma. 2012;53:1515–24.PubMedCrossRef

220.

Chung BH, Kim Y, Jeong HS, Hong YA, Choi BS, Park CW, et al. Clinical outcome in patients with chronic antibody-mediated rejection treated with and without rituximab and intravenous immunoglobulin combination therapy. Transpl Immunol. 2014;31:140–4.PubMedCrossRef

221.

Ito K, Okamoto M, Maruyama F, Handa K, Yamamoto Y, Watanabe M, et al. Alteration in antibody-mediated immunity in patients with rituximab-combined chemotherapy and incidence of herpes zoster. Gan To Kagaku Ryoho. 2010;37:99–102.PubMed

222.

Kurokawa T, Hase M, Tokuman N, Yoshida T. Immune reconstitution of B-cell lymphoma patients receiving CHOP-based chemotherapy containing rituximab. Hematol Oncol. 2011;29:5–9.PubMedCrossRef

223.

Lee SD, Kim SH, Kong SY, Kim YK, Lee SA, Park SJ. ABO-incompatible living donor liver transplantation without graft local infusion and splenectomy. HPB (Oxford). 2014;16:807–13.CrossRef

224.

Tu MF, Zheng W, Lin NJ, Zhang YT, Wang XP, Song YQ, et al. Efficacy and safety of fludarabine-based combination chemotherapy in patients with previously untreated follicular non-Hodgkin's lymphoma. Tumor. 2011;31:58–63.

225.

Furie R, Nicholls K, Cheng TT, Houssiau F, Burgos-Vargas R, Chen SL, et al. Efficacy and safety of abatacept in lupus nephritis: A twelve-month, randomized, double-blind study. Arthritis Rheum. 2014;66:379–89.CrossRef

226.

Lee EB, Fleischmann R, Hall S, Wilkinson B, Bradley JD, Gruben D, et al. Tofacitinib versus methotrexate in rheumatoid arthritis. N Engl J Med. 2014;370:2377–86.PubMedCrossRef

227.

Winthrop KL, Yamanaka H, Valdez H, Mortensen E, Chew R, Krishnaswami S, et al. Herpes zoster and tofacitinib therapy in patients with rheumatoid arthritis. Arthritis Rheum. 2014;66:2675–84.CrossRef

228.

Wang X, Zhao J, Zhu S, Xia B. Herpes zoster in Crohn's disease during treatment with infliximab. Eur J Gastroenterol Hepatol. 2014;26:237–9.PubMedCrossRef

229.

Choi KD, Song HJ, Kim JS, Jung HC, Song IS. Efficacy and safety of treatment with infliximab in Crohn's disease-the experience of single center in Korea. Korean J Gastroenterol. 2005;46:48–55.PubMed

230.

Kim YJ, Kim JW, Lee CK, Park HJ, Shim JJ, Jang JY, et al. Clinical outcome of treatment with infliximab in Crohn's disease: a single-center experience. Korean J Gastroenterol. 2013;61:270–8.PubMedCrossRef

231.

Yi YS, Chung JS, Song MK, Shin HJ, Seol YM, Choi YJ, et al. The risk factors for herpes zoster in bortezomib treatment in patients with multiple myeloma. Korean J Hematol. 2010;45:188–92.PubMedPubMedCentralCrossRef

232.

Kim SJ, Kim K, Kim BS, Lee HJ, Kim H, Lee NR, et al. Bortezomib and the increased incidence of herpes zoster in patients with multiple myeloma. Clin Lymphoma Myeloma. 2008;8:237–40.PubMedCrossRef

233.

Kim MG, Kim YJ, Kwon HY, Park HC, Koo TY, Jeong JC, et al. Outcomes of combination therapy for chronic antibody-mediated rejection in renal transplantation. Nephrology (Carlton). 2013;18:820–6.CrossRef

234.

Tong Y, Qian J, Li Y, Meng H, Jin J. The high incidence of varicella herpes zoster with the use of bortezomib in 10 patients. Am J Hematol. 2007;82:403–4.PubMedCrossRef

235.

Zhong YP, Chen SL, Li X, Hu Y, Zhang JJ. Bortezomib combined with other drugs for treating 60 cases of multiple myeloma. Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2009;17:214–7.PubMed

236.

Khalafallah AA, Woodgate M, Koshy K, Patrick A. Ophthalmic manifestations of herpes zoster virus in patients with multiple myeloma following bone marrow transplantation. BMJ Case Rep. 2013; doi:10.1136/bcr-2012-007625.

237.

Zhang YQ, Liang R, Bai QX, Zhang T, Yang L, Wang YW, et al. PAD regimen for relapsed or refractory patients with multiple myeloma. Zhonghua Xue Ye Xue Za Zhi. 2009;30:260–3.PubMed

238.

Muta T, Nakanishi H, Yasunaga M, Senba S, Murakami H, Kan S, et al. Safety evaluation of bortezomib in multiple myeloma patients with severe renal failure. Jpn J Cancer Chemother. 2011;38:237–41.

239.

Li CM, Lu H, Wu HX, Qiu HX, Qian SX, Xu W, et al. Therapeutic efficacy of bortezomib-based chemotherapy on 40 patients with multiple myeloma. Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2010;18:1511–4.PubMed

240.

Yang G, Chen W, Wu Y. Bortezomib, dexamethasone plus thalidomide for treatment of newly diagnosed multiple myeloma patients with or without renal impairment. Chin J Cancer Res. 2013;25:155–60.PubMedPubMedCentral

241.

He J, Yang L, Han X, Zheng G, Zheng W, Wei G, et al. The choice of regimens based on bortezomib for patients with newly diagnosed multiple myeloma. PLoS One. 2014;9:e99174.PubMedPubMedCentralCrossRef

242.

Huang B, Li J, Xu X, Zheng D, Zhou Z, Liu J. Successful treatment of renal light chain (AL) amyloidosis with bortezomib and dexamethasone (VD). Pathol Biol (Paris). 2015;63:17–20.CrossRef

243.

Zhang Y, Shi B, Chen X, Xia Y, Ye L, Liu L, et al. Bortezomib combined with doxorubicin and dexamethasone for patients with refractory senile mantle cell lymphoma. Chin J Clin Oncol. 2011;38:1092–4.

244.

Zhong YP, Chen SL. Effect of treatment by bortezomib with other drugs for the refractory multiple myeloma. J Leuk Lymphoma. 2009;18:538–40.

245.

Zhu JJ, Li L, Ye XJ, He JS, Cai Z. Bortezomib combined with epirubicin and dexamethasone in treatment of multiple myeloma. J Pract Oncol. 2013;28:520–2.

246.

Ohguchi H, Sugawara T, Ishikawa I, Okuda M, Tomiya Y, Yamamoto J, et al. A retrospective analysis of bortezomib therapy for Japanese patients with relapsed or refractory multiple myeloma: beta2-microglobulin associated with time to progression. Int J Hematol. 2009;89:342–7.PubMedCrossRef

247.

Coiffier B, Osmanov EA, Hong X, Scheliga A, Mayer J, Offner F, et al. Bortezomib plus rituximab versus rituximab alone in patients with relapsed, rituximab-naive or rituximab-sensitive, follicular lymphoma: a randomised phase 3 trial. Lancet Oncol. 2011;12:773–84.PubMedCrossRef

248.

Yang GZ, Chen WM, Shen M, Fu LN, Jiang L, Gao W, et al. Sequential therapy of BTD and MPT regimen for the newly-diagnosed multiple myeloma patients no eligible for bone marrow transplantation. J Leuk Lymphoma. 2011;20:350–2.

249.

Zhai YP, Liu HN, Yu YP, Zhou XG, Song P, Li F, et al. Treatment of primary systemic amyloidosis with the combination of bortezomib and dexamethasone. Zhonghua Xue Ye Xue Za Zhi. 2010;31:319–22.PubMed

250.

Gu HT, Shu MM, Gao GX, Dong BX, Liang R, Yang L, et al. Efficacy comparison between standard and reduced doses of bortezomib combined with adriamycin and dexamethasone in the treatment of patients with multiple myeloma. Zhonghua Xue Ye Xue Za Zhi. 2013;34:622–5.PubMed

251.

Zhao Y, Dou LP, Wang SH, Bo J, Wang QS, Huang WR, et al. The efficacy and safety of PAD and VAD regimens for untreated multiple myeloma. Zhonghua Nei Ke Za Zhi. 2010;49:762–4.PubMed

252.

Hung MH, Kuo JR, Huang KF, Wang WC. Sacral herpes zoster presenting as sciatica. CMAJ. 2010;182:E534.PubMedPubMedCentralCrossRef

253.

Sachdeva S, Prasher P. Herpes zoster following saphenous venectomy for coronary bypass surgery. J Card Surg. 2010;25:28–9.PubMedCrossRef

254.

Basavaraj S, Prakash BG, Shetty TS, Sandhya D, Kallada S. Delayed facial nerve weakness after intact canal wall tympanomastoidectomy. Otol Neurotol. 2014;35:1003–6.PubMedCrossRef

255.

Lee MR, Ryman W. Herpes zoster following cryosurgery. Australas J Dermatol. 2005;46:42–3.PubMedCrossRef

256.

Brandon EL, Akers J, Rapeport D. Development of bilateral herpes zoster following thoracoscopic splanchnicectomy. Anaesth Intensive Care. 2006;34:382–3.PubMed

257.

Park KS, Yoon TR, Kim SK, Park HW, Song EK. Acute postoperative herpes zoster with a sciatic nerve distribution after total joint arthroplasty of the ipsilateral hip and contralateral knee. J Arthroplasty. 2010;25:497. e11-5.PubMed

258.

Choi HJ, Kim JH, Lee YM. Herpes zoster developing within recent subciliary incision scar. J Craniofac Surg. 2012;23:930–1.PubMedCrossRef

259.

Lin KC, Wang CC, Wang KY, Liao YC, Kuo JR. Reactivation of herpes zoster along the trigeminal nerve with intractable pain after facial trauma: a case report and literature review. BMJ Case Rep. 2009; doi:10.1136/bcr.07.2008.0525.

260.

Furuta Y, Ohtani F, Fukuda S, Inuyama Y, Nagashima K. Reactivation of varicella-zoster virus in delayed facial palsy after dental treatment and oro-facial surgery. J Med Virol. 2000;62:42–5.PubMedCrossRef

261.

Furukawa K, Sakoh M, Kumon Y, Teraoka M, Ohta S, Ohue S, et al. Delayed facial palsy after microvascular decompression for hemifacial spasm due to reactivation of varicella-zoster virus. No Shinkei Geka. 2003;31:899–902.PubMed

262.

Baba T, Yamasaki A, Miyake A, Funakoshi T, Yakura K, Miyazaki D, et al. Varicella zoster virus iridocyclitis following macular hole surgery in a case of von Hippel-Lindau disease. Jpn J Clin Ophthalmol. 2011;65:333–7.

263.

Fujitani A, Hayasaka S. Herpes zoster ophthalmicus after cataract surgery in a patient with a history of gastric cancer. Ann Ophthalmol Glaucoma. 1997;29:57–8.

264.

Koide C. Multiple cranial nerve dysfunction after uncomplicated neurovascular decompression for hemifacial spasm. Otolaryngol Head Neck Surg Tokyo. 1997;69:72–5.

265.

Tsukahara T, Huang J, Oyamada T, Uchio E. Herpetic corneal endotheliitis in a case after deep lamellar keratoplasty for bacterial keratitis. Jpn J Clin Ophthalmol. 2010;64:1287–91.

266.

Gyo K, Honda N. Delayed facial palsy after middle-ear surgery due to reactivation of varicella-zoster virus. J Laryngol Otol. 1999;113:914–5.PubMedCrossRef

267.

Kohjitani A, Miyawaki T, Kasuya K, Shimada M. Sympathetic activity-mediated neuropathic facial pain following simple tooth extraction: a case report. Cranio. 2002;20:135–8.PubMedCrossRef

268.

Walland MJ. Presumed ophthalmic Herpes zoster after contralateral cataract extraction. Acta Ophthalmol Scand. 1995;73:83–5.PubMedCrossRef

269.

Kam AC, Dan NG, Maclean J, Higgins D. Zoster related multiple cranial nerve palsies: an unusual complication following percutaneous balloon compression for trigeminal neuralgia. J Clin Neurosci. 1999;6:261–4.PubMedCrossRef

270.

Makkar JK, Singh NP, Rastogi V. Herpes zoster: Are selective nerve root injections the treatment or the cause? Pain Phys. 2010;13:196–8.

271.

Oh IH, Choi SK, Park BJ, Kim TS, Rhee BA, Lim YJ. The treatment outcome of elderly patients with idiopathic trigeminal neuralgia : Micro-vascular decompression versus gamma knife radiosurgery. J Korean Neurosurg Soc. 2008;44:199–204.PubMedPubMedCentralCrossRef

272.

Chen YH, Rau RH, Keller JJ, Lin HC. Possible effects of anaesthetic management on the 1 yr followed-up risk of herpes zoster after Caesarean deliveries. Br J Anaesth. 2012;108:278–82.PubMedCrossRef

273.

Terao M, Yamamoto T, Umeda J, Shirabe H. Drug induced herpes zoster (Do statin induce herpes zoster?). Skin Res. 2005;4:335–8.

274.

Chung SD, Tsai MC, Liu SP, Lin HC, Kang JH. Herpes zoster is associated with prior statin use: a population-based case–control study. PLoS One. 2014;9:e111268.PubMedPubMedCentralCrossRef

275.

Kano Y, Horie C, Inaoka M, Tadashi I, Mizukawa Y, Shiohara T. Herpes zoster in patients with drug-induced hypersensitivity syndrome/DRESS. Acta Derm-Venereol. 2012;92:206–7.PubMedCrossRef

276.

Follezou JY, Lan NY, Lien TX, Lafon ME, Tram LT, Hung PV, et al. Clinical and biological characteristics of human immunodeficiency virus- infected and uninfected intravascular drug users in Ho Chi Minh City, Vietnam. Am J Trop Med Hyg. 1999;61:420–4.PubMed

277.

Sivayathorn A, Srihra B, Leesanguankul W. Prevalence of skin disease in patients infected with human immunodeficiency virus in Bangkok, Thailand. Ann Acad Med Singapore. 1995;24:528–33.PubMed

278.

Supanaranond W, Desakorn V, Sitakalin C, Naing N, Chirachankul P. Cutaneous manifestations in HIV positive patients. Southeast Asian J Trop Med Public Health. 2001;32:171–6.PubMed

279.

Li ZH, Hua YH. Clinical analysis of skin and mucosa manifestations in 130 patients with HIV. J Clin Dermatol. 2013;42:720–2.

280.

Wiwanitkit V. Prevalence of dermatological disorders in Thai HIV-infected patients correlated with different CD4 lymphocyte count statuses: a note on 120 cases. Int J Dermatol. 2004;43:265–8.PubMedCrossRef

281.

Sungkanuparph S, Vibhagool A, Mootsikapun P, Chetchotisakd P, Tansuphaswaswadikul S, Bowonwatanuwong C. Opportunistic infections after the initiation of highly active antiretroviral therapy in advanced AIDS patients in an area with a high prevalence of tuberculosis. AIDS. 2003;17:2129–31.PubMedCrossRef

282.

Tzung TY, Yang CY, Chao SC, Lee JY. Cutaneous manifestations of human immunodeficiency virus infection in Taiwan. Kaohsiung J Med Sci. 2004;20:216–24.PubMedCrossRef

283.

Dwiyana RF, Rowawi R, Lestari M, Alisjahbana B, van der Ven AJ, Djajakusumah TS. Skin disorders in HIV-infected patients from West Java. Acta Med Indones. 2009;41 Suppl 1:18–22.PubMed

284.

Wong KH, Lee SS, Lo YC, Li PC, Ho HF, Sitt WH, et al. Profile of opportunistic infections among HIV-1 infected people in Hong Kong. Zhonghua Yi Xue Za Zhi (Taipei). 1995;55:127–36.

285.

Huang XJ, Li HY, Chen DX, Wang XC, Li ZC, Wu YS, et al. Clinical analysis of skin lesions in 796 Chinese HIV- positive patients. Acta Derm Venereol. 2011;91:552–6.PubMedCrossRef

286.

Chen XC, Lu XJ, Ye H, Gao YY. Clinical analysis of 109 HIV/AIDS patients. Chin J Infect Chemother. 2008;8:183–6.

287.

Oh MD, Park SW, Kim HB, Kim US, Kim NJ, Choi HJ, et al. Spectrum of opportunistic infections and malignancies in patients with human immunodeficiency virus infection in South Korea. Clin Infect Dis. 1999;29:1524–8.PubMedCrossRef

288.

Wani KA. Clinical profile of HIV/Aids patients in Srinagar, Kashmir, India. Int J Collab Res Intern Med Public Health. 2012;4:1703–12.

289.

Wadia RS, Pujari SN, Kothari S, Udhar M, Kulkarni S, Bhagat S, et al. Neurological Manifestations of HIV Disease. J Assoc Physicians India. 2001;49:343–8.PubMed

290.

Shobhana A, Guha SK, Neogi DK. Mucocutaneous manifestations of HIV infection. Indian J Dermatol Venereol Leprol. 2004;70:82–6.PubMed

291.

Arora U, Chopra S, Jindal N. HIV infection in families in and around Amritsar. J Indian Acad Clin Med. 2008;9:184–7.

292.

Ghate M, Deshpande S, Tripathy S, Nene M, Gedam P, Godbole S, et al. Incidence of common opportunistic infections in HIV-infected individuals in Pune, India: analysis by stages of immunosuppression represented by CD4 counts. Int J Infect Dis. 2009;13:e1–8.PubMedCrossRef

293.

Solomon SS, Hawcroft CS, Narasimhan P, Subbaraman R, Srikrishnan AK, Cecelia AJ, et al. Comorbidities among HIV-infected injection drug users in Chennai, India. Indian J Med Res. 2008;127:447–52.PubMed

294.

Jindal N, Aggarwal A, Kaur S. HIV seroprevalence and HIV associated dermatoses among patients presenting with skin and mucocutaneous disorders. Indian J Dermatol Venereol Leprol. 2009;75:283–6.PubMedCrossRef

295.

Kar HK, Narayan R, Gautam RK, Jain RK, Doda V, Sengupta D, et al. Mucocutaneous disorders in Hiv positive patients. Indian J Dermatol Venereol Leprol. 1996;62:283–5.PubMed

296.

Srirangaraj S, Venkatesha D. Opportunistic infections in relation to antiretroviral status among AIDS patients from south India. Indian J Med Microbiol. 2011;29:395–400.PubMedCrossRef

297.

Shahapur PR, Bidri RC. Recent trends in the spectrum of opportunistic infections in human immunodeficiency virus infected individuals on antiretroviral therapy in South India. J Nat Sci Biol Med. 2014;5:392–6.PubMedPubMedCentralCrossRef

298.

Song JY, Lee JS, Jung HW, Choi HJ, Lee JS, Eom JS, et al. Herpes zoster among HIV-infected patients in the highly active antiretroviral therapy era: Korean HIV cohort study. J Acquired Immune Defic Syndr. 2010;53:417–9.CrossRef

299.

Kim JM, Cho GJ, Hong SK, Chung JS, Jang KH, Kim CO, et al. Epidemiologic and clinical features of HIV infection/AIDS in Koreans. Korean J Med. 2001;61:355–64.CrossRef

300.

Nam TS, Seo KS, Lee KI, Kim YS, Hong JH, Kim GH, et al. The clinical study of hematoimmunologic features and opportunistic infections of patients with AIDS. Korean J Med. 1997;52:15–23.

301.

Choe KW, Oh MD, Park SW, Kim HB, Kim US, Kang SW, et al. Opportunistic infections and malignancies in 173 patients with HIV infection. Korean J Infect Dis. 1998;30:507–15.

302.

McNulty A, Li Y, Radtke U, Kaldor J, Rohrsheim R, Cooper DA, Donovan B. Herpes zoster and the stage and prognosis of HIV-1 infection. Genitourin Med. 1997;73:467–70.PubMedPubMedCentral

303.

Hung CC, Hsiao CF, Wang JL, Chen MY, Hsieh SM, Sheng WH, et al. Herpes zoster in HIV-1-infected patients in the era of highly active antiretroviral therapy: a prospective observational study. Int J STD AIDS. 2005;16:673–6.PubMedCrossRef

304.

Chopra S, Arora U. Skin and mucocutaneous manifestations: Useful clinical predictors of HIV/AIDS. J Clin Diagn Res. 2012;6:1695–8.PubMedPubMedCentral

305.

Kore SD, Kanwar AJ, Vinay K, Wanchu A. Pattern of mucocutaneous manifestations in human immunodeficiency virus-positive patients in North India. Indian J Sex Transm Dis. 2013;34:19–24.PubMedPubMedCentralCrossRef

306.

Mali RJ, Wankhade AB, Ghadage DP, Muley VA, Bhore AV. Cutaneous manifestations in HIV infected patients in rural area. J Pure Appl Microbiol. 2012;6:467–70.

307.

Panda S, Sarkar S, Mandal BK, Singh TB, Singh KL, Mitra DK, et al. Epidemic of herpes zoster following HIV epidemic in Manipur, India. J Infect. 1994;28:167–73.PubMedCrossRef

308.

Panda S, Kamei G, Pamei M, Sarkar S, Sarkar K, Singh ND, et al. Clinical features of HIV infection in drug users of Manipur. Natl Med J India. 1994;7:267–9.PubMed

309.

Antwal M, Gurjar R, Chidrawar S, Pawar J, Gaikwad S, Panchal N, et al. Clinical profile of HIV infected patients attending a HIV referral clinic in Pune. India Indian J Med Res. 2014;140:271–7.PubMed

310.

Lloyd A. HIV infection and AIDS. P N G Med J. 1996;39:174–80.PubMed

311.

Satishchandra P, Nalini A, Gourie-Devi M, Khanna N, Santosh V, Ravi V, et al. Profile of neurologic disorders associated with HIV/AIDS from Bangalore, south India (1989–96). Indian J Med Res. 2000;111:14–23.PubMed

312.

Srikanth KP, Vijayakumar S, Aparna, Mallikarjun. A hospital based cross sectional study of mucocutaneous manifestations in the HIV infected. Int J Collab Res Intern Med Public Health. 2010;2:50–78.

313.

Fernandes MS, Bhat RM. Spectrum of mucocutaneous manifestations in human immunodeficiency virus-infected patients and its correlation with CD4 lymphocyte count. Int J STD AIDS. 2015;26:414–9.PubMedCrossRef

314.

Singh HR, Singh NG, Singh TB. Estimation of CD4+ and CD8+ T-lymphocytes in human immunodeficiency virus infection and acquired immunodeficiency syndrome patients in Manipur. Indian J Med Microbiol. 2007;25:126–32.PubMedCrossRef

315.

Price P, Murdoch DM, Agarwal U, Lewin SR, Elliott JH, French MA. Immune restoration diseases reflect diverse immunopathological mechanisms. Clin Microbiol Rev. 2009;22:651–63.PubMedPubMedCentralCrossRef

316.

Choi WR, Seo MC, Sung KU, Lee HE, Yoon HJ. Herpes zoster immune reconstitution inflammatory syndrome in a HIV-infected patient: Case report and literature review. Infect Chemother. 2012;44:391–4.CrossRef

317.

Handa S, Narang T, Wanchu A. Dermatologic immune restoration syndrome: report of five cases from a tertiary care center in north India. J Cutan Med Surg. 2008;12:126–32.PubMedCrossRef

318.

Sharma A, Makrandi S, Modi M, Sharma A, Marfatia Y. Immune reconstitution inflammatory syndrome. Indian J Dermatol Venereol Leprol. 2008;74:619–21.PubMedCrossRef

319.

Terada K, Yoshihiro K, Kawano S, Morita T. Incidence of herpes zoster in pediatricians and family practitioners Estimation of efficacy of varicella vaccine for protection against herpes zoster in the elderly. Kawasaki Med J. 1994;20:99–102.

320.

Mittal RR. Infectivity of varicella and herpes zoster. Indian J Dermatol Venereol Leprol. 1996;62:196–7.PubMed

321.

Chandak SO, Pandilwar PK. Epidemic of herpes zoster in a family. J Oral Maxillofacial Surg Med Pathol. 2012;24:42–4.CrossRef

322.

Suzuki K, Yoshikawa T, Tomitaka A, Matsunaga K, Asano Y. Detection of aerosolized varicella-zoster virus DNA in patients with localized herpes zoster. J Infect Dis. 2004;189:1009–12.PubMedCrossRef

323.

Suzuki K, Yoshikawa T, Tomitaka A, Suzuki K, Matsunaga K, Asano Y. Detection of varicella-zoster virus DNA in throat swabs of patients with herpes zoster and on air purifier filters. J Med Virol. 2002;66:567–70.PubMedCrossRef

324.

Yoshikawa T, Ihira M, Suzuki K, Suga S, Tomitaka A, Ueda H, et al. Rapid contamination of the environments with varicella-zoster virus DNA from a patient with herpes zoster. J Med Virol. 2001;63:64–6.PubMedCrossRef

325.

Zhai JX, Ji J, Li M. Cutaneous tuberculosis complicated with squamous cell carcinoma. J Clin Dermatol. 2010;39:713–5.

326.

Kansal HM, Goel S. Cutaneous manifestations in cases of pulmonary tuberculosis: A clinical profile. J Indian Acad Clin Med. 2013;14:284–6.

327.

Kulkarni AG, Brid NS. Images in clinical medicine. Herpes zoster. N Engl J Med. 1995;332:1684.PubMedCrossRef

328.

Regunath H, Shivashankara KN, Sundeep KB, Bhaskar AP. Reactivation of Herpes zoster in an adult with Plasmodium infection. J Vector Borne Dis. 2008;45:251–3.PubMed

329.

Park B, Yun SJ, Lee JB, Lee SC, Won YH, Kim SJ. Analysis of dermatoses in pregnant patients. Korean J Dermatol. 2013;51:249–57.

330.

Kim WJ, Kim JY, Lee WJ, Lee SJ, Kim DW, Ko HC, et al. Investigation of the clinical manifestations of herpes zoster during pregnancy and its impact on the perinatal outcome. Korean J Dermatol. 2010;48:941–7.

331.

Thami GP, Kanwar AJ. Herpes zoster during pregnancy near term: to treat or not to treat? Aust N Z J Obstet Gynaecol. 1999;39:371.PubMedCrossRef

332.

Tsai YG, Lai JH, Kuo SY, Chen HC, Chang DM. Thymoma and hypogammaglobulinemia (Good’s syndrome): a case report. J Microbiol Immunol Infect. 2005;38:218–20.PubMed

333.

Chen JY, Chang CY, Lin YS, Hu ML. Nutritional factors in herpes zoster, postherpetic neuralgia, and zoster vaccination. Popul Health Manag. 2012;15:391–7.PubMedCrossRef

334.

Chao CT, Lee SY, Yang WS, Yen CJ, Chiang CK, Huang JW, et al. Serum vitamin D levels are positively associated with varicella zoster immunity in chronic dialysis patients. Sci Rep. 2014;4:7371.PubMedCrossRef

335.

Chao CT, Lai CF, Huang JW. Risk factors for herpes zoster reactivation in maintenance hemodialysis patients. Eur J Intern Med. 2012;23:711–5.PubMedCrossRef

336.

Chi CY, Chu CC, Liu JP, Lin CH, Ho MW, Lo WJ, et al. Anti-IFN-γ autoantibodies in adults with disseminated nontuberculous mycobacterial infections are associated with HLA-DRB1*16:02 and HLA-DQB1*05:02 and the reactivation of latent varicella-zoster virus infection. Blood. 2013;121:1357–66.PubMedCrossRef

337.

Cho JW, Shin DH, Lee KS. Polymorphism of the IL-10 gene is associated with susceptibility to herpes zoster in Korea. J Dermatol Sci. 2007;45:213–5.PubMedCrossRef

338.

Park SJ, Cho JW, Lee KS. Single nucleotide polymorphisms of interleukin-10 promoter gene in Korean herpes zoster patients. Korean J Dermatol. 2006;44:1325–31.

339.

Yuan LL, Wang LX, Xie YM, Yang W, Yang ZX, Zhuang Y, et al. Analysis on clinical features and treatment of herpes zoster patients hospitalized in real world. Zhongguo Zhongyao Zazhi. 2014;39:3469–73.PubMed

340.

Oh HM, Ho AY, Chew SK, Monteiro EH. Clinical presentation of herpes zoster in a Singapore hospital. Singapore Med J. 1997;38:471–4.PubMed

341.

Vikrant S. Long-term clinical outcomes of peritoneal dialysis patients: 9-year experience of a single center from north India. Perit Dial Int. 2014;34:426–33.PubMedPubMedCentralCrossRef

342.

Sato T, Inoue T, Endo K, Watanabe Y, Kikuta T, Tsuda M, et al. End-stage renal disease (ESRD) contributes to the increasing prevalence of herpes zoster. NDT Plus. 2009;2:263–4.PubMedPubMedCentral

343.

Muraya Y. Clinical and immunological evaluation of infection in patients on hemodialysis. J Infect Chemother. 1996;2:247–53.CrossRef

344.

Iwamoto M, Kamimura T, Nagashima T, Kamata Y, Aoki Y, Onishi S, et al. Healthcare-associated infections in rheumatology in Japan. Rheumatol Int. 2012;32:801–4.PubMedCrossRef

345.

Nishimaki T, Watanabe K, Satho Y, Okubo M, Kaise S, Miyata M, et al. Viral, fungal and mycobacterial infections in patients with systemic lupus erythematosus. Jpn J Rheumatol. 1999;9:45–54.

346.

Ishikawa O, Abe M, Miyachi Y. Herpes zoster in Japanese patients with systemic lupus erythematosus. Clin Exp Dermatol. 1999;24:327–8.PubMedCrossRef

347.

Naganuma M, Kunisaki R, Yoshimura N, Takeuchi Y, Watanabe M. A prospective analysis of the incidence of and risk factors for opportunistic infections in patients with inflammatory bowel disease. J Gastroenterol. 2013;48:595–600.PubMedCrossRef

348.

Binitha MP, Sarita SP, Manju M. Photoletter to the editor: Squamous cell carcinoma associated with and masquerading as molluscum contagiosum. J Dermatol Case Rep. 2013;7:103–5.PubMedPubMedCentralCrossRef

349.

Rajagopal R, Arora PN, Ramasastry CV, Kar PK. Skin changes in internal malignancy. Indian J Dermatol Venereol Leprol. 2004;70:221–5.PubMed

350.

Ayyamperumal A, Tharini G, Ravindran V, Parveen B. Cutaneous manifestations of internal malignancy. Indian J Dermatol. 2012;57:260–4.PubMedPubMedCentralCrossRef

351.

Okamoto S, Hata A, Sadaoka K, Yamanishi K, Mori Y. Comparison of varicella-zoster virus-specific immunity of patients with diabetes mellitus and healthy individuals. J Infect Dis. 2009;200:1606–10.PubMedCrossRef

352.

Mahajan S, Koranne R, Sharma S. Cutaneous manifestation of diabetes melitus. Indian J Dermatol Venereol Leprol. 2003;69:105–8.PubMed

353.

Yang YW, Chen YH, Lin HW. Risk of herpes zoster among patients with psychiatric diseases: a population-based study. J Eur Acad Dermatol Venereol. 2011;25:447–53.PubMedCrossRef

354.

Lee JY, Yoon NH, Park SD. A clinical study of the nature of pain associated with herpes zoster. Korean J Dermatol. 2006;44:1298–303.

355.

Yang YD, Wu JJ, Bi JJ, Lu YG, Zhu TY. Retrospective study of the characteristics of postherpetic neuralgia in 178 cases. Chin J Clin Rehab. 2005;9:23–5.

356.

Herr H. Prognostic factors of postherpetic neuralgia. J Korean Med Sci. 2002;17:655–9.PubMedPubMedCentralCrossRef

357.

Cho SI, Lee CH, Park GH, Park CW, Kim HO. Use of S-LANSS, a tool for screening neuropathic pain, for predicting postherpetic neuralgia in patients after acute herpes zoster events: a single-center, 12-month, prospective cohort study. J Pain. 2014;15:149–56.PubMedCrossRef

358.

Zhu SM, Liu YM, An ED, Chen QL. Influence of systemic immune and cytokine responses during the acute phase of zoster on the development of postherpetic neuralgia. J Zhejiang Univ Sci B. 2009;10:625–30.PubMedPubMedCentralCrossRef

359.

Imafuku S, Nakayama J, Higa K, Furue M, Takahara M, Katayama I, et al. One-year follow-up of zoster-associated pain in 764 immunocompetent patients with acute herpes zoster treated with famciclovir (FAMILIAR study). J Eur Acad Dermatol Venereol. 2014;28:1716–22.PubMedCrossRef

360.

Kanbayashi Y, Onishi K, Fukazawa K, Okamoto K, Ueno H, Takagi T, et al. Predictive factors for postherpetic neuralgia using ordered logistic regression analysis. Clin J Pain. 2012;28:712–14.PubMedCrossRef

361.

Zhang DP, He L. Risk factors and prevention measures of postherpetic neuralgia. Chin J Clin Rehab. 2005;9:118–9.

362.

Nithyanandam S, Dabir S, Stephen J, Joseph M. Eruption severity and characteristics in herpes zoster ophthalmicus: correlation with visual outcome, ocular complications, and postherpetic neuralgia. Int J Dermatol. 2009;48:484–7.PubMedCrossRef

363.

Nahm FS, Kim SH, Kim HS, Shin JW, Yoo SH, Yoon MH, et al. Survey on the treatment of postherpetic neuralgia in Korea; multicenter study of 1,414 patients. Korean J Pain. 2013;26:21–6.PubMedPubMedCentralCrossRef

364.

Chen JY, Lan KM, Sheu MJ, Tseng SF, Weng SF, Hu ML. Peptic ulcer as a risk factor for postherpetic neuralgia in adult patients with herpes zoster. J Med Virol. 2015;87:222–9.PubMedCrossRef

365.

Sumiyama D, Kikkawa EF, Kita YF, Shinagawa H, Mabuchi T, Ozawa A, et al. HLA alleles are associated with postherpetic neuralgia but not with herpes zoster. Tokai J Exp Clin Med. 2008;33:150–3.PubMed

366.

Sato M, Ohashi J, Tsuchiya N, Kashiwase K, Ishikawa Y, Arita H, et al. Association of HLA-A*3303-B*4403-DRB1*1302 haplotype, but not of TNFA promoter and NKp30 polymorphism, with postherpetic neuralgia (PHN) in the Japanese population. Genes Immun. 2002;3:477–81.PubMedCrossRef

367.

Ozawa A, Sasao Y, Iwashita K, Miyahara M, Sugai J, Iizuka M, et al. HLA-A33 and -B44 and susceptibility to postherpetic neuralgia (PHN). Tissue Antigens. 1999;53:263–8.PubMedCrossRef

368.

Sato-Takeda M, Ihn H, Ohashi J, Tsuchiya N, Satake M, Arita H, et al. The human histocompatibility leukocyte antigen (HLA) haplotype is associated with the onset of postherpetic neuralgia after herpes zoster. Pain. 2004;110:329–36.PubMedCrossRef

369.

Kirizume K, Imataki O, Shintani T, Fujihara S, Waki F, Ohue Y, et al. Aggravated post-herpetic neuralgia due to bortezomib. Rinsho Ketsueki. 2008;49:331–4.PubMed

370.

Choi WS, Kwon SS, Lee J, Choi SM, Lee JS, Eom JS, et al. Immunity and the burden of herpes zoster. J Med Virol. 2014;86:525–30.PubMedCrossRef

371.

Mehta J, Mahajan V, Khanna S. Disseminated zoster with polyneuritis cranialis and motor radiculopathy: Letter to editor. Neurol India. 2002;50:228–9.PubMed

372.

Kim SH, Suh MK. The clinical features of herpes zoster ophthalmicus in inpatients. Korean J Dermatol. 2008;46:1337–43.

373.

Ando K, Kohmoto H. Clinical features of herpes zoster ophthalmicus. Jpn J Clin Ophthalmol. 2000;54:385–7.

374.

Amaki S, Suzuki S, Shinbo R, Ando R, Oguchi Y, Shimizu H, et al. A statistical study of ocular complications of herpes zoster ophthalmicus and its prolongation factors. Nihon Ganka Gakkai Zasshi. 1995;99:289–95.PubMed

375.

Yoshida M, Hayasaka S, Yamada T, Yanagisawa S, Hayasaka Y, Nakamura N, et al. Ocular findings in Japanese patients with varicella-zoster virus infection. Ophthalmologica. 2005;219:272–5.PubMedCrossRef

376.

Kimata N, Nakagawa H, Araki H. Clinical features of herpes zoster keratitis. Jpn J Clin Ophthalmol. 1996;50:1113–6.

377.

Matsuda A, Tagawa Y, Abe N, Tsuda K, Matsuda H. Classification of corneal complications from varicella zoster virus. Jpn J Clin Ophthalmol. 1995;49:1519–23.

378.

McDonald EM, Patel DV, McGhee CN. A prospective study of the clinical characteristics of patients with herpes simplex and varicella zoster keratitis, presenting to a New Zealand emergency eye clinic. Cornea. 2015;34:279–84.PubMedCrossRef

379.

Zheng Y, Shi J. Clinical analysis of 58 cases of herpetic keratouveitis. Chin Ophthalmic Res. 2009;27:809–11.

380.

Thean JH, Hall AJ, Stawell RJ. Uveitis in Herpes zoster ophthalmicus. Clin Experiment Ophthalmol. 2001;29:406–10.PubMedCrossRef

381.

Hanajiri M, Matsumoto T, Hatano H, Ohno S. Herpes zoster ophthalmicus without skin eruptions. Jpn J Clin Ophthalmol. 1994;48:658–60.

382.

Kwok SK, Ho PCP, Chau GKO. Herpes zoster ophthalmicus - A family physician’s perspective. Hong Kong Pract. 2001;23:57–62.

383.

Albietz JM, Lenton LM. Late reactivation of herpes zoster keratitis results in band keratopathy. Optom Vis Sci. 2014;91:e149–55.PubMedCrossRef

384.

Cao L. Ophthalmic symptoms in AIDS. Int J Ophthalmol. 2009;9:393–4.

385.

Nithyanandam S, Joseph M, Stephen J. Ocular complications and loss of vision due to herpes zoster ophthalmicus in patients with HIV infection and a comparison with HIV-negative patients. Int J STD AIDS. 2013;24:106–9.PubMedCrossRef

386.

Gupta N, Sachdev R, Sinha R, Titiyal JS, Tandon R. Herpes zoster ophthalmicus: disease spectrum in young adults. Middle East Afr J Ophthalmol. 2011;18:178–82.PubMedPubMedCentralCrossRef

387.

Babu K, Kini R, Philips M, Subbakrishna DK. Clinical profile of isolated viral anterior uveitis in a South Indian patient population. Ocul Immunol Inflamm. 2014;22:356–9.PubMedCrossRef

388.

Ichikawa T, Sakai J, Yamauchi Y, Minoda H, Usui M. A study of 44 patients with Kirisawa type uveitis. Nihon Ganka Gakkai Zasshi. 1997;101:243–7.PubMed

389.

Tan WJ, Poh EW, Wong PY, Ho SL, Lim WK, Teoh SC. Trends in patterns of anterior uveitis in a tertiary institution in Singapore. Ocul Immunol Inflamm. 2013;21:270–5.PubMedCrossRef

390.

Wang TJ, Hu CC, Lin HC. Increased risk of anterior uveitis following herpes zoster: a nationwide population-based study. Arch Ophthalmol. 2012;130:451–5.PubMedCrossRef

391.

Sims JL, Yeoh J, Stawell RJ. Acute retinal necrosis: A case series with clinical features and treatment outcomes. Clin Exp Ophthalmol. 2009;37:473–7.PubMedCrossRef

392.

Roy R, Pal BP, Mathur G, Rao C, Das D, Biswas J. Acute retinal necrosis: clinical features, management and outcomes–a 10 year consecutive case series. Ocul Immunol Inflamm. 2014;22:170–4.PubMedCrossRef

393.

Sodeyama H, Todokoro D, Yamada N, Kishi S. Identification of causative virus and clinical course of acute retinal necrosis. Jpn J Clin Ophthalmol. 2014;68:947–52.

394.

Itoh N, Matsumura N, Ogi A, Nishide T, Imai Y, Kanai H, et al. High prevalence of herpes simplex virus type 2 in acute retinal necrosis syndrome associated with herpes simplex virus in Japan. Am J Ophthalmol. 2000;129:404–5.PubMedCrossRef

395.

Grover R, Ratho RK, Gupta V, Mahajan RC, Gupta A. Role of viral serology in the diagnosis of acute retinal necrosis syndrome. Ind J Pathol Microbiol. 2002;45:269–71.

396.

Madhavan HN. Laboratory investigations on viral and Chlamydia trachomatis infections of the eye: Sankara Nethralaya experiences. Indian J Ophthalmol. 1999;47:241–6.PubMed

397.

Mizuuchi K, Namba K, Kotake S, Ohno S. Clinical features of acute retinal necrosis at Hokkaido University Hospital. Nihon Ganka Gakkai Zasshi. 2008;112:136–40.PubMed

398.

Shimakawa M, Sato N. A case of AIDS complicated by progressive outer retinal necrosis. Nihon Ganka Gakkai Zasshi. 1999;103:137–43.PubMed

399.

Sittivarakul W, Aui-aree N. Clinical features, management and outcomes of progressive outer retinal necrosis (PORN) in southern Thailand. J Med Assoc Thai. 2009;92:360–6.PubMed

400.

Oshitari K, Arimoto H, Suzuki S, Oguchi Y. Rapidly progressive outer retinal necrosis in a patient with acquired immunodeficiency syndrome. Nihon Ganka Gakkai Zasshi. 1994;98:1141–6.PubMed

401.

Gill H, Cheung J, Wong I, Lie AK, Kwong YL. Varicella zoster virus progressive outer retinal necrosis after allogeneic haematopoietic stem cell transplantation. Br J Haematol. 2012;157:279.PubMedCrossRef

402.

Kim SJ, Park SJ, Yu HG, Kim NJ, Jang HC, Oh MD. Ocular manifestations of acquired immunodeficiency syndrome in Korea. J Korean Med Sci. 2012;27:542–6.PubMedPubMedCentralCrossRef

403.

Lim WK, Chee SP, Nussenblatt RB. Progression of varicella-zoster virus necrotizing retinopathy in an HIV-negative patient with transient immune deviation. Graefes Arch Clin Exp Ophthalmol. 2005;243:607–9.PubMedCrossRef

404.

Tseng CC, Chen SN, Hwang JF, Lin CJ, Chen HS. Progressive outer retinal necrosis associated with occlusive vasculitis in acquired immunodeficiency syndrome. J Formos Med Assoc. 2015;114:469–72.PubMedCrossRef

405.

Inoue Y, Takano M, Kawai H, Ichibe Y, Shimizu K. Progressive outer retinal necrosis in a patient with interstitial nephritis. Jpn J Clin Ophthalmol. 2006;60:1087–90.

406.

Miyaoka Y, Suzuki J, Yamauchi Y, Goto H. A bilateral case of progressive outer retinal necrosis with retinal detachment resistant to antiviral treatments. Jpn J Clin Ophthalmol. 2008;62:489–92.

407.

Ozaki H, Jane H, Inoue H, Kozawa M, Kondo H, Uchio E. Outcome of treatment for acute retinal necrosis. Jpn J Clin Ophthalmol. 2011;65:1819–25.

408.

Hong J. Discuss on the diagnosis and treatment of viral cornea endotheliitis. Ophthalmol China. 2010;19:158–60.

409.

Wang AG, Liu JH, Hsu WM, Lee AF, Yen MY. Optic neuritis in herpes zoster ophthalmicus. Jpn J Ophthalmol. 2000;44:550–4.PubMedCrossRef

410.

Menon V, Kumar G, Tandon R. Optic neuropathy secondary to herpes zoster ophthalmicus. Indian J Ophthalmol. 1995;43:78–9.PubMed

411.

Suraiya MS, Norazlina B, Carmen C, Muhaya M. Bilateral optic neuritis in pregnancy. Med J Malaysia. 2003;58:771–3.PubMed

412.

Obata H, Yamagami S, Saito S, Sakai O, Tsuru T. A case of acute dacryoadenitis associated with herpes zoster ophthalmicus. Jpn J Ophthalmol. 2003;47:107–9.PubMedCrossRef

413.

Yokoyama C, Mori S, Kamada A, Kase S, Ishida S. A case of herpes zoster ophthalmicus with acute dacryoadenitis as the initial manifestation. Jpn J Clin Ophthalmol. 2011;65:945–8.

414.

Yong VK, Yip CC, Yong VS. Herpes zoster ophthalmicus and the superior orbital fissure syndrome. Singapore Med J. 2001;42:485–6.PubMed

415.

Bourke RD, Pyle J. Herpes zoster ophthalmicus and the orbital apex syndrome. Aust New Zealand J Ophthalmol. 1994;22:77–80.CrossRef

416.

Saxena R, Phuljhele S, Aalok L, Sinha A, Menon V, Sharma P, et al. A rare case of orbital apex syndrome with herpes zoster ophthalmicus in a human immunodeficiency virus-positive patient. Indian J Ophthalmol. 2010;58:527–30.PubMedPubMedCentralCrossRef

417.

Biswas J, Deka S, Padmaja S, Madhavan HN, Kumarasamy N, Solomon S. Central retinal vein occlusion due to herpes zoster as the initial presenting sign in a patient with acquired immunodeficiency syndrome (AIDS). Ocul Immunol Inflamm. 2001;9:125–30.PubMedCrossRef

418.

Min SU, Li K, Won CH, Cho S, Huh CH, Kim BJ, et al. Clinical analysis of Ramsay Hunt syndrome. Korean J Dermatol. 2007;45:1121–6.

419.

Gondivkar S, Parikh V, Parikh R. Herpes zoster oticus: A rare clinical entity. Contemp Clin Dent. 2010;1:127–9.PubMedPubMedCentralCrossRef

420.

Murakami S, Hato N, Horiuchi J, Miyamoto Y, Aono H, Honda N, et al. Clinical features and prognosis of facial palsy and hearing loss in patients with Ramsay Hunt syndrome. J Otolaryngol Jpn. 1996;99:1772–9.

421.

Ou CY, Chao WY. Herpes zoster oticus. J Otolaryngol Soc Repub China. 1997;32:379–85.

422.

Hung CW, Wang SJ, Chen SP, Lirng JF, Fuh JL. Trigeminal herpes zoster and Ramsay Hunt syndrome with a lesion in the spinal trigeminal nucleus and tract. J Neurol. 2010;257:1045–46.PubMedCrossRef

423.

McCullough MJ, Savage NW. Oral viral infections and the therapeutic use of antiviral agents in dentistry. Aust Dent J. 2005;50 Suppl 2:S31–5.PubMedCrossRef

424.

Sengoku R, Yaguchi H, Matsushima S, Mochio S. Zoster sine herpete: detection by skin exudates and contrast magnetic resonance imaging. Eur Neurol. 2012;67:154.PubMedCrossRef

425.

Lu YC, Young YH. Vertigo from herpes zoster oticus: superior or inferior vestibular nerve origin? Laryngoscope. 2003;113:307–11.PubMedCrossRef

426.

Isawa M. Unilateral deafness and vestibular dysfunction caused by herpes zoster virus. Otolaryngol Head Neck Surg Tokyo. 2001;73:938–41.

427.

Shim HJ, Jung H, Park DC, Lee JH, Yeo SG. Ramsay Hunt syndrome with multicranial nerve involvement. Acta Oto-Laryngol. 2011;131:210–5.CrossRef

428.

Lee HH, Huang LK, Hu CJ, Chen CC. Atypical Ramsay Hunt syndrome. Acta Neurol Taiwan. 2014;23:80–1.PubMed

429.

Miyazaki Y, Tajima Y, Sudo K, Matsumoto A, Kikuchi S, Tashiro K. A case of Ramsay Hunt syndrome initiated with hoarseness and dysphagia: Consideration on spreading mechanisms of cranial neuropathy. Clin Neurol. 2002;42:855–8.

430.

Choi HN, Kim JE, Chung DY, Park SY, Oh JH. Herpes zoster oticus with cranial polyneuropathy without involvement of facial nerve. Korean J Audiol. 2011;15:155–8.

431.

Sun WL, Yan JL, Chen LL. Ramsay Hunt syndrome with unilateral polyneuropathy involving cranial nerves V, VII, VIII, and XII in a diabetic patient. Quintessence Int. 2011;42:873–7.PubMed

432.

Sakane S, Enomoto H, Tamaki N, Oridate N. Cases of laryngeal paralysis caused by the varicella-zoster virus (VZV). Pract Oto-Rhino-Laryngol. 2014;107:399–404.CrossRef

433.

Kato T. Vocal cord paralysis caused by varicella zoster virus. Otolaryngol Head Neck Surg Tokyo. 2005;77:389–91.

434.

Wu CL, Linne OC, Chiang CW. Herpes zoster laryngis with prelaryngeal skin erythema. Ann Otol Rhinol Laryngol. 2004;113:113–4.PubMedCrossRef

435.

Morinaka S. Herpes zoster laryngitis with intractable hiccups. Auris Nasus Larynx. 2009;36:606–8.PubMedCrossRef

436.

Tamakawa S, Takada M. A case of herpes zoster affecting the glossopharyngeal nerve. J Anesth. 1999;13:230–2.PubMedCrossRef

437.

Ling B, Novakovic D, Sulica L. Cough after laryngeal herpes zoster: a new aspect of post-herpetic sensory disturbance. J Laryngol Otol. 2014;128:209–11.PubMedCrossRef

438.

Yoshida T, Fujisaki N, Nakachi R, Sueyoshi T, Suwazono S, Suehara M. Persistent hiccups and vomiting with multiple cranial nerve palsy in a case of zoster sine herpete. Intern Med. 2014;53:2373–6.PubMedCrossRef

439.

Shim JH, Park JW, Kwon BS, Ryu KH, Lee HJ, Lim WH, et al. Dysphagia in Ramsay Hunt's Syndrome - A Case Report -. Ann Rehabil Med. 2011;35:738–41.PubMedPubMedCentralCrossRef

440.

Ono N, Sakabe A, Nakajima M. Herpes zoster oticus-associated jugular foramen syndrome. Brain Nerve. 2010;62:81–4.PubMed

441.

Fang CW, Lin CC. Ramsay Hunt syndrome with hemiparesis and hemihypoesthesia: report of 2 cases. Acta Neurol Taiwan. 2009;18:276–80.PubMed

442.

Furuta Y, Ohtani F, Kawabata H, Fukuda S, Bergström T. High prevalence of varicella-zoster virus reactivation in herpes simplex virus-seronegative patients with acute peripheral facial palsy. Clin Infect Dis. 2000;30:529–33.PubMedCrossRef

443.

Kawaguchi K, Inamura H, Abe Y, Koshu H, Takashita E, Muraki Y, et al. Reactivation of herpes simplex virus type 1 and varicella-zoster virus and therapeutic effects of combination therapy with prednisolone and valacyclovir in patients with Bell's palsy. Laryngoscope. 2007;117:147–56.PubMedCrossRef

444.

Terada K, Niizuma T, Kawano S, Kataoka N, Akisada T, Orita Y. Detection of varicella-zoster virus DNA in peripheral mononuclear cells from patients with Ramsay Hunt syndrome or zoster sine herpete. J Med Virol. 1998;56:359–63.PubMedCrossRef

445.

Takahash K, Aono T, Shichinohe M, Tamura M, Iwata Y, Yamanishi K, et al. Herpesvirus DNA in peripheral blood mononuclear cells of some patients with Meniere's disease. Microbiol Immunol. 2001;45:635–8.PubMedCrossRef

446.

Yazawa Y, Suzuki M, Hanamitsu M, Kimura H, Tooyama I. Detection of viral DNA in the endolymphatic sac in Ménière's disease by in situ hybridization. ORL J Otorhinolaryngol Relat Spec. 2003;65:162–8.PubMedCrossRef

447.

Hoshino C, Yamabe A. Where is reactivation after a long latency? BMJ Case Rep. 2012; doi:10.1136/bcr.01.2012.5538.

448.

Son HH, Sim HS, Lee SK. Clinical study of motor paresis in in-patients with herpes zoster. Korean J Dermatol. 2011;49:961–8.

449.

Gopal KVT, Sarvani D, Krishnam Raju PV, Rao GR, Venkateswarlu K. Herpes zoster motor neuropathy: A clinical and electrophysiological study. Indian J Dermatol Venereol Leprol. 2010;76:569–71.PubMedCrossRef

450.

Takahashi T, Tamura M, Miki K, Yamaguchi M, Kanno A, Nunomura S, et al. Varicella zoster virus myelitis in two elderly patients: diagnostic value of nested polymerase chain reaction assay and antibody index for cerebrospinal fluid specimens. Case Rep Neurol. 2013;5:81–90.PubMedPubMedCentralCrossRef

451.

Liu W, Zhu YY, Jiang FX, He J, Hu B. A case of systemic lupus erythematosus with herpes zoster myelitis. J Clin Dermatol. 2013;42:412–3.

452.

Ong OL, Churchyard AC, New PW. The importance of early diagnosis of herpes zoster myelitis. Med J Aust. 2010;193:546–7.PubMed

453.

Mehndiratta MM, Bansal J, Gupta M, Puri V. Herpes zoster cervical myelitis in an immunocompetent subject. Neurol India. 2000;48:189–90.PubMed

454.

Akiyama N. Herpes zoster infection complicated by motor paralysis. J Dermatol. 2000;27:252–7.PubMedCrossRef

455.

Tak WJ, Chong YS, Seo SJ, Hong CK. A case of motor paralysis caused by herpes zoster. Korean J Dermatol. 2002;40:1157–60.

456.

Shin SJ, Yoo CS, Kil MS, Kim CW, Kim SS. A case of motor paralysis of the limb caused by herpes zoster. Korean J Dermatol. 2012;50:621–3.

457.

Fujimoto S, Matsuno O, Matsumoto T, Kumamoto T, Tsuda T. A case of diaphragmatic paralysis following herpes zoster. Clin Neurol. 1996;36:345–7.

458.

Her Y, Kim CW, Kim SS. A clinical study of motor involvement by herpes zoster. Korean J Dermatol. 2010;48:468–73.

459.

Lee CC, Wu JC, Huang WC, Shih YH, Cheng H. Herpes zoster cervical myelitis in a young adult. J Chin Med Assoc. 2010;73:605–10.PubMedCrossRef

460.

Hosaka A, Nakamagoe K, Watanabe M, Tamaoka A. Magnetic resonance images of herpes zoster myelitis presenting with Brown-Séquard syndrome. Arch Neurol. 2010;67:506.PubMedCrossRef

461.

Lee MH, Song JH, Lee DI, Ahn HS, Park JW, Cha YD. Newly developed urinary retention and motor weakness of lower extremities in a postherpetic neuralgia patient. Korean J Pain. 2013;26:76–9.PubMedPubMedCentralCrossRef

462.

Tseng YH. Acute orbital myositis heralding herpes zoster ophthalmicus: report of a case. Acta Neurol Taiwan. 2008;17:47–9.PubMed

463.

Kang JH, Sheu JJ, Lin HC. Increased risk of Guillain-Barré Syndrome following recent herpes zoster: a population-based study across Taiwan. Clin Infect Dis. 2010;51:525–30.PubMedCrossRef

464.

Wakasugi K, Imaizumi T, Nishimura Y, Fujimoto H, Ayabe M, Shoji H, et al. Guillain-Barré syndrome associated with herpes zoster. Intern Med. 2001;40:552.PubMedCrossRef

465.

Nagane Y, Utsugisawa K, Obara D. A case of herpes zoster associated Guillain-Barré syndrome with a relapse of eruptions after intravenous immunoglobulin therapy. Clin Neurol. 2006;46:664–7.

466.

Sheu JJ, Keller JJ, Lin HC. Increased risk of cancer after Bell's palsy: a 5-year follow-up study. J Neurooncol. 2012;110:215–20.PubMedCrossRef

467.

Sanjay S, Chan EW, Gopal L, Hegde SR, Chang BC. Complete unilateral ophthalmoplegia in herpes zoster ophthalmicus. J Neuroophthalmol. 2009;29:325–37.PubMedCrossRef

468.

Shin HM, Lew H, Yun YS. A case of complete ophthalmoplegia in herpes zoster ophthalmicus. Korean J Ophthalmol. 2005;19:302–4.PubMedCrossRef

469.

Sato R, Yamada M, Tamai K. Total ophthalmoplegia in a case of herpes zoster ophthalmicus. Jpn J Clin Ophthalmol. 2008;62:1279–83.

470.

Im M, Kim BJ, Seo YJ, Park JK, Lee JH. Complete ophthalmoplegia after herpes zoster. Clin Exp Dermatol. 2007;32:162–4.PubMedCrossRef

471.

Nakazawa T, Omura M, Sugita R. A case of herpes zoster ophthalmicus with total ophthalmoplegia. Jpn J Clin Ophthalmol. 1998;52:1933–7.

472.

Ying XH, Wagle AM, Tan L, Sanjay S, Hedge SR, Chew YC, et al. A rare case of herpes zoster ophthalmicus with complete ophthalmoplegia. J Am Geriatr Soc. 2008;56:2160–2.PubMedCrossRef

473.

Jang SJ, Choe YB, Ahn KJ. A Case of motor paralysis caused by herpes zoster. Korean J Dermatol. 2004;42:236–8.

474.

Tam TC, Chan KY, Ho SL, Luk JK, Chu LW. Herpetic shoulder paresis in a Chinese elderly patient. Hong Kong Med J. 2005;11:399–402.PubMed

475.

Kang SH, Song HK, Jang Y. Zoster-associated segmental paresis in a patient with cervical spinal stenosis. J Int Med Res. 2013;41:907–13.PubMedCrossRef

476.

Siddalingappa K, Lokanatha K. Segmental motor paralysis of the right upper limb in herpes zoster. Indian J Dermatol Venereol Leprol. 2006;72:252.CrossRef

477.

Wu CM, Hsu CY, Shie HH. Herpes zoster motor neuropathy in an elderly man. Eur Geriatr Med. 2014;5:216–7.CrossRef

478.

Kawajiri S, Tani M, Noda K, Fujishima K, Hattori N, Okuma Y. Segmental zoster paresis of limbs: report of three cases and review of literature. Neurologist. 2007;13:313–7.PubMedCrossRef

479.

Namekawa M, Kameda T, Kumabe A, Mise J. Segmental zoster paresis of the right shoulder. Intern Med. 2013;52:2839.PubMedCrossRef

480.

Fabian VA, Wood B, Crowley P, Kakulas BA. Herpes zoster brachial plexus neuritis. Clin Neuropathol. 1997;16:61–4.PubMed

481.

Choi JY, Kang CH, Kim BJ, Park KW, Yu SW. Brachial plexopathy following herpes zoster infection: two cases with MRI findings. J Neurol Sci. 2009;285:224–6.PubMedCrossRef

482.

Bessho M, Nakajima H, Ito T, Kitaoka H. A case of incomplete Brown-Séquard syndrome after thoracic herpes zoster infection. Clin Neurol. 2010;50:175–89.

483.

Seo DH, Lee SJ, Hyun JK, Kim TU. A case of herpes zoster peripheral polyneuropathy manifested by foot drop in chronic myeloid leukemia. Ann Rehabil Med. 2012;36:724–8.PubMedPubMedCentralCrossRef

484.

Kim JB, Jung HJ, Lee JM, Im KS, Joo CH, Kim JW. Disseminated herpes zoster with a zoster paresis-induced femoral fracture. Geriatr Gerontol Int. 2012;12:168–71.PubMedCrossRef

485.

Kim SY, Hwang KE, Jung JH, Park JH, Kim HJ, Kim HR, et al. Diaphragmatic paralysis following cervical herpes zoster. Tuberc Respir Dis. 2006;61:80–2.CrossRef

486.

Koh YM, Baik JJ, Woo SI, Park KW, Chung Y. Diaphragmatic paralysis induced by herpes zoster. Tuberc Respir Dis. 1996;43:92–5.CrossRef

487.

Lin CM, Shieh WB, Chiang PC, Shieh MG, Liu YC, Chiou CC, et al. An unusual cause of dyspnea in a patient with cervical herpes zoster. J Clin Neurosci. 2012;19:608–9.PubMedCrossRef

488.

Zhou SR, Liu CY. A case report of abdominal distention caused by herpes zoster. World J Gastroenterol. 2012;18:4627–8.PubMedPubMedCentralCrossRef

489.

Lee UH, Park HS, Choi JC, Chun DK. A case of abdominal protrusion caused by herpes zoster. Korean J Dermatol. 2004;42:659–61.

490.

Chang TCC, Chin YY, Lan CCE. Herpes zoster with autonomic dysregulation presented as alteration in local microcirculation: A case report. Dermatol Sin. 2011;29:72–4.CrossRef

491.

Sharma PK, Gautam RK, Basistha C, Jain RK, Kar HK. Abdominal hernia following abdominal herpes zoster. Indian J Dermatol Venereol Leprol. 2001;67:39–40.PubMed

492.

Tashiro S, Akaboshi K, Kobayashi Y, Mori T, Nagata M, Liu M. Herpes zoster-induced trunk muscle paresis presenting with abdominal wall pseudohernia, scoliosis, and gait disturbance and its rehabilitation: a case report. Arch Phys Med Rehabil. 2010;91:321–5.PubMedCrossRef

493.

Kim ED, Kang BG, Kim JH, Roh M, Jo DH. Abdominal distention and constipation followed by herpes zoster infection. Korean J Anesthesiol. 2013;65 Suppl 6:S143–4.PubMedPubMedCentralCrossRef

494.

Maeda K, Furukawa K, Sanada M, Kawai H, Yasuda H. Constipation and segmental abdominal paresis followed by herpes zoster. Intern Med. 2007;46:148–8.

495.

Kim JH, Lee SH, Na GJ, Lee SJ, Jo YG, Lee TH, et al. A rare case of Ogilvie syndrome associated with herpes zoster. Intest Res. 2012;10:379–82.CrossRef

496.

Hiramatsu S, Nebiki H, Ueno A, Wakahara Y, Maruyama H, Suekane T, et al. A case of paralytic ileus associated with varicella zoster virus infection. Nihon Shokakibyo Gakkai Zasshi. 2013;110:1007–13.PubMed

497.

Imafuku S, Takahara M, Uenotsuchi T, Iwato K, Furue M. Herpes zoster-associated voiding dysfunction in hematopoietic malignancy patients. Int J Dermatol. 2008;47:36–9.PubMedCrossRef

498.

Chen PH, Hsueh HF, Hong CZ. Herpes zoster-associated voiding dysfunction: a retrospective study and literature review. Arch Phys Med Rehabil. 2002;83:1624–8.PubMedCrossRef

499.

Tsai HN, Wu WJ, Huang SP, Su CM, Chen CC, Wang CJ, et al. Herpes zoster induced neuropathic bladder–a case report. Kaohsiung J Med Sci. 2002;18:39–44.PubMed

500.

Hiraga A, Nagumo K, Sakakibara R, Kojima S, Fujinawa N, Hashimoto T. Loss of urinary voiding sensation due to herpes zoster. Neurourol Urodyn. 2003;22:335–7.PubMedCrossRef

501.

Matsuo T, Oba K, Miyata Y, Igawa T, Sakai H. Four cases of urinary dysfunction associated with sacral herpes zoster. Acta Urol Jpn. 2014;60:87–90.

502.

Addison B, Harvey M. Herpes zoster-induced acute urinary retention. Emerg Med Australas. 2013;25:279–81.PubMedCrossRef

503.

Yamanishi T, Yasuda K, Sakakibara R, Hattori T, Uchiyama T, Minamide M, et al. Urinary retention due to herpes virus infections. Neurourol Urodyn. 1998;17:613–9.PubMedCrossRef

504.

Fukao M, Isogai R, Kawada A, Shimizu N, Matsumoto S. Herpes zoster associated with bladder/rectum symptom. Skin Res. 2005;4:386–9.

505.

Matsumoto H, Shimizu T, Tokushige S, Mizuno H, Igeta Y, Hashida H. Rectal ulcer in a patient with VZV sacral meningoradiculitis (Elsberg syndrome). Intern Med. 2012;51:651–4.PubMedCrossRef

506.

Chen JH, Chen KY. Acute sciatica in a patient with herpes zoster infection. Acta Clin Belg. 2011;66:70–1.PubMedCrossRef

507.

Kang JH, Ho JD, Chen YH, Lin HC. Increased risk of stroke after a herpes zoster attack: a population-based follow-up study. Stroke. 2009;40:3443–8.PubMedCrossRef

508.

Lin HC, Chien CW, Ho JD. Herpes zoster ophthalmicus and the risk of stroke: a population-based follow-up study. Neurology. 2010;74:792–7.PubMedCrossRef

509.

Chen WH, Chui C, Yin HL. Zoster sine herpete, vertebral artery stenosis, and ischemic stroke. J Stroke Cerebrovasc Dis. 2013;22:e234–7.PubMedCrossRef

510.

Verma R, Lalla R, Patil TB. Extensive extracranial and intracranial Varicella zoster vasculopathy. BMJ Case Rep. 2012; doi:10.1136/bcr-2012-006845.

511.

Hoshino S, Hayashi A, Yoshizawa T, Tamaoka A, Shoji S. A case of delayed cerebral infarction occurring in puerperium preceded by herpes zoster ophthalmicus in late pregnancy. No To Shinkei. 1999;51:529–33.PubMed

512.

Kim MJ, Lee KO, Lee KY, Oh SH, Na SJ, Yoon B, et al. Hemichorea caused by intracranial hemorrhage following contralateral herpes zoster ophthalmicus. J Clin Neurosci. 2013;20:738–9.PubMedCrossRef

513.

Song HJ, Hong WK, Lee HS, Choi GS, Shin JH. Herpes zoster complicated by delayed intracranial haemorrhage. Clin Exp Dermatol. 2009;34:518–9.PubMedCrossRef

514.

Verma R, Singh D, Sharma P. Contralateral stroke with rapid recovery in a patient of herpes zoster ophthalmicus. Neurol Asia. 2011;16:247–50.

515.

Kalita J, Das M, Misra UK. Herpes zoster ophthalmicus leading to middle cerebral artery infarction: A case report. Int J Angiol. 2004;13:51–3.CrossRef

516.

Fukutake T, Hatakeyama H, Shinotoh H, Hattori T. Herpes zoster ophthalmicus and delayed contralateral hemiparesis: a case of ipsilateral midbrain involvement. Eur Neurol. 1998;40:57–8.PubMed

517.

Lee SJ, Lee DG. Isolated gait ataxia as a sole manifestation of right lateral medullary infarct following ipsilateral trigeminal herpes zoster. Case Rep Neurol. 2014;6:193–6.PubMedPubMedCentralCrossRef

518.

Yasuda C, Okada K, Ohnari N, Akamatsu N, Tsuji S. Cerebral infarction and intracranial aneurysm related to the reactivation of varicella zoster virus in a Japanese acquired immunodeficiency syndrome (AIDS) patient. Clin Neurol. 2013;53:701–5.

519.

Bhat G, Mathur DS, Saxena GN, Jain S, Singh AP, Bhaduria D. Granulomatous angiitis of the central nervous system associated with herpes zoster. J Assoc Physicians India. 2002;50:977–8.PubMed

520.

Vibha D, Prabhakar S, Khurana D, Khandelwal N. Varicella zoster vasculopathy presenting as lateral medullary syndrome. J Neurovirol. 2012;18:538–40.PubMedCrossRef

521.

Nagafuchi M, Nagafuchi Y, Sato R, Imaizumi T, Ayabe M, Shoji H, et al. Adult meningism and viral meningitis, 1997–2004: Clinical data and cerebrospinal fluid cytokines. Intern Med. 2006;45:1209–12.PubMedCrossRef

522.

Fujita H, Kurokawa S, Imaizumi S, Kawasaki H, Harada K. Two cases of meningitis developed while undergoing therapy for herpes zoster. Nishinihon J Dermatol. 1994;56:992–5.CrossRef

523.

Takeshima S, Neshige S, Himeno T, Hara N, Yoshimoto T, Takamatsu K, et al. Clinical, epidemiological, and etiological studies of aseptic meningitis in adults. Clin Neurol. 2014;54:791–7.

524.

Choi R, Kim GM, Jo IJ, Sim MS, Song KJ, Kim BJ, et al. Incidence and clinical features of herpes simplex viruses (1 and 2) and varicella-zoster virus infections in an adult Korean population with aseptic meningitis or encephalitis. J Med Virol. 2014;86:957–62.PubMedCrossRef

525.

Srivastava T, Nagpal K. Herpes zoster meningoencephalitis complicated with peripheral vascular disease: an uncommon presentation of a common disease. Scand J Infect Dis. 2014;46:716–8.PubMedCrossRef

526.

Ohtomo R, Shirota Y, Iwata A, Shimizu J, Tsuji S. Cerebral microbleeding in varicella-zoster viral meningitis: an early sign of vasculopathy? Neurology. 2014;82:814–5.PubMedCrossRef

527.

Park HK, Lee JH. A case of ramsay hunt syndrome complicated by cerebellitis. J Clin Neurol. 2006;2:198–201.PubMedPubMedCentralCrossRef

528.

Saxena A, Khiangte B, Tiewsoh I, Jajoo UN. Herpes zoster encephalitis presenting as multiple cerebral hemorrhages - a rare presentation: a case report. J Med Case Rep. 2013;7:155.PubMedPubMedCentralCrossRef

529.

Baek W, Lee SG, Kim YS, Kim JH, Jun JB, Kim HY. Fatal varicella-zoster virus vasculopathy associated with adalimumab therapy. Arch Neurol. 2012;69:1193–6.PubMedCrossRef

530.

Sasson SC, Oon A, Chagantri J, Brew BJ, Carr A. Posterior reversible encephalopathy syndrome (PRES) in an HIV-1 infected patient with disseminated varicella zoster virus: a case report. BMC Infect Dis. 2013;13:396.PubMedPubMedCentralCrossRef

531.

Wang L, Holthaus EA, Jimenez XF, Tavee J, Li Y. MRI evolution of CLIPPERS syndrome following herpes zoster infection. J Neurol Sci. 2015;348:277–8.PubMedCrossRef

532.

McKelvie PA, Collins S, Thyagarajan D, Trost N, Sheorey H, Byrne E. Meningoencephalomyelitis with vasculitis due to varicella zoster virus: a case report and review of the literature. Pathology. 2002;34:88–93.PubMedCrossRef

533.

Douglas A, Harris P, Francis F, Norton R. Herpes zoster meningoencephalitis: Not only a disease of the immunocompromised? Infection. 2010;38:73–5.PubMedCrossRef

534.

Sugisaki K, Yoshida H. Varicella zoster virus meningoencephalitis accompanied by sporadic skin lesions in an older immunocompetent adult. J Infect Chemother. 2007;13:270–2.PubMedCrossRef

535.

Chun WC, Kin MT, Wing KT, Tin CL, Wai KK. Hypoglycorrhachia in herpes zoster associated encephalitis of an immunocompetent young male: An unusual presentation. J Neurol. 2005;252:987–8.CrossRef

536.

Miyazaki Y, Riku Y, Goto Y, Mano K, Yoshida M, Hashizume Y. VZV vasculopathy associated with myelo-radiculoganglio-meningo-encephalitis: an autopsy case of an immunocompetent 66-year-old male. J Neurol Sci. 2008;275:42–5.PubMedCrossRef

537.

Byun JW, Song HJ, Choi GS, Shin JH. A clinical study on herpes zoster meningoencephalitis. Korean J Dermatol. 2011;49:328–33.

538.

Yoshifuku A, Ueki Y, Tamai M, Miyoshi H, Higashi Y, Kanekura T, et al. A case of herpes zoster associated with meningoencephalitis. Nishinihon J Dermatol. 2009;71:494–6.CrossRef

539.

Pandey PK, Garg D, Bhatia A, Jain V. Horner’s syndrome and sixth nerve palsy due to herpes zoster ophthalmicus arteritis. Eye. 2005;19:224–6.PubMedCrossRef

540.

Kobayashi Y, Yamamoto T. A case of Horner’s syndrome associated with ophthalmic herpes zoster. Clin Neurol. 2007;47:105–8.

541.

Tsuda H, Tanaka K. Internal carotid artery involvement in herpes zoster ophthalmicus. Intern Med. 2012;51:2067–8.PubMedCrossRef

542.

Nishitani M, Kodama T, Ohashi Y, Tatematsu Y, Maruo H. A case of cavernous sinus syndrome following herpes zoster ophthalmicus. Folia Ophthalmol Jpn. 2002;53:898–903.

543.

Cho BJ, Kim JS, Hwang JM. Horner’s syndrome and contralateral abducens nerve palsy associated with zoster meningitis. Korean J Ophthalmol. 2013;27:474–7.PubMedPubMedCentralCrossRef

544.

Camuglia JE, Beltz JE, Khurana K, Hall AJ. An unusual cause of visual loss after Herpes zoster ophthalmicus: a case report. Cases J. 2010;3:17.PubMedPubMedCentralCrossRef

545.

Roberts TV, Francis IC, Kappagoda MB, Dick AD. Herpes zoster chorioretinopathy. Eye (Lond). 1995;9:594–8.CrossRef

546.

Wang CC, Lin CL, Chang YJ, Wang GJ, Sung FC, Kao CH. Herpes zoster infection associated with acute coronary syndrome: a population-based retrospective cohort study. Br J Dermatol. 2014;170:1122–9.PubMedCrossRef

547.

Wu PY, Lin CL, Sung FC, Chou TC, Lee YT. Increased risk of cardiovascular events in patients with herpes zoster: a population-based study. J Med Virol. 2014;86:772–7.PubMedCrossRef

548.

Maity PK, Chakrabarti N, Mondal M, Patar K, Mukhopadhyay M. Deep vein thrombosis: A rare signature of herpes zoster. J Assoc Physicians India. 2014;62:72–4.PubMed

549.

Kundu AK. Herpes zoster-induced myocarditis in a patient with diabetes mellitus. J Assoc Physicians India. 1999;47:286–7.

550.

Cheung MY, Viney M. A unique case of recurrent asystole secondary to paroxysmal pain of acute herpetic ophthalmicus. Anesth Analg. 2007;105:1127–9.PubMedCrossRef

551.

Kume T, Hirose M, Yamashita T, Mizuno S, Hosokawa T, Sekimoto M, et al. Analysis of blood pressure in elderly patients with postherpetic neuralgia. Pain Clinic. 2001;13:153–7.CrossRef

552.

Lee HW, Kim KJ, Chang SE, Lee MW, Choi JH, Moon KC, et al. A case of generalized herpes zoster associated with herpetic folliculitis and syringitis. Korean J Dermatol. 2005;43:274–6.

553.

Park JS, Ryu H, Ha SH, Park HS, Lee J, Son SJ. Two cases of herpetic syringitis. Korean J Dermatol. 2002;40:1449–51.

554.

Tanaka A, Hayaishi N, Kondo Y, Kurachi K, Tanemura A, Katayama I. Severe gangrene accompanied by varicella zoster virus-related vasculitis mimicking rheumatoid vasculitis. Case Rep Dermatol. 2014;6:103–7.PubMedPubMedCentralCrossRef

555.

Khong JJ, Casson RJ, Huilgol SC, Selva D. Madarosis. Surv Ophthalmol. 2006;51:550–60.PubMedCrossRef

556.

Baek JH, Hong KC, Lee DY, Kim MS, Lee UH, Park HS. Alopecia areata associated with Herpes zoster. J Dermatol. 2013;40:672.PubMedCrossRef

557.

Garg P, Mathur U, Athmanathan S, Rao GN. Treatment outcome of Moraxella keratitis: our experience with 18 cases–a retrospective review. Cornea. 1999;18:176–81.PubMedCrossRef

558.

Yang SC, Ho HC, Lay CJ, Tsai CC. Aspergillus invasive otitis externa as a complication of herpes zoster oticus. Tzu Chi Med J. 2011;23:28–30.CrossRef

559.

Seo JK, Lee SM, Lee SK. Clinical observation of bacterial studies in the skin lesions of patients with herpes zoster. Korean J Dermatol. 2007;45:1031–40.

560.

Yamada Y, Ito R, Bito M, Tashima S, Sakamoto K, Konishi K. A case of subcutaneous abscess at the site of herpes zoster in a patient with poorly controlled diabetes. Skin Res. 2014;13:13–5.

561.

Jarrett P, Ha T, Oliver F. Necrotizing fasciitis complicating disseminated cutaneous herpes zoster. Clin Exp Dermatol. 1998;23:87–8.PubMedCrossRef

562.

Ong CW, Ang BS, Lee CC. Severe varicella infection occurring after herpes zoster reactivation in a patient with AIDS. BMJ Case Rep. 2009; doi:10.1136/bcr.09.2008.0952

563.

Gupta S, Gupta S, Thomas M, Mahendra A, Jindal N, Bhaskar G, et al. Herpes Zoster with disseminated lesions. What is it? J Med Life. 2013;6:84–5.PubMedPubMedCentral

564.

Garg G, Thami GP. Psoriasis herpeticum due to varicella zoster virus: A Kaposi's varicelliform eruption in erythrodermic psoriasis. Indian J Dermatol. 2012;57:213–4.PubMedPubMedCentralCrossRef

565.

Gupta S. Many faces of Koebner phenomenon in psoriasis. Indian J Dermatol Venereol Leprol. 2002;68:222–4.PubMed

566.

Terao M, Tanemura A, Katayama I. Vitiligo exacerbated after herpes zoster. J Dermatol. 2012;39:938–9.PubMedCrossRef

567.

Huang CW, Tu ME, Wu YH, Lin YC. Isotopic response of fungal granuloma following facial herpes zoster infections - report of three cases. Int J Dermatol. 2007;46:1141–5.PubMedCrossRef

568.

Ghorpade A. Wolf’s isotopic response - Furuncles at the site of healed herpes zoster in an Indian male. Int J Dermatol. 2010;49:105–7.PubMedCrossRef

569.

Kim SM, Lee SY, Rhee CH, Lee JS, Yun SK, Kim HU, et al. A case of papular granuloma annulare occurring on the site of herpes zoster: Isotopic response. Korean J Dermatol. 2008;46:818–20.

570.

Ohata C, Shirabe H, Takagi K, Kawatsu T. Granuloma annulare in herpes zoster scars. J Dermatol. 2000;27:166–9.PubMedCrossRef

571.

Wang T, Liu YH, Zheng HY, Yu BT, Fang K. A case of nonspecific granulomatous perivasculitis on herpes zoster scars. J Clin Dermatol. 2010;39:163–4.

572.

Inaoka M, Kano Y, Horie C, Shiohara T. Cutaneous granulomatous reaction after herpes zoster in drug-induced hypersensitivity syndrome. Am J Dermatopathol. 2011;33:872–4.PubMedCrossRef

573.

Suh KS, Choi SY, Jeon YS, Sim HJ, Kim ST. A case of granuloma annulare occurring on herpes zoster. Korean J Dermatol. 2005;43:834–6.

574.

Chang SE, Bae GY, Moon KC, Do SH, Lim YJ. Subcutaneous granuloma annulare following herpes zoster. Int J Dermatol. 2004;43:298–9.PubMedCrossRef

575.

Ohmori S, Sugita K, Ikenouchi-Sugita A, Nakamura M. Erythema annulare centrifugum associated with herpes zoster. J UOEH. 2012;34:225–9.PubMedCrossRef

576.

Sugita K, Kabashima K, Tokura Y. Erythema annulare centrifugum associated with herpes zoster. Eur J Dermatol. 2008;18:205–6.PubMed

577.

Lee HW, Lee DK, Rhee DY, Chang SE, Choi JH, Moon KC, et al. Erythema annulare centrifugum following herpes zoster infection: Wolf’s isotopic response? Br J Dermatol. 2005;153:1241–3.PubMedCrossRef

578.

Onishi I, Kishimoto S. Erythema multiforme after resolution of herpes zoster by acyclovir. Eur J Dermatol. 2002;12:370–2.PubMed

579.

Kim JS, Kim MH, Choi HY, Myung KB. A Case of zosteriform lichen planus occurring on herpes zoster lesions. Korean J Dermatol. 2004;42:217–9.

580.

Choi HJ, Chang SE, Lee MW, Choi JH, Moon KC, Koh JK. A case of zosteriform lichen planus on the site of healed herpes zoster: Wolf’s isotopic response. Korean J Dermatol. 2004;42:456–9.

581.

Noh TW, Park SH, Kang YS, Lee UH, Park HS, Jang SJ. Morphea developing at the site of healed herpes zoster. Ann Dermatol. 2011;23:242–5.PubMedPubMedCentralCrossRef

582.

Qu T, Fang K. Bullous morphea arising at the site of a healed herpes zoster. J Dermatol. 2014;41:553–4.PubMedCrossRef

583.

Endo Y, Tanioka M, Tanizaki H, Mori M, Kawabata H, Miyachi Y. Bullous variant of Sweet's syndrome after herpes zoster virus infection. Case Rep Dermatol. 2011;3:259–62.PubMedPubMedCentralCrossRef

584.

Ghorpade AK. Reactive perforating collagenosis with a giant lesion at the site of healed herpes zoster. Indian J Dermatol Venereol Leprol. 2011;77:202–3.PubMedCrossRef

585.

Bang SW, Kim YK, Whang KU. Acquired reactive perforating collagenosis: unilateral umbilicated papules along the lesions of herpes zoster. J Am Acad Dermatol. 1997;36:778–9.PubMedCrossRef

586.

Lee HJ, Roh KY, Ha SJ, Kim JW. Pitted keratolysis of the palm arising after herpes zoster. Br J Dermatol. 1999;140:974–5.PubMedCrossRef

587.

Miura T, Yamamoto T. Post-herpes zoster sarcoidosis. J Dermatol. 2014;41:458–9.PubMedCrossRef

588.

Watanabe D, Kuhara T, Ishida N, Tamada Y, Matsumoto Y. Sarcoid tissue reaction on herpes zoster scars in a myelodysplastic syndrome patient: Wolf's isotopic response. J Eur Acad Dermatol Venereol. 2009;23:475–7.PubMedCrossRef

589.

Verma KK, Mittal R. Cutaneous lesions of multicentric reticulohystiocytosis developing in herpes zoster lesions. Acta Derm Venereol. 2000;80:150.PubMedCrossRef

590.

Yamamoto T, Yokoyama A. Nodular solar degeneration following herpes zoster. Br J Dermatol. 1996;134:606.PubMedCrossRef

591.

Mittal RR, Singh SP, Gupta S, Sethi PS. Nodular colloid degeneration over herpes zoster scars. Indian J Dermatol Venereol Leprol. 1996;62:181–2.PubMed

592.

Kwon JI, Cho JW, Lee KS. A case of verrucous hyperplasia at the site of healed herpes zoster: Isotopic response. Korean J Dermatol. 2011;49:726–9.

593.

Kim MB, Jwa SW, Ko HC, Kim SJ, Kwon KS, Oh CH. A case of secondary cutaneous mucinosis following herpes zoster: Wolf’s isotopic response. Int J Dermatol. 2009;48:212–4.PubMedCrossRef

594.

Lee HJ, Ahn WK, Chae KS, Ha SJ, Kim JW. Localized chronic urticaria at the site of healed herpes zoster. Acta Derm Venereol. 1999;79:168.PubMedCrossRef

595.

De D, Dogra S, Kanwar AJ. Prurigo nodularis in healed herpes zoster scar: An isotopic response. J Eur Acad Dermatol Venereol. 2007;21:711–2.PubMed

596.

Lee YB, Park HJ, Lee JY, Cho BK. Two cases of chronic cutaneous graft-versus-host-reaction on the site of healed herpes zoster as an isotopic response. Korean J Dermatol. 2008;46:90–3.

597.

Matsumura T, Watanabe H, Batchelor J, Sueki H, Iijima M. Drug eruption caused by the nonionic contrast medium iohexol. Recall-like phenomenon' appearing on an area previously affected by herpes zoster. J Dermatol. 2006;33:705–8.PubMedCrossRef

598.

Na SY, Lee HY, Baek JO, Roh JY, Lee JR. A case of cutaneous zosteriform metastatic carcinoma arising on the healed site of herpes zoster. Korean J Dermatol. 2008;46:347–51.

599.

Hapgood G, Mooney E, Dinh HV, Gin D, McLean C, Ting SB. Leukaemia cutis in chronic lymphocytic leukaemia following varicella zoster virus reactivation. Intern Med J. 2012;42:1355–8.PubMedCrossRef

600.

Kim TH, Kim DH, Yeom JS, Lee GY, Kim WS, Kim KJ. A case of AIDS-associated Kaposi's sarcoma on the site of healed herpes zoster as an isotopic response. Korean J Dermatol. 2009;47:1172–6.

601.

Kim CY, Nam YH, Kim GD, Oh CW. Tufted angioma in site of healed herpes zoster: Isotopic response. Clin Exp Dermatol. 2006;31:714–5.PubMedCrossRef

602.

Siwamogstham P, Kuansuwan C, Reichart PA. Herpes zoster in HIV infection with osteonecrosis of the jaw and tooth exfoliation. Oral Dis. 2006;12:500–5.PubMedCrossRef

603.

Volvoikar P, Patil S, Dinkar A. Tooth exfoliation, osteonecrosis and neuralgia following herpes zoster of trigeminal nerve. Indian J Dent Res. 2002;13:11–4.PubMed

604.

Pillai KG, Nayar K, Rawal YB. Spontaneous tooth exfoliation, maxillary osteomyelitis and facial scarring following trigeminal herpes zoster infection. Prim Dent Care. 2006;13:114–6.PubMedCrossRef

605.

Jain MK, Manjunath KS, Jagadish SN. Unusual oral complications of herpes zoster infection: report of a case and review of literature. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2010;110:e37–41.PubMedCrossRef

606.

Lambade P, Lambade D, Saha TK, Dolas RS, Pandilwar PK. Maxillary osteonecrosis and spontaneous teeth exfoliation following herpes zoster. Oral Maxillofac Surg. 2012;16:369–72.PubMedCrossRef

607.

Yamamoto K, Inagake K, Tatebayashi S, Yamakawa N, Inoue M, Yasumoto J, et al. Alveolar osteonecrosis of the mandible after varicella zoster infection of the trigeminal nerve. Asian J Oral Maxillofac Surg. 2004;16:204–8.CrossRef

608.

Badjate SJ, Cariappa KM, Shenoi SR, Nakhate S. Ramsay-Hunt syndrome complicating osteonecrosis of edentulous maxilla and mandible: report of a rare case. J Maxillofac Oral Surg. 2009;8:188–91.PubMedPubMedCentralCrossRef

609.

Pushpanshu K, Kaushik R, Srivastava S, Punyani SR. An unusual complication of tooth exfoliation and osteonecrosis following herpes zoster infection of trigeminal nerve: a case report and literature review. Minerva Stomatol. 2013;62:241–5.PubMed

610.

Mahima VG, Patil K, Srikanth HS. Herpes zoster induced alveolar necrosis in an immunocompetent patient. Iran J Clin Infect Dis. 2010;5:235–8.

611.

Liu YC, Yang YH, Hsiao HH, Yang WC, Liu TC, Chang CS, et al. Herpes zoster is associated with an increased risk of subsequent lymphoid malignancies - a nationwide population-based matched-control study in Taiwan. BMC Cancer. 2012;12:503.PubMedPubMedCentralCrossRef

612.

Ho JD, Xirasagar S, Lin HC. Increased risk of a cancer diagnosis after herpes zoster ophthalmicus: a nationwide population-based study. Ophthalmology. 2011;118:1076–81.PubMedCrossRef

613.

Yamamoto M, Mine H, Akazawa K, Maehara Y, Sugimachi K. Gastrointestinal cancer and herpes zoster in adults. Hepatogastroenterology. 2003;50:1043–6.PubMed

614.

Lin SY, Liu JH, Yeh HC, Lin CL, Tsai IJ, Chen PC, et al. Association between herpes zoster and end stage renal disease entrance in chronic kidney disease patients: a population-based cohort study. Eur J Clin Microbiol Infect Dis. 2014;33:1809–15.PubMedCrossRef

615.

Jiang ZM, Gao YH, Meng W, Wu WY, Jin L, Shen FM. The study on familial aggregation of systemic lupus erythematosus. Fudan Univ J Med Sci. 2005;32:270–4.

616.

Kang JH, Sheu JJ, Kao S, Lin HC. Increased risk of multiple sclerosis following herpes zoster: a nationwide, population-based study. J Infect Dis. 2011;204:188–92.PubMedCrossRef

617.

Tsai SY, Yang TY, Chen HJ, Chen CS, Lin WM, Shen WC, et al. Increased risk of chronic fatigue syndrome following herpes zoster: a population-based study. Eur J Clin Microbiol Infect Dis. 2014;33:1653–9.PubMedCrossRef

618.

Chen MH, Wei HT, Su TP, Li CT, Lin WC, Chang WH, et al. Risk of depressive disorder among patients with herpes zoster: a nationwide population-based prospective study. Psychosom Med. 2014;76:285–91.PubMedCrossRef

619.

Wang X, Zhang L, Lei Y, Liu X, Zhou X, Liu Y, et al. Meta-analysis of infectious agents and depression. Sci Rep. 2014;4:4530.PubMed

620.

Chen YH, Chen YK, Keller JJ, Lin HC. A population-based case–control analysis of the association between herpes zoster and erectile dysfunction. J Infect. 2012;65:150–6.PubMedCrossRef

621.

Chiu HF, Chen BK, Yang CY. Herpes zoster and subsequent risk of cancer: a population-based study. J Epidemiol. 2013;23:205–10.PubMedPubMedCentralCrossRef

622.

Wang YP, Liu CJ, Hu YW, Chen TJ, Lin YT, Fung CP. Risk of cancer among patients with herpes zoster infection: a population-based study. CMAJ. 2012;184:E804–9.PubMedPubMedCentralCrossRef

623.

Wang CC, Shiang JC, Chen JT, Lin SH. Syndrome of inappropriate secretion of antidiuretic hormone associated with localized herpes zoster ophthalmicus. J Gen Intern Med. 2011;26:216–20.PubMedCrossRef

624.

O'Rourke F, Chilov M. Localised herpes zoster infection and SIADH. Aust Fam Physician. 2006;35:789–90.PubMed

625.

Furuta E, Yasuda M, Yoshioka K, Isayama T, Nobunaga M. Syndrome of inappropriate secretion of antidiuretic hormone in elderly patients with rheumatoid arthritis associated with infections: Report of two cases. Intern Med. 1996;35:478–81.PubMedCrossRef

626.

Reid AB, Gome JJ. Localized herpes zoster infection causing the syndrome of inappropriate antidiuretic hormone secretion. Intern Med J. 2009;39:486–7.PubMedCrossRef

627.

Tsutsumi R, Adachi K, Yoshida Y, Yamamoto O. Drug-induced hypersensitivity syndrome in association with varicella. Acta Derm Venereol. 2015;95:503–4.PubMedCrossRef

628.

Tamayose K, Sugimoto K, Ando M, Oshimi K. Mononucleosis syndrome and acute monocytic leukemia. Eur J Haematol. 2002;68:236–8.PubMedCrossRef

629.

Eun YB, Bo KK, Seok GC, Jin WK. A case of disseminated herpes zoster with thrombocytopenia. Korean J Dermatol. 2005;43:410–12.

630.

Kawano N, Gondo H, Kamimura T, Aoki K, Iino T, Ishikawa F, et al. Chronic graft-versus-host disease following varicella-zoster virus infection in allogeneic stem cell transplant recipients. Int J Hematol. 2003;78:370–3.PubMedCrossRef

631.

Park BC, Choe YS, Kim DW, Lee WJ, Lee SJ, Na GY. Clinical study on dermatologic disease of the elderly. Korean J Dermatol. 2006;44:818–23.

632.

Furue M, Yamazaki S, Jimbow K, Tsuchida T, Amagai M, Tanaka T, et al. Prevalence of dermatological disorders in Japan: a nationwide, cross-sectional, seasonal, multicenter, hospital-based study. J Dermatol. 2011;38:310–20.PubMedCrossRef

633.

Yoon NY, Hong SP, Jeon SY, Shin JS, Ahn SK. A clinical study of dermatologic diseases in elderly patients. Korean J Dermatol. 2011;49:887–95.

634.

Go JW, Cho HK, Kang WH, Ro BI. A statistical study of dermatoses in Goyang City (2004 ∼ 2008). Korean J Dermatol. 2009;47:896–903.

635.

Choi HS, Yun SK, Kim HU, Ihm CW. A statistical study of dermatoses in the Jeonbuk Province (1979–1980, 1987–2002). Korean J Dermatol. 2005;43:606–18.

636.

Hong S, Lee ES, Yoon KH. A statistical study of dermatoses in the Suwon area and southern area of Kyonggi (1995–2001). Korean J Dermatol. 2003;41:728–39.

637.

Shin BJ, Choe SW, Seo SJ, Hong CK. A clinical study of skin diseases in elderly patients(IV). Korean J Dermatol. 2002;40:1346–52.

638.

Wang E, Lim BL, Than KY. Dermatological conditions presenting at an emergency department in Singapore. Singapore Med J. 2009;50:881–4.PubMed

639.

Chan CY, Kam KL, Graham CA, Rainer TH, Luk NM. Clinical profile of skin diseases in accident and emergency department attenders. Hong Kong J Dermatol Venereol. 2007;15:4–9.

640.

Zhang Y, Zhou SX, Zhang TF, Huang GF. Analysis of the distribution of diseases in 6435 inpatients from the department of acupuncture and moxibustion. Zhongguo Zhen Jiu. 2011;31:941–4.PubMed

641.

Park EJ, Han KR, Kim DW, Kim C. A clinical survey of the patients in neuro-pain clinic at Ajou University. Korean J Pain. 2007;20:181–5.CrossRef

642.

Ministry of Health. Immunisation Handbook 2014 (3rd edn). Wellington: Ministry of Health. 2016. http://www.health.govt.nz/system/files/documents/publications/imm-handbk-2014-3rd-edn-dec16.pdf. Accessed 17 Jan 2017.

643.

Gan EY, Tian EA, Tey HL. Management of herpes zoster and post-herpetic neuralgia. Am J Clin Dermatol. 2013;14:77–85.PubMedCrossRef

644.

Wehrhahn MC, Dwyer DE. Herpes zoster: Epidemiology, clinical features, treatment and prevention. Aust Prescr. 2012;35:143–7.CrossRef

645.

Cunningham AL, Litt J. Shingles: How to prevent it, how to treat it. Med Today. 2014;15:20–7.

646.

Cunningham AL, Breuer J, Dwyer DE, Gronow DW, Helme RD, Litt JC, et al. The prevention and management of herpes zoster. Med J Aust. 2008;188:171–6.PubMed

647.

Chopra A, Jassal JS, Bahl RK. Role of acyclovir and laser therapy in herpes zoster. Indian J Dermatol Venereol Leprol. 1994;60:208–9.

648.

Hayashibe K, Ichihashi M. Efficacy of acyclovir 400 mg tablet (Zovirax® tablet 400) in herpes zoster. Skin Res. 1994;36:543–50.

649.

Sugiyama Y, Tamura T, Seguchi T, Yoshida M, Tezuka T. Evaluation of efficacy of oral acyclovir in herpes zoster Trial of 2400 mg 3 times daily. Skin Res. 1994;36:459–64.

650.

Yoshikawa K, Doi T. Clinical evaluation of Zovirax® (acyclovir) tablet 400 on herpes zoster. Skin Res. 1994;36:441–58.

651.

Chen YH. Observation of oral acyclovir combined with sodium hyaluronate and fluorometholone eye drops on the treatment of herpes zoster keratitis. Intern Eye Sci. 2014;14:729–30.

652.

McDonald EM, de Kock J, Ram FS. Antivirals for management of herpes zoster including ophthalmicus: a systematic review of high-quality randomized controlled trials. Antivir Ther. 2012;17:255–64.PubMedCrossRef

653.

Lin WR, Lin HH, Lee SS, Tsai HC, Huang CK, Wann SR, et al. Comparative study of the efficacy and safety of valaciclovir versus acyclovir in the treatment of herpes zoster. J Microbiol Immunol Infect. 2001;34:138–42.PubMed

654.

Shen MC, Lin HH, Lee SS, Chen YS, Chiang PC, Liu YC. Double-blind, randomized, acyclovir-controlled, parallel-group trial comparing the safety and efficacy of famciclovir and acyclovir in patients with uncomplicated herpes zoster. J Microbiol Immunol Infect. 2004;37:75–81.PubMed

655.

Chen A, Sun X. Comparative study of treatment of herpes zoster with valaciclovir and acyclovir. Med J Wuhan Univ. 2006;27:537–8.

656.

Gopal MG, Shannoma, Sharath Kumar BC, Ramesh M, Nandini AS, Manjunath NC. A comparative study to evaluate the efficacy and safety of acyclovir and famciclovir in the management of herpes zoster. J Clin Diagn Res. 2013;7:2904–7.PubMedPubMedCentral

657.

Liao R, Wu J, Yang H. Contrast of acycloguanosine, famciclovir, ribavirin in treatment of herps zoster pruritus. Chin J Clin Rehab. 2003;7:904–5.

658.

Li W, Guo ZP, Xiong L. Domestic penciclovir powder through injection for improving cutaneous deficiency and residual neuralgia in patients with herpes zoster: A randomized, double-blind and controlled trial. Chin J Clin Rehab. 2005;9:34–7.

659.

Sodhi PK, Ratan SK. A case of chronic renal dysfunction following treatment with oral acyclovir. Scand J Infect Dis. 2003;35:770–2.PubMedCrossRef

660.

Kitching AR, Fagg D, Hay NM, Hatfield PJ, Macdonald A. Neurotoxicity associated with acyclovir in end stage renal failure. New Zealand Med J. 1997;110:167–9.PubMed

661.

Takayanagi A, Maehana T, Kyoda Y, Yanase M. Neurotoxicity of valacyclovir in a peritoneal dialysis patient. Hinyokika Kiyo. 2010;56:617–9.PubMed

662.

Asahi T, Tsutsui M, Wakasugi M, Tange D, Takahashi C, Tokui K, et al. Valacyclovir neurotoxicity: clinical experience and review of the literature. Eur J Neurol. 2009;16:457–60.PubMedCrossRef

663.

Yang HH, Hsiao YP, Shih HC, Yang JH. Acyclovir-induced neuropsychosis successfully recovered after immediate hemodialysis in an end-stage renal disease patient. Int J Dermatol. 2007;46:883–4.PubMedCrossRef

664.

Fujii H, Tanioka M, Matsumura Y, Miyachi Y, Matsubara T. A case of valaciclovir induced encephalopathy in a patient with peritoneal dialysis. Skin Res. 2007;6:372–5.

665.

Sagawa N, Tsurutani Y, Nomura K, Okuyama T, Kondo M, Sata A, et al. Acyclovir-Induced neurotoxicity and acute kidney injury in an elderly diabetic patient treated with valacyclovir: Report of a case. Nihon Ronen Igakkai Zasshi. 2014;51:581–5.PubMedCrossRef

666.

Ng HW, Pang CT. Confusion in patients with shingles and renal failure: Acyclovir neurotoxicity or herpes encephalitis. Hong Kong J Emerg Med. 2012;19:205–9.

667.

Matsumoto R, Yoshida T, Tabata KI, Nakagawa SI, Yanagisawa N. A patient with thyroid carcinoma who developed consciousness disturbance during acyclovir administration for herpes zoster. Clin Neurol. 1996;36:590–3.

668.

Mihara A, Mori T, Nakazato T, Ikeda Y, Okamoto S. Acute renal failure caused by intravenous acyclovir for disseminated varicella zoster virus infection. Scand J Infect Dis. 2007;39:94–5.PubMedCrossRef

669.

Yamamoto Y, Suganuma A, Mishima N, Horibe C, Saito Y. A case of acute renal failure due to valacyclovir in an elderly patient with progressive supranuclear palsy. IRYO Jpn J Natl Med Serv. 2009;63:735–9.

670.

Kusakari Y, Tanita M, Egawa T, Yoshida H, Shingou T, Nakamura K, et al. Efficacy and safety of famciclovir for the treatment of herpes zoster patients with renal dysfunction. Nishinihon J Dermatol. 2014;76:44–51.CrossRef

671.

Yoon H, Rhew KY. Famciclovir as an antiviral agent for a patient with acute renal failure. Int J Clin Pharm. 2013;35:173–5.PubMedCrossRef

672.

Okamoto S, Ishibashi Y, Inoue Y, Uchio E, Ohashi Y, Kitagawa K, et al. Multicentered survey of ocular complications of acyclovir ophthalmic ointment. Jpn J Clin Ophthalmol. 1997;51:1112–4.

673.

Zhang JS. Clinical effect comparison of ganciclovir ophthalmic gel and ganciclovir eye drops in the treatment of herpes zoster keratitis. Int J Ophthalmol. 2011;11:309–10.

674.

Li SQ, Jia J, Zhang ZY. Clinical observation on eyelid herpes zoster with external use ganciclovir ophthalmic gel. Intern Eye Sci. 2014;14:1356–7.

675.

Nakamura H, Ishimoto S, Fujisawa K, Okada T, Tahara Y, Nakamura T, et al. Systemic ganciclovir with vitrectomy was effective in two cases of acute retinal necrosis. Jpn J Clin Ophthalmol. 1999;53:1599–603.

676.

Lee MY, Kim KS, Lee WK. Intravitreal foscarnet for the treatment of acyclovir-resistant acute retinal necrosis caused by varicella zoster virus. Ocul Immunol Inflamm. 2011;19:212–3.PubMedCrossRef

677.

Hwangbo H, Jung SW, Son HH, Lee SK. Comparison between famciclovir and valacyclovir for the treatment of herpes zoster in adults. Korean J Dermatol. 2014;52:720–7.

678.

Ono F, Yasumoto S, Furumura M, Hamada T, Ishii N, Gyotoku T, et al. Comparison between famciclovir and valacyclovir for acute pain in adult Japanese immunocompetent patients with herpes zoster. J Dermatol. 2012;39:902–8.PubMedCrossRef

679.

Bodsworth NJ, Boag F, Burdge D, Généreux M, Borleffs JC, Evans BA, et al. Evaluation of sorivudine (BV-araU) versus acyclovir in the treatment of acute localized herpes zoster in human immunodeficiency virus-infected adults. The Multinational Sorivudine Study Group. J Infect Dis. 1997;176:103–11.PubMedCrossRef

680.

Watabe T, Okuda H, Ogura K. Lethal drug interactions of the new antiviral, sorivudine, with anticancer prodrugs of 5-fluorouracil. Yakugaku Zasshi. 1997;117:910–21.PubMed

681.

Chen N, Li Q, Yang J, Zhou M, Zhou D, He L. Antiviral treatment for preventing postherpetic neuralgia. Cochrane Database Syst Rev. 2014;2:CD006866.

682.

Liu G, Zhan H, Deng R. A clinical study of 32 Hunt syndrome. Acta Acad Med Hubei. 1996;17:73.

683.

Ho KY, Pasutharnchat K. Intrathecal dexamethasone for the treatment of intractable postherpetic neuralgia: A case report. Internet J Pain Symptom Control Palliative Care. 2009;6:4.

684.

Achar A, Chakraborty PP, Bisai S, Biswas A, Guharay T. Comparative study of clinical efficacy of amitriptyline and pregabalin in postherpetic neuralgia. Acta Dermatovenerol Croat. 2012;20:89–94.PubMed

685.

Wrigley P, Cousins M. Postherpetic neuralgia: An update on management and prevention. Med Today. 2008;9:36–44.

686.

Kochar DK, Agarwal RP, Joshi A, Kumawat BL. Herpes zoster and post-herpetic neuralgia – a clinical trial of aspirin in chloroform for anodyne. J Assoc Physicians India. 1998;46:337–40.PubMed

687.

Kanodia SK, Singhal KC. A study on efficacy of Pregabalin in acute Herpetic Neuralgia. Ann Neurosci. 2011;18:148–50.PubMedPubMedCentralCrossRef

688.

Kanodia SK, Seth AK, Dixit AM. Dose related efficacy of gabapentin in acute herpetic neuralgia among geriatric patients. Indian J Dermatol. 2012;57:362–5.PubMedPubMedCentralCrossRef

689.

Sabatowski R, Galvez R, Cherry DA, Jacquot F, Vincent E, Maisonobe P, et al. Pregabalin reduces pain and improves sleep and mood disturbances in patients with post-herpetic neuralgia: Results of a randomised, placebo-controlled clinical trial. Pain. 2004;109:26–35.PubMedCrossRef

690.

Meng FY, Zhang LC, Liu Y, Pan LH, Zhu M, Li CL, et al. Efficacy and safety of gabapentin for treatment of postherpetic neuralgia: a meta-analysis of randomized controlled trials. Minerva Anestesiol. 2014;80:556–7.PubMed

691.

Doggrell SA. Pregabalin or morphine and gabapentin for neuropathic pain. Expert Opin Pharmacother. 2005;6:2535–9.PubMedCrossRef

692.

Zhang LX, Li GL. Effect of oxycodone-acetaminophen therapy in patients with intractable postherpetic neuralgia. Chin J New Drugs. 2009;18:427–8.

693.

Zhao G, Zhang H. Analgesic effect of oxycodone-acetaminophen tablets on herpes zoster. Chin J New Drugs. 2009;18:720–1.

694.

Liu GH, Liu JM. Efficacy of oxycodone-acetamainophen on postherpetic neuralgia in patients with zoster. Chin J New Drugs. 2009;18:722–3. 740.

695.

Wu XM, Zhu SM. Effect of oxycodone-acetaminophen in 58 patients with herpes zoster. Chin J New Drugs. 2009;18:718–9. 721.

696.

Yang Y, Yan JQ, Guo QL, Chen ZG. Safety and efficacy of oral oxycodone-acetaminophen versus tramadol in treatment of postherpetic neuralgia. Chin J New Drugs. 2009;18:527–9.

697.

Lin PL, Fan SZ, Huang CH, Huang HH, Tsai MC, Lin CJ, et al. Analgesic effect of lidocaine patch 5% in the treatment of acute herpes zoster: a double-blind and vehicle-controlled study. Reg Anesth Pain Med. 2008;33:320–5.PubMed

698.

Garnock-Jones KP, Keating GM. Lidocaine 5% medicated plaster: a review of its use in postherpetic neuralgia. Drugs. 2009;69:2149–65.PubMedCrossRef

699.

Iseki M, Mitsuhata H, Miyazaki T, Toriumi E, Yoshino K. Relief of subacute herpetic pain and postherpetic neuralgia with repeated application of 10% lidocaine cream. Jpn J Anesthesiol. 2000;49:1204–9.

700.

Cousins MJ, Pickthorn K, Huang S, Critchley L, Bell G. The safety and efficacy of KAI-1678– an inhibitor of epsilon protein kinase C (εPKC)–versus lidocaine and placebo for the treatment of postherpetic neuralgia: a crossover study design. Pain Med. 2013;14:533–40.PubMedCrossRef

701.

Chen SM, Chen JT, Kuan TS, Hong CZ. Myofascial trigger points in intercostal muscles secondary to herpes zoster infection of the intercostal nerve. Arch Phys Med Rehabil. 1998;79:336–8.PubMedCrossRef

702.

Xiao LZ, Zhang DR, Jiang J, Zhang KL, Zhang M, Zhu HQ. Feasibility of transdermal fentanyl for pain relief of herpes zoster and postherpetic neuralgia. Chin J Clin Rehab. 2004;8:216–7.

703.

Lee GY. The effect of fentanyl patch in the treatment of intractable postherpetic neuralgia. Korean J Dermatol. 2007;45:422–8.

704.

Guo WJ, Xiao ZY, Yang YX. Effectiveness of transdermal fentanyl combined with clodine for pain control of acute herpes zoster. J Dalian Med Univ. 2007;29:255–6.

705.

Pan BC, Hou XW, Li XP. Curative effect of recombinant human interferon α2b gel combined with aciclovir on herpes zoster. Chin J Biol. 2008;21:711–2.

706.

Miyoshi H, Hirotsuji N, Kino T, Katsu K. Interferon alpha gel for herpes zoster. Dermatology. 1997;194:306.PubMedCrossRef

707.

Akimoto T. Clinical evaluation of 3% Ara-A ointment on herpes zoster and herpes simplex. Skin Res. 1995;37:164–79.

708.

Ishii N, Baba N, Nakajima H, Yoshida S, Katoh Y. Clinical studies of Arasena-A® ointment I Clinical effects on herpes zoster. Skin Res. 1994;36:220–7.

709.

Shann F. Povidone-iodine for herpes zoster. Lancet. 2004;364:502.PubMedCrossRef

710.

Sun W, Xiang X, Zeng X. Compound ribavirin paint: Preparation and application. Chin Pharm J (China). 1996;31:150–3.

711.

Keam SJ, Chapman TM, Figgitt DP. Brivudin (bromovinyl deoxyuridine). Drugs. 2004;64:2091–7.PubMedCrossRef

712.

Kanai A, Osawa S, Suzuki A, Ishimaru R, Hoka S. Effectiveness of prostaglandin E1 for the treatment of patients with neuropathic pain following herpes zoster. Pain Med. 2007;8:36–40.PubMedCrossRef

713.

Kanai A, Wang G, Hoshi K, Okamoto H. Effects of intravenous prostaglandin E1 on pain and body temperature in patients with post-herpetic neuralgia. Pain Med (USA). 2010;11:609–16.CrossRef

714.

Lu YG, Wu JJ, Yang YD. Study of efficacy of Lipo PGE1 in treatment of postherpetic neuralgia in patients with herpes zoster. Chin J Clin Rehab. 2002;6:3092–3.

715.

Kushida Y, Yoshida M, Akaike Y, Yamada K, Nishizuka K, Kita M, et al. The effects of Lipo-PGE1 on shooting pain of postherpetic neuralgia. Hokuriku J Anesthesiol. 1999;33:59–62.

716.

Fujii K, Kanno Y, Konishi K, Ohgou N. A specific thrombin inhibitor, argatroban, alleviates herpes zoster-associated pain. J Dermatol. 2001;28:200–7.PubMedCrossRef

717.

Komori M, Fukuuchi A, Mae T, Nishiyama K, Kawamata M, Ozaki M. Milnacipran hydrochloride for the treatment of postherpetic neuralgia. Pain Clinic. 2006;18:421–3.CrossRef

718.

Sekiguchi T, Fujihara K, Sato H. Clinical effects of immunoglobulin (Polyglobin® N) for severe infectious disorders in dermatology. Jpn Pharmacol Ther. 1995;23:195–208.

719.

Xu G, Lv ZW, Feng Y, Tang WZ, Xu GX. A single-center randomized controlled trial of local methylcobalamin injection for subacute herpetic neuralgia. Pain Med. 2013;14:884–94.PubMedCrossRef

720.

Han G, Kim SH, Lee KS, Cho JW. Effect of botulinum toxin a on acute and chronic pain in herpes zoster patients. Korean J Dermatol. 2014;52:845–50.

721.

Zacest A, Anderson VC, Burchiel KJ. The glass half empty or half full – how effective are long-term intrathecal opioids in post-herpetic neuralgia? A case series and review of the literature. Neuromodulation. 2009;12:219–23.PubMedCrossRef

722.

Ji G, Niu J, Shi Y, Hou L, Lu Y, Xiong L. The effectiveness of repetitive paravertebral injections with local anesthetics and steroids for the prevention of postherpetic neuralgia in patients with acute herpes zoster. Anesth Analg. 2009;109:1651–5.PubMedCrossRef

723.

Ji CM, Li XM, Sun DH, Jiang CL, Li SL. Clinical study on stellate ganglion block combined with pregabalin for treating postherpetic neuralgia at chest and back. Chin J New Drugs. 2012;21:1503–6.

724.

Wang JS. The comparison of therapeutic effect of three methods for the treatment of acute herpes zoster. Curr Opin Clin Exp Res. 2002;4:12–5.

725.

Manabe H, Dan K, Hirata K, Hori K, Shono S, Tateshi S, et al. Optimum pain relief with continuous epidural infusion of local anesthetics shortens the duration of zoster-associated pain. Clin J Pain. 2004;20:302–8.PubMedCrossRef

726.

Bhargava R, Bhargava S, Haldia KN, Bhargava P. Jaipur block in postherpetic neuralgia. Int J Dermatol. 1998;37:465–8.PubMedCrossRef

727.

Puri N. Modified Jaipur block for the treatment of post-herpetic neuralgia. Int J Dermatol. 2011;50:1417–20.PubMedCrossRef

728.

Chaturvedi A, Dash HH. Sympathetic blockade for the relief of chronic pain. J Indian Med Assoc. 2001;99:698–703.PubMed

729.

Hwang SM, Kang YC, Lee YB, Yoon KB, Ahn SK, Choi EH. The effects of epidural blockade on the acute pain in herpes zoster. Arch Dermatol. 1999;135:1359–64.PubMedCrossRef

730.

Ahn HJ, Lim HK, Lee YB, Hwang SM, Lee WS, Ahn SK, et al. The effects of famciclovir and epidural block in the treatment of herpes zoster. J Dermatol. 2001;28:208–16.PubMedCrossRef

731.

Ahn SY, Lee YB, Lee KH, Lim HK, Lee WS, Ahn SK, et al. The effect of stellate ganglion block on herpes zoster. Korean J Dermatol. 2006;44:681–7.

732.

Jun JH, Ro YS, Kim JH, Shim JC. The effects of continuous epidural blockade in the treatment of postherpetic neuralgia. Korean J Dermatol. 1998;36:584–8.

733.

Koh WS, Park SM, Kim BS, Shin DY. The effect of sympathetic blocks in the prevention of postherpetic neuralgia. Korean J Dermatol. 1997;35:620–6.

734.

Shin HY, Kim DS, Kim SS. Superficial cervical plexus block for management of herpes zoster neuralgia in the C3 dermatome: a case report. J Med Case Rep. 2014;8:59.PubMedPubMedCentralCrossRef

735.

Lee JY, Sim WS, Kim KM, Oh MS, Lee JE. The effect of ketamine as an additive in epidural block on the intractable herpetic neuralgia: a case report. Korean J Anesthesiol. 2014;66:64–6.PubMedPubMedCentralCrossRef

736.

Chau SW, Soo LY, Lu DV, Chen TI, Cheng KI, Chu KS. Clinical experience of pain treatment for postherpetic neuralgia in elderly patients. Acta Anaesthesiol Taiwan. 2007;45:95–101.PubMed

737.

Dan K. Nerve block therapy and postherpetic neuralgia. Crit Rev Phys Rehabil Med. 1995;7:93–112.CrossRef

738.

Higa K, Hori K, Harasawa I, Hirata K, Dan K. High thoracic epidural block relieves acute herpetic pain involving the trigeminal and cervical regions: Comparison with effects of stellate ganglion block. Reg Anesth. 1998;23:25–9.

739.

Mizuno J, Sugimoto S, Ikeda M, Kamakura T, Machida K, Kusume S. Treatment with stellate ganglion block, continuous epidural block and ulnar nerve block of a patient with postherpetic neuralgia who developed complex regional pain syndrome (CRPS). Jpn J Anesthesiol. 2001;50:548–51.

740.

Tajima K, Iseki M, Inada E, Miyazaki T. The effects of early nerve blocks for prevention of postherpetic neuralgia and analysis of prognostic factors. Jpn J Anesthesiol. 2009;58:153–9.

741.

Tajima K, Kawagoe I, Kanai M, Mitsuhata H. Effective treatment of acute pain and related symptoms in elderly with herpes zoster. Jpn J Anesthesiol. 2008;57:874–8.

742.

Kishimoto N, Kato J, Suzuki T, Arakawa H, Ogawa S, Suzuki H. A case of RSD with complete disappearance of symptoms following intravenous ketamine infusion combined with stellate ganglion block and continuous epidural block. Jpn J Anesthesiol. 1995;44:1680–4.

743.

Tsai YC, Wang LK, Chen BS, Chen HP. Home-based patient-controlled epidural analgesia with bupivacaine for patients with intractable herpetic neuralgia. J Formos Med Assoc. 2000;99:659–62.PubMed

744.

Kang FC, Chang PJ, Chen HP, Tsai YC. Patient-controlled epidural analgesia for postherpetic neuralgia in an HIV-infected patient as a therapeutic ambulatory modality. Acta Anaesthesiol Sin. 1998;36:235–9.PubMed

745.

Okano K, Kondo H, Tsuchiya R, Naruke T, Sato M, Yokoyama R. Spinal epidural abscess associated with epidural catheterization: report of a case and a review of the literature. Jpn J Clin Oncol. 1999;29:49–52.PubMedCrossRef

746.

Taga K, Tomita M, Watanabe I, Sato K, Awamori K, Fujihara H, et al. Complete recovery of consciousness in a patient with decorticate rigidity following cardiac arrest after thoracic epidural injection. Br J Anaesth. 2000;85:632–4.PubMedCrossRef

747.

Iseki M, Okuno S, Tanabe Y, Mitsuhata H, Miyazaki T. Methicillin-resistant Staphylococcus aureus sepsis resulting from infection in paravertebral muscle after continuous epidural infusion for pain control in a patient with herpes zoster. Anesth Analg. 1998;87:116–8.PubMed

748.

Hamaguchi K, Ikegami S, Morita N, Fukushima H, Miyata K, Fujiki N, et al. A case of dyspnea caused by deep cervical hematoma following stellate ganglion block. Pract Oto-Rhino-Laryngol. 2007;100:391–5.CrossRef

749.

Miyamoto T, Nakatani T, Narai Y, Sakakibara M, Hashimoto T, Saito Y. A case of spinal epidural abscess after continuous epidural block to manage the pain of herpes zoster. Jpn J Anesthesiol. 2014;63:353–7.

750.

Son H, Sakuma Y, Kamada T, Kawano M, Suwa I, Kotani J, et al. A patient with respiratory arrest after stellate ganglion blockade. J Jpn Dent Soc Anesthesiol. 1996;24:489–92.

751.

Sugino N, Ohta A, Abe H, Mori H. Three cases of bacterial contaminations associated with epidural catheterization in patients of herpes zoster. Hokuriku J Anesthesiol. 1995;29:47–9.

752.

Suzuki T, Takemura H, Shida K, Higuchi H, Ohtsuka N, Masuda Y. The development of methicillin-resistant Staphylococcus aureus sepsis in a patient with herpes zoster during treatment with continuous epidural infusion. Jpn J Anesthesiol. 2002;51:293–5.

753.

Uematsu H, Hiei K, Kawasaki H. Unknown fever and abnormal liver functions after repeated epidural blocks with lidocaine for management of herpes zoster pain. Jpn J Anesthesiol. 1994;43:405–8.

754.

Wajima Z, Ishikawa G, Kaneko K, Inoue T, Ogawa R. A case of using continuous double-tapped epidural analgesia for herpes zoster duplex. Jpn J Anesthesiol. 1995;44:841–4.

755.

Jeon Y, Baek SU, Yeo JS. Spinal myoclonus developed during cervical epidural drug infusion in postherpetic neuralgia patient. Korean J Pain. 2011;24:169–71.PubMedPubMedCentralCrossRef

756.

Min BM, Kim JH. Epidural catheterization with a subcutaneous injection port for the long-term administration of opioids and local anesthetics to treat zoster-associated pain -a report of two cases-. Korean J Anesthesiol. 2013;65:462–7.PubMedPubMedCentralCrossRef

757.

Higa K, Shono S, Nitahara K. Postherpetic neuralgia. Jpn J Anesthesiol. 2010;59:1342–9.

758.

Moryama K. Effect of temporary spinal cord stimulation on postherpetic neuralgia in the thoracic nerve area. Neuromodulation. 2009;12:39–43.CrossRef

759.

Hirabayashi H, Kawata K, Hoshida T, Tamura K, Youngsu P, Nakase H. Neuromodulation therapy for neuropathic pain. Jpn J Neurosurg. 2011;20:93–102.

760.

Hijikata Y, Yamada S. Effect of Ganoderma lucidum on postherpetic neuralgia. Am J Chin Med. 1998;26:375–81.PubMedCrossRef

761.

Hijikata Y, Yasuhara A, Sahashi Y. Effect of an herbal formula containing Ganoderma lucidum on reduction of herpes zoster pain: a pilot clinical trial. Am J Chin Med. 2005;33:517–23.PubMedCrossRef

762.

Nakanishi M, Arimitsu J, Kageyama M, Otsuka S, Inoue T, Nishida S, et al. Efficacy of traditional Japanese herbal medicines-Keishikajutsubuto (TJ-18) and Bushi-matsu (TJ-3022)-against postherpetic neuralgia aggravated by self-reported cold stimulation: a case series. J Altern Complement Med. 2012;18:686–92.PubMedCrossRef

763.

Lee SM, Lim J, Lee JD, Choi DY, Lee S. Bee venom treatment for refractory postherpetic neuralgia: a case report. J Altern Complement Med. 2014;20:212–4.PubMedPubMedCentralCrossRef

764.

Byun SH, Jeon Y. Administration of Vitamin C in a Patient with Herpes Zoster - A case report -. Korean J Pain. 2011;24:108–11.PubMedPubMedCentralCrossRef

765.

Huang B, Zhou XY, Lu YP, Zhu ZF, Hou J, Sun JL, et al. Selective percutaneous dorsal root ganglion radiofrequency thermocoagulation guided by CT scanning in treatment of post-herpetic neuralgia. Nat Med J China. 2008;88:885–8.

766.

Lim SM, Park HL, Moon HY, Kang KH, Kang H, Baek CH, et al. Ultrasound-guided infraorbital nerve pulsed radiofrequency treatment for intractable postherpetic neuralgia - a case report -. Korean J Pain. 2013;26:84–8.PubMedPubMedCentralCrossRef

767.

Ko YK, Lee HY, Lee WY. Clinical experiences on the effect of scrambler therapy for patients with postherpetic neuralgia. Korean J Pain. 2013;26:98–101.PubMedPubMedCentralCrossRef

768.

Chen HM. Zoster Chinese medicine treatment. Zhonghua Shi Yan He Lin Chuang Bing Du Xue Za Zhi. 2007;21:285–7.PubMed

769.

Cao H, Li X, Liu J. An updated review of the efficacy of cupping therapy. PLoS One. 2012;7:e31793.PubMedPubMedCentralCrossRef

770.

Bourke A, Hui B. Weak evidence that HBOT is of benefit in the treatment of patients with herpes zoster. Diving Hyperbaric Med. 2013;43:174.

771.

National Centre for Immunisation Research & Surveilance. Zoster vaccine for Australian adults | NCIRS Fact sheet: July 2015. http://www.ncirs.edu.au/assets/provider_resources/fact-sheets/herpes-zoster-vaccine-fact-sheet.pdf. Accessed 3 Sept 2015.

772.

Fujiwara O, Mitamura Y, Ohtsuka K. Herpes zoster panuveitis progression despite acyclovir treatment in a patient following bone marrow transplantation. Jpn J Ophthalmol. 2005;49:536–8.PubMedCrossRef

773.

Abe T, Kuboki J, Tamai M. Sensitivity to acyclovir in acute retinal necrosis syndrome. Jpn J Clin Ophthalmol. 1997;51:1161–3.

774.

Leung AY, Chow HC, Kwok JS, Lui CK, Cheng VC, Yuen KY, et al. Safety of vaccinating sibling donors with live-attenuated varicella zoster vaccine before hematopoietic stem cell transplantation. Bone Marrow Transplant. 2007;39:661–5.PubMedCrossRef

775.

Kanda Y, Mineishi S, Saito T, Saito A, Yamada S, Ohnishi M, et al. Long-term low-dose acyclovir against varicella-zoster virus reactivation after allogeneic hematopoietic stem cell transplantation. Bone Marrow Transplant. 2001;28:689–92.PubMedCrossRef

776.

Kawamura K, Wada H, Yamasaki R, Ishihara Y, Sakamoto K, Ashizawa M, et al. Prophylactic role of long-term ultra-low-dose acyclovir for varicella zoster virus disease after allogeneic hematopoietic stem cell transplantation. Int J Infect Dis. 2014;19:26–32.PubMedCrossRef

777.

Uchiyama M, Tamai Y, Ikeda T. Low-dose acyclovir against reactivation of varicella zoster virus after unrelated cord blood transplantation. Int J Infect Dis. 2010;14:e451–2.PubMedCrossRef

778.

Asano-Mori Y, Kanda Y, Oshima K, Kako S, Shinohara A, Nakasone H, et al. Long-term ultra-low-dose acyclovir against varicella-zoster virus reactivation after allogeneic hematopoietic stem cell transplantation. Am J Hematol. 2008;83:472–6.PubMedCrossRef

779.

Oshima K, Takahashi T, Mori T, Matsuyama T, Usuki K, Asano-Mori Y, et al. One-year low-dose valacyclovir as prophylaxis for varicella zoster virus disease after allogeneic hematopoietic stem cell transplantation. A prospective study of the Japan Hematology and Oncology Clinical Study Group. Transpl Infect Dis. 2010;12:421–7.PubMedCrossRef

780.

Aoki T, Nishiyama T, Imahashi N, Kitamura K. Efficacy of continuous, daily, oral, ultra-low-dose 200 mg acyclovir to prevent herpes zoster events among bortezomib-treated patients: a report from retrospective study. Jpn J Clin Oncol. 2011;41:876–81.PubMedCrossRef

781.

Fukushima T, Sato T, Nakamura T, Iwao H, Nakajima A, Miki M, et al. Daily 500 mg valacyclovir is effective for prevention of Varicella zoster virus reactivation in patients with multiple myeloma treated with bortezomib. Anticancer Res. 2012;32:5437–40.PubMed

782.

Steer CB, Szer J, Sasadeusz J, Matthews JP, Beresford JA, Grigg A. Varicella-zoster infection after allogeneic bone marrow transplantation: Incidence, risk factors and prevention with low-dose aciclovir and ganciclovir. Bone Marrow Transplant. 2000;25:657–64.PubMedCrossRef

783.

Takahashi M, Kamiya H, Asano Y, Shiraki K, Baba K, Otsuka T, et al. Immunization of the elderly to boost immunity against varicella-zoster virus (VZV) as assessed by VZV skin test reaction. In: Gershon AA, Arvin AM, Calisher CH, editors. Archives of Virology, Supplement 17: Immunity to and prevention of herpes zoster. Vienna: Springer; 2001. p. 161–72. doi:10.1007/978-3-7091-6259-0_17.CrossRef

784.

Takahashi M, Okada S, Miyagawa H, Amo K, Yoshikawa K, Asada H, et al. Enhancement of immunity against VZV by giving live varicella vaccine to the elderly assessed by VZV skin test and IAHA, gpELISA antibody assay. Vaccine. 2003;21:3845–53.PubMedCrossRef

785.

Hata A, Inoue F, Yamasaki M, Fujikawa J, Kawasaki Y, Hamamoto Y, et al. Safety, humoral and cell-mediated immune responses to herpes zoster vaccine in subjects with diabetes mellitus. J Infect. 2013;67:215–9.PubMedCrossRef

786.

Marumoto T, Ono K. Varicella vaccine was effective in a case of recurrent ophthalmic zoster sine herpete. Jpn J Clin Ophthalmol. 2013;67:575–9.

787.

Sasadeusz J, Prince HM, Schwarer A, Szer J, Stork A, Bock HL, et al. Immunogenicity and safety of a two-dose live attenuated varicella vaccine given to adults following autologous hematopoietic stem cell transplantation. Transplant Infect Dis. 2014;16:1024–31.CrossRef

788.

Cheuk DK, Chiang AK, Lee TL, Chan GC, Ha SY. Vaccines for prophylaxis of viral infections in patients with hematological malignancies. Cochrane Database Syst Rev. 2011;3:CD006505.

789.

Frazer IH, Levin MJ. Paradigm shifting vaccines: prophylactic vaccines against latent varicella-zoster virus infection and against HPV-associated cancer. Curr Opin Virol. 2011;1:268–79.PubMedPubMedCentralCrossRef

790.

Choi WS. Herpes zoster vaccine in Korea. Clin Exp Vaccine Res. 2013;2:92–6.PubMedPubMedCentralCrossRef

791.

Recommended immunization schedule for adults in Korea, by the Korean Society of Infectious Diseases, 2012. Clin Exp Vaccine Res. 2014;3:110–2.

792.

Chun GTW, Chong LP, Bailey P. Malaysian Society of Geriatric Medicine position statement on vaccination against the herpes zoster virus in older adults (updated June 2014). https://sites.google.com/a/ummc.edu.my/msgm/position-statements/the-herpes-zoster-vaccine. Accessed 2 Feb 2015.

793.

Specialist Doctors Association of Indonesia. Adult Immunization Schedule. 2014. http://pbpapdi.net/images/file_unduh/Catatan Imunisasi &Jadwal Imunisasi Dewasa_103.zip. Accessed 18 Jan 2017.

794.

Philippine Society for Microbiology and Infectious Diseases. Handbook on Adult Immunization for Filipinos. 2012. www.psmid.org.ph/contents/handbook-on-adult-immunization-2012.pdf. Accessed 1 Apr 2015.

795.

Thailand Royal College of Physicians. Recommended Adult and Elderly Immunization Schedule, 2014. www.rcpt.org/index.php/2012-10-03-16-53-39/category/6-2013-02-02-09-02-52.html?download=140:-2014. Accessed 1 Apr 2015.

796.

Taiwan Association of Family Medicine. Clinical Handbook for Adult Immunization. 1st ed. Taipei: Taiwan Association of Family Medicine; 2010. p. 31–6.

797.

Chen N, Li Q, Zhang Y, Zhou M, Zhou D, He L. Vaccination for preventing postherpetic neuralgia. Cochrane Database Syst Rev. 2011;3:CD007795.

798.

Loke XY, Tran W, Alderman CP. Survey of Australian inpatients on vaccination status and perceptions of influenza vaccination. Consult Pharm. 2012;27:553–63.PubMedCrossRef

799.

Macaladad N, Marcano T, Guzman M, Moya J, Jurado F, Thompson M, et al. Safety and immunogenicity of a zoster vaccine in varicella-zoster virus seronegative and low-seropositive healthy adults. Vaccine. 2007;25:2139–44.PubMedCrossRef

800.

Hales CM, Harpaz R, Ortega-Sanchez I, Bialek SR. Centers for Disease Control and Prevention (CDC). Update on recommendations for use of herpes zoster vaccine. MMWR Morb Mortal Wkly Rep. 2014;63:729–31.PubMed

801.

Keating GM. Shingles (herpes zoster) vaccine (zostavax®): a review of its use in the prevention of herpes zoster and postherpetic neuralgia in adults aged ≥50 years. Drugs. 2013;73:1227–44.PubMedCrossRef

802.

World Health Organization, SAGE Working Group on Varicella and Herpes Zoster Vaccines. Background paper on herpes zoster. SAGE Meeting 1–3 April 2014, Geneva, Switzerland. at: http://www.who.int/immunization/sage/meetings/2014/april/2_Background_document_Herpes_Zoster.pdf. Accessed 3 Oct 2016.

803.

Association of Physicians of India. Medicine Update (Volume 23, 2013). Adult immunization. http://www.apiindia.org/medicine_update_2013/chap101.pdf. Accessed 9 Feb 2015.

804.

MacIntyre CR, Egerton T, McCaughey M, et al. Concomitant administration of zoster and pneumococcal vaccines in adults ≥60 years old. Hum Vaccin. 2010;6:894–902.

805.

Tseng HF, Smith N, Sy LS, Jacobsen SJ. Evaluation of the incidence of herpes zoster after concomitant administration of zoster vaccine and polysaccharide pneumococcal vaccine. Vaccine. 2011;29:3628–32.PubMedCrossRef

806.

United States Census Bureau, International Programs, International Data Base. Revised December 19, 2013. https://www.census.gov/population/international/data/idb/informationGateway.php. Accessed 8 May 2015.

807.

MacIntyre R, Stein A, Harrison C, Britt H, Mahimbo A, Cunningham A, Thompson R. Increasing Trends of Herpes Zoster in Australia. PLoS One. 2015;10:e0125025.

Titel: Looking back to move forward: a twenty-year audit of herpes zoster in Asia-Pacific
verfasst von: Liang-Kung Chen
Hidenori Arai
Liang-Yu Chen
Ming-Yueh Chou
Samsuridjal Djauzi
Birong Dong
Taro Kojima
Ki Tae Kwon
Hoe Nam Leong
Edward M. F. Leung
Chih-Kuang Liang
Xiaohong Liu
Dilip Mathai
Jiun Yit Pan
Li-Ning Peng
Eduardo Rommel S. Poblete
Philip J. H. Poi
Stewart Reid
Terapong Tantawichien
Chang Won Won
Publikationsdatum: 01.12.2017
Verlag: BioMed Central
Erschienen in: BMC Infectious Diseases / Ausgabe 1/2017
Elektronische ISSN: 1471-2334
DOI: https://doi.org/10.1186/s12879-017-2198-y

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

25.04.2024 | Hypertonie | Nachrichten

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

Abstract

Background

Methods

Results

Conclusions

Electronic supplementary material

Background

Methodology

Literature search strategy

Data management

Inclusion and inclusion criteria

Literature search results

Clinicopathology

Atypical HZ

Zoster sine herpete

Multidermatomal, disseminated and visceral HZ

Pain

Epidemiology and risk factors

Seroepidemiology

Incidence

Recurrence

Risk factors and comorbidities

Immunosuppressant therapies

Anti-inflammatory and cytotoxic agents

Other iatrogenic risk factors

Infections

Intrinsic risk factors

Associated diseases

Complicating presentations and disease associations

Post-herpetic neuralgia

Neuropathy, inflammation and secondary complications

Eye

Ear, nose and throat

Neuromuscular

Vasculopathy

Skin

Dental

Disease associations

Healthcare utilisation

Hospitalisation

Healthcare expenditure

Management and prevention

Antiviral therapies

Pain relief

Corticosteroids

Analgesia

Alternative treatment modalities

Unmet treatment needs

Prevention approaches

Antiviral prophylaxis in high-risk patients

VZV immunisation

HZ immunisation guidelines and recommendations

Discussion

Knowledge and data gaps

Conclusions

Call to action

Acknowledgements

Funding

Availability of data and materials

Authors’ contributions

Competing interests

Consent for publication

Ethics approval and consent to participate

Additional file

Weitere Artikel der Ausgabe 1/2017

Pyrazinamide resistance-conferring mutations in pncA and the transmission of multidrug resistant TB in Georgia

Results of an early intervention programme for patients with bacteraemia: analysis of prognostic factors and mortality

Spondylodiscitis in a healthy 12-year-old girl with Extraintestinal pathogenic Escherichia coli (ExPEC) bacteraemia

Sero-epidemiology study of leptospirosis in febrile patients from Terai region of Nepal

Hepatic iron overload is associated with hepatocyte apoptosis during Clonorchis sinensis infection

Hepatitis a virus genotypes and strains from an endemic area of Europe, Bulgaria 2012–2014

Leitlinien kompakt für die Innere Medizin

Neu im Fachgebiet Innere Medizin

Therapiestart mit Blutdrucksenkern erhöht Frakturrisiko

Adjuvante Immuntherapie verlängert Leben bei RCC

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

Metformin rückt in den Hintergrund

Update Innere Medizin